

CALIFORNIA HORSE RACING BOARD

1010 Hurley Way, Suite 300

Sacramento, CA 95825

www.chrb.ca.gov

(916) 263-6000 Fax (916) 263-6042



REGULAR MEETING

Of the **California Horse Racing Board (CHRB/Board)** will be held on **Wednesday, February 17, 2021**, commencing at **9:30 a.m. via teleconference**. The audio portion only of the California Horse Racing Board regular meeting will be available online through a link at the CHRB website (www.chrb.ca.gov) under “Webcasts.”

Please be advised, in accordance with Executive Order N-29-20, the CHRB will provide a teleconference option for its upcoming public meeting, to be held on **February 17, 2021 at 9:30 a.m.** Board members and members of the public are strongly encouraged to participate using the teleconference phone number provided below so as to minimize the spread of COVID-19 and reduce the risk of infection during this current state of emergency. No physical location will be provided.

To participate in the teleconference, dial 888-392-4564 and enter 6896291# when prompted. To comment on an agenda item, press *1 during the call to be added to the queue. If you are a member of the public and wish to listen to the meeting and not participate, we request that you please listen to the meeting via the webcast link on our website to avoid congestion and potential technical difficulties.

The agenda for the regular meeting will consist of the following matters:

AGENDA

Action Items:

1. **Approval of the minutes of January 21, 2021.**
2. Reports
 - A. **Executive Director’s Report.**
 - B. **Equine Medical Director’s Report.**
3. Discussion and action by the Board regarding the **distribution of race day charity proceeds of the Del Mar Thoroughbred Club, Combined 2020 race meetings**, in the amount of \$114,215, to nine beneficiaries.
4. Discussion and action by the Board regarding the **proposed amendment of CHRB Rule 1843.2, Classification of Drug Substances**, to update the Alphabetical Substances List to align with the Association of Racing Commissioners International (ARCI) Uniform Classification Guidelines for Foreign Substances.

5. Discussion and action by the Board on the **Renewal Application for License to Operate a Minisatellite Wagering Facility at the Sahara Dunes Casino dba Lake Elsinore Hotel and Casino in Lake Elsinore, California.**
6. Discussion and action by the Board on the **Approval for a distribution from ADW Market Access fees for wagers placed by California residents on all live and imported races hosted by the signatory racing associations for the period April 1 through December 31, 2021,** to be utilized to fund a California co-op marketing program as permitted under Business & Professions Code section 19604(f)(5)(E).
7. **Public Comment:** Communications, reports, requests for future actions of the Board. **Note:** During the public comment period, a total of thirty minutes will be allowed for public comments via the teleconference line. After thirty minutes, no further comments will be accepted. Each person will be limited to two minutes.
8. **Closed Session:** For the purpose of receiving advice from counsel, considering pending litigation, reaching decisions on administrative licensing and disciplinary hearings, and personnel matters, as authorized by section 11126 of the Government Code.
 - A. The Board may convene a Closed Session to confer with and receive advice from its legal counsel regarding the pending litigation described in the attachment to this agenda captioned "Pending Litigation," and as authorized by Government Code section 11126(e).
 - B. The Board may convene a Closed Session to confer with and receive advice from its legal counsel regarding pending administrative licensing or disciplinary matters as authorized by Government Code section 11126(e).
 - C. The Board may convene a Closed Session for the purposes of considering personnel matters as authorized by Government Code section 11126(a).

Additional information regarding this meeting may be obtained from the CHRB Administrative Office, 1010 Hurley Way, Suite 300, Sacramento, CA 95825; telephone (916) 263-6000; fax (916) 263-6042. This notice is located on the CHRB website at www.chrb.ca.gov. *Information for requesting disability related accommodation for persons with a disability who require aid or services in order to participate in this public meeting, should contact Amanda Drummond. Requests will be swiftly resolved by CHRB staff.

CALIFORNIA HORSE RACING BOARD

Gregory L. Ferraro, DVM, Chairman
Oscar Gonzales, Vice Chair
Dennis Alfieri, Member
Damascus Castellanos, Member
Brenda Davis, Member
Wendy Mitchell, Member
Alex Solis, Member
Scott Chaney, Executive Director
Cynthia Alameda, Assistant Executive Director

CALIFORNIA HORSE RACING BOARD

1010 HURLEY WAY, SUITE 300
SACRAMENTO, CA 95825
(916) 263-6000
FAX (916) 263-6042



PENDING ADMINISTRATIVE ADJUDICATIONS FEBRUARY 2021

The Board may convene a Closed Session to confer with and receive advice from its legal counsel regarding the pending administrative licensing or disciplinary matters as authorized by Government Code section 11126(e). This shall include any matters mentioned below and/or permitted by law.

CASE

- A. Proposed Decision**
Trainer Paul Aguirre
Case Number: 19LT0061

CALIFORNIA HORSE RACING BOARD

1010 HURLEY WAY, SUITE 300
SACRAMENTO, CA 95825
(916) 263-6000
FAX (916) 263-6042



PENDING LITIGATION FEBRUARY 2021

COURT LITIGATION

- A. Charles Fipke v. California Horse Racing Board**
Court of Appeal of the State of California, Second Appellate District in Los Angeles
- B. Luster v. California Horse Racing Board**
Superior Court of California, County of Sacramento
- C. Zvi Kriple v. California Horse Racing Board**
Superior Court of California, County of San Diego
- D. Ruis Racing, LLC v. California Horse Racing Board**
Superior Court of California, County of Los Angeles
- E. Hollendorfer v. California Horse Racing Board**
Superior Court of California, County of San Diego
- F. Pacific Racing Association and Pacific Racing Association II v. California Horse Racing Board**
Superior Court of California, County of Orange

CALIFORNIA HORSE RACING BOARD

1010 Hurley Way, Suite 300

Sacramento, CA 95825

www.chrb.ca.gov

(916) 263-6000 Fax (916) 263-6042

**REGULAR BOARD MEETING MINUTES****Date and Time:** January 21, 2021 at 9:30 a.m.**Location:** Teleconference**Board Members Present:** Gregory Ferraro, Chairman
Oscar Gonzales, Vice-Chairman
Alex Solis, Member
Dennis Alfieri, Member
Wendy Mitchell, Member
Demascus Castellanos, Member
Brenda Washington Davis, Member**Staff Members Present:** Scott Chaney, Executive Director
Cynthia Alameda, Assistant Executive Director
Robert Brodrik, General Counsel**1. APPROVAL OF THE MINUTES OF DECEMBER 17, 2020.****Motion:** Approve**Motioned/Seconded:** Washington Davis/Gonzales**Roll call vote: Aye:** Washington Davis, Castellanos, Mitchell, Alfieri, Gonzales, Ferraro.**Nay:** None. **Abstain:** Solis. **Motion carried.**

Page 4 in the Board transcript.

2. REPORTS.**A. EXECUTIVE DIRECTOR'S REPORT**

Pages 4–9 in the Board transcript.

B. EQUINE MEDICAL DIRECTOR'S REPORT.

Pages 9–25 in the Board transcript.

3. DISCUSSION AND ACTION BY THE BOARD ON THE RENEWED APPLICATION FOR LICENSE TO CONDUCT A HORSE RACING MEETING OF THE LOS ALAMITOS QUARTER HORSE RACING ASSOCIATION (QH) AT LOS ALAMITOS RACE COURSE, COMMENCING DECEMBER 23, 2020 THROUGH DECEMBER 21, 2021.**Motion:** Approve license for proposed term**Motioned/Seconded:** Castellanos/Solis**Roll call vote: Aye:** Castellanos, Solis, Alfieri, Ferraro. **Nay:** Washington Davis, Mitchell, Gonzales. **Motion passed** 4-3.

Proceedings of the Regular Meeting of January 21, 2021

Pages 25–119 in the Board transcript.

4. DISCUSSION AND ACTION BY THE BOARD REGARDING THE **PROPOSED AMENDMENT OF CHRB RULE 1843.2, CLASSIFICATION OF DRUG SUBSTANCES**, TO UPDATE THE ALPHABETICAL SUBSTANCES LIST TO ALIGN WITH THE ASSOCIATION OF RACING COMMISSIONERS INTERNATIONAL (ARCI) UNIFORM CLASSIFICATION GUIDELINES FOR FOREIGN SUBSTANCES.

Motion: Postpone action by Board until February 2021 regular Board meeting to allow Board to review regulation and receive additional input.

Motioned/Seconded: Gonzales/Mitchell

Roll call vote: Aye: Washington Davis, Castellanos, Mitchell, Gonzales. **Nay:** Solis, Alfieri, Ferraro. **Motion passed** 4-3.

Pages 119–138 in the Board transcript.

5. DISCUSSION AND ACTION BY THE BOARD REGARDING THE **DELEGATION OF AUTHORITY TO THE EXECUTIVE DIRECTOR** PURSUANT TO CALIFORNIA BUSINESS AND PROFESSIONS CODE SECTION 19428 FOR ONE YEAR.

Motion: Approve

Motioned/Seconded: Alfieri/Ferraro

Roll call vote: Aye: Washington Davis, Castellanos, Solis, Mitchell, Alfieri, Gonzales, Ferraro. **Nay:** None.

Motion carried.

Pages 138–142 in the Board transcript.

6. DISCUSSION AND ACTION BY THE BOARD ON THE **PROPOSAL TO PARTIALLY SUSPEND CHRB RULE 1845(k), AUTHORIZED BLEEDER MEDICATION, PURSUANT TO CHRB RULE 1406, SUSPENSION OF RULE.**

Motion: Approve

Motioned/Seconded: Castellanos/Solis

Roll call vote: Aye: Washington Davis, Castellanos, Solis, Alfieri, Gonzales, Ferraro, Mitchell. **Nay:** None. **Motion carried.**

Pages 142–155 in the Board transcript.

7. DISCUSSION AND ACTION BY THE BOARD REGARDING THE **PROPOSED AMENDMENT OF CHRB RULE 1845, AUTHORIZED BLEEDER MEDICATION**, TO CLARIFY THE USAGE OF FUROSEMIDE IN SPECIFIC AREAS.

Motion: Approve

Motioned/Seconded: Solis/Alfieri

Roll call vote: Aye: Washington Davis, Castellanos, Solis, Mitchell, Alfieri, Ferraro. **Nay:** None. **Motion carried.**

Pages 155–165 in the Board transcript.

Proceedings of the Regular Meeting of January 21, 2021

- 8. DISCUSSION AND ACTION BY THE BOARD REGARDING APPROVAL OF THE CHANGE OF OWNERSHIP FOR THE MINISATELLITE RACE & SPORTS AUTHORITY LLC, DBA 58 FLAT, PURSUANT TO BOARD RULE 2066(h).**

Motion: Approve

Motioned/Seconded: Mitchell/Gonzales

Roll call vote: Aye: Washington Davis, Castellanos, Solis, Mitchell, Alfieri, Gonzales, Ferraro. **Nay:** None. **Motion carried.**

Pages 165–173 in the Board transcript.

- 9. PUBLIC COMMENT.**

Pages 173–187 in the Board transcript.

MEETING ADJOURNED AT 2:08 P.M.

Proceedings of the Regular Meeting of January 21, 2021

A full and complete transcript of the aforesaid proceedings are on file at the office of the California Horse Racing Board, 1010 Hurley Way, Suite 300, Sacramento, California, and therefore made a part hereof.

Chairman

Executive Director

CALIFORNIA HORSE RACING BOARD

February 17, 2021
REGULAR BOARD MEETING

There is no board package material for Item 2A

CALIFORNIA HORSE RACING BOARD

February 17, 2021
REGULAR BOARD MEETING

There is no board package material for Item 2B

STAFF ANALYSIS
DISCUSSION AND ACTION BY THE BOARD REGARDING THE DISTRIBUTION OF
RACE DAY CHARITY PROCEEDS OF DEL MAR THOROUGHBRED CLUB,
COMBINED 2020 RACE MEETINGS, IN THE AMOUNT OF \$114,215, TO NINE
BENEFICIARIES

Regular Board Meeting
February 17, 2021

ISSUE

The Del Mar Thoroughbred Club (DMTC) is requesting approval to distribute race day charity proceeds generated at two live race meetings for the period of July 8, 2020, through September 8, 2020, and from October 28, 2020, through December 1, 2020. The combined race meetings statutory distribution amount is \$9,157. DMTC is proposing to supplement the 2020 combined race day charity day proceeds and increase the distribution by \$105,058, and distribute a total amount of \$114,215, to nine beneficiaries. The charitable organizations selected and amounts to be distributed are listed on the attachment. Staff notes that 100 percent of the proposed charity distributions are made to equine related charity organizations.

BACKGROUND

Business and Professions Code section 19550 states the Board shall require each licensed racing association that conducts 14 or less weeks of racing to designate three racing days, and each licensed racing association that conducts more than 14 weeks of racing to designate five racing days during any one meeting, to be conducted as charity days by the licensee for the purpose of distribution of the net proceeds there from to beneficiaries through the distribution agent. No racing association shall be required to pay to a distributing agent for the purpose of distribution to beneficiaries more than an amount equal to two-tenths of one percent of the association's total on-track handle on live races conducted by the association at the meeting. Business and Professions Code section 19555 requires that proceeds are to be distributed to beneficiaries within 12 calendar months after the last day of the meet during which charity days were conducted. Business and Professions Code section 19556 provides that the distributing agent shall make the distribution to beneficiaries qualified under this article. At least 30 percent of the distribution shall be made to charities associated with the horse racing industry. An additional five percent shall be paid to a welfare fund and another five percent shall be paid to a nonprofit corporation, the primary purpose of which is to assist horsemen and backstretch personnel who are being affected adversely as a result of alcohol or substance abuse. In addition to the above distributions, a separate 20 percent shall be made to a nonprofit corporation or trust, the directors or trustees of which shall serve without compensation except for reimbursement for reasonable expenses, and which has as its sole purpose the accumulation of endowment funds, the income on which shall be distributed to qualified disabled jockeys.

RECOMMENDATION


This item is presented for Board discussion and action.

CHRB ANALYSIS

Del Mar Thoroughbred Club (DMTC), Combined Charity Day Proceeds
July 8, 2020 - September 8, 2020, and October 28, 2020 - December 1, 2020

#	Nonprofit Organization	Statutory Distribution Amounts	Disbursement Percentage	Percentage Required By Horse Racing Law (from the 2/10 of 1%)	Notes	DMTC Voluntary - Supplemental Distributions	Total Distributions
1	CARMA*	\$ 6,410.00	70%	minimum of 30%	a	\$ 53,305.00	\$ 59,715.00
2	Permanently Disabled Jockeys Fund *	1,831.00	20%	minimum of 20%	d	8,169.00	10,000.00
3	Racing & Medication Consortium*	-	0%		a	20,000.00	20,000.00
4	Winners Foundation*	458.00	5%	minimum of 5%	c	4,542.00	5,000.00
5	California Thoroughbred Horsemen's Foundation*	458.00	5%	minimum of 5%	b	4,542.00	5,000.00
6	Race Track Chaplaincy/Southern California*	-	0%		a	5,000.00	5,000.00
7	Edwin J. Gregson Foundation*	-	0%		a	5,000.00	5,000.00
8	California Center for Equine Health & Performance*	-	0%		a	2,500.00	2,500.00
9	UC Davis - JD Wheat Veterinary Research*	-	0%		a	2,000.00	2,000.00
	Total	\$ 9,157.00	100%		e	\$ 105,058.00	\$ 114,215.00
	Notes						
	a	30% to charities associated with the horse racing industry (B&P 19556(b))					
	b	5% to welfare fund (19556 (b)) described in subdivision (b) of Section 19641					
	c	5% to nonprofit organization to assist horsemen and backstretch personnel affected by alcohol and substance abuse(B&P 19556 (b))					
	d	20% to nonprofit organization that benefits qualified disabled jockeys (B&P 19556 (c)(1))					
	e	overall a minimum of 60% of the charity distribution should go to horse racing industry related nonprofit organizations.					

*Equine and/or horse racing related organization



Josh Rubinstein
President & COO

February 3, 2021

Mr. Scott Chaney
Executive Director
California Horse Racing Board
1010 Hurley Way, Suite 300
Sacramento, CA 95825

Executive Director Chaney:

Unfortunately, the COVID pandemic negatively impacted many facets of Del Mar Thoroughbred Club's (DMTC) 2020 operations, including charity days proceeds generated during our summer and fall race meets. As charity days represent a portion of on-track handle, and spectators were not allowed on-site at DMTC in 2020, proceeds were limited to \$9,157 (\$6,488 summer season and \$2,669 fall season) as compared to \$104,582 in 2019.

DMTC is proud of our long-standing commitment to industry charities. In 2020 we are supplementing our charity days distributions by \$105,058 for a total commitment of \$114,215. As such, DMTC is allocating the \$9,157 charity days proceeds from our 2020 summer and fall meets with an additional \$105,058 supplement as set forth in the attached DMTC 2020 Charity Days Distribution spreadsheet, for the California Horse Racing Board's consideration and approval.

Attached you will also find a schedule describing the charitable organizations listed in the distribution spreadsheet. Thank you for your attention to this matter. If you need further information please contact me.

Sincerely,

A handwritten signature in black ink, appearing to read "Josh Rubinstein", is written over a white background.

Josh Rubinstein
President and COO

Del Mar Thoroughbred Club						
2020 Charity Day						
	Summer	Fall	Combined	DMTC	Combined	
Organizations	2020	2020	2020	Contribution	Contribution	
California Retirement Management Account (CARMA) *	4,542	1,868	6,410	53,305	59,715	
Permanently Disabled Jockeys Fund *	1,298	534	1,831	8,169	10,000	
Racing & Medication Consortium *				20,000	20,000	
Winners Foundation *	324	133	458	4,542	5,000	
California Thoroughbred Horsemen Foundation *	324	133	458	4,542	5,000	
Race Track Chaplaincy/Southern California *				5,000	5,000	
Edwin J. Gregson Foundation *				5,000	5,000	
California Center for Equine Health & Performance *				2,500	2,500	
UC Davis - JD Wheat Veterinary Research *				2,000	2,000	
Totals	6,488	2,669	9,157	105,058	114,215	
* Equine Related Charities	6,488	2,669	9,157	105,058	114,215	
Non-Equine Related	0	0	0	0	0	
Percentage of Equine Related Charities	100%	100%	100%	100%	100%	



2020 CHARITABLE ORGANIZATIONS – SUMMER/FALL

CARMA – The California Retirement Management Account (CARMA) provides funding for retirement of California-raced Thoroughbred horses and serves as an educational resource for the public and racing community. CARMA is a charitable 501(c)(3) non-profit organization founded in 2007 to raise money for retired racehorses. It is responsible for hosting fundraising events, educating owners and trainers on equine retirement, raising awareness and working to unify the racing industry in support of its equine athletes. Ways in which this is accomplished include facilitating the transition of racehorses off the track through its Placement Program and showcasing the breed's versatility as equestrian mounts at its Thoroughbred Classic Horse Show. It is dedicated to the goal of providing funding for their rehabilitation, retraining and/or retirement. CARMA collects funds from racehorse owners, racetracks and other racing groups and organizations, then redistributes the funds to those farms and facilities that prove themselves worthy and capable of fulfilling the group's goal. Madeline Auerbach is CARMA's Founders Chair, Candace Coder-Chew-President, Howard Zucker-Vice President, Billy Koch-Treasurer and Samantha Siegel-Secretary. (Contact phone: 626-574-6654; www.carma4horses.org)

Permanently Disabled Jockeys Fund – Promotes awareness of the needs of permanently disabled jockeys – Provides financial support to permanently disabled jockeys – Provides financial support and assistance in obtaining medical coverage for permanently disabled jockeys – Promotes medical research dedicated to reducing catastrophic injuries within the horse racing industry. Founded in 2006, it is a collaborative effort of many leaders in the horse racing industry, including racetracks, jockeys, horsemen and many others who had a vision of a program that would bring much-needed financial assistance to a group of athletes who have given so much to the sport of horse racing. The PDJF is governed by an independent board comprised of stakeholders from a broad cross-section of the horse racing industry. The mission of PDJF is to promote financial support to permanently disabled jockeys living with a catastrophic on-track injury; provide financial support and assistance for permanently disabled jockeys; and to promote medical research dedicated to reducing catastrophic injuries within the horse racing industry. Nancy LaSala is the group's president. (Contact phone: 630-595-7660; www.pdjf.org/)

Racing Medication and Testing Consortium -- Striving to develop and promote uniform rules, policies and testing standards at the national level; coordinate research and educational programs that seek to ensure the integrity of racing and the health and welfare of racehorses and participants; and protect the interests of the racing public. Founded in 2000 by a cross-section of racing leaders, the Racing Medication and Testing Consortium (RMTC) has a primary goal of developing and promoting uniform rules, policies and testing standards at the national level for racehorses. The tax-deductible organization strives to develop and promote uniform rules, policies and testing standards at the national level; coordinate research and educational programs that seek to ensure the integrity of racing and the health and welfare of racehorses and participants; and to protect the interest of the racing public. It is currently governed by a Board of Directors consisting of 23 racing industry stakeholders. RMTC Executive Director and COO is Dr. Mary Scollay, Administrative Manager is Christopher Ware (Contact phone: 859-759-4081; www.rmtcnet.com/); Communications & Development Consultant is Hallie Roach-Lewis (Contact phone: 858-224-2848).

California Thoroughbred Horsemen's Foundation – The California Thoroughbred Horsemen's Foundation (CTHF) is a non-profit charitable foundation dedicated to improving the quality of life in the community of stable workers at California's racetracks and training centers. It was founded in 1983 and, among its other projects, currently conducts Monday through Friday medical and dental clinics in both Northern and Southern California that are free for stable workers and their families. Ken Smole is President and Chair of CTHF, Cliff Goodrich, Executive Director. (Contact phone: 626-446-0169; www.cthf.info/)

Winners Foundation – The Winners Foundation was established in 1984 as a non-profit organization to provide information, support and referral sources to employees and family members of the California horse racing community who are being adversely affected as a result of mental illness, alcohol and/or substance abuse. There is no charge to anyone seeking aid through the group, which has aided and guided thousands of individuals since its inception. It is currently headed by Darin Scharer, Executive Director. (Contact phone: 626-574-6498; <http://winnersfoundation.org/>)

Race Track Chaplaincy/Southern California (RTCA/SC) – The RTCA/SC is a nonprofit organization that was established in 1971 and ministers to the spiritual, emotional, physical and social/educational needs of horse racing’s workers. RTCA/SC is an affiliate of Race Track Chaplaincy of America, which has 77 chaplains serving over 117 race tracks throughout the United States and Canada. RTCA/SC offers support, direction and guidance, as well as Church services, at Santa Anita, Los Alamitos and Del Mar. Contact: Chaplain Eli Hernandez, Cell 562-479-4924 (Contact phone: 626-574-6438; <http://rtcasc.com/>)

Edwin J. Gregson Foundation – The foundation has a primary goal of benefitting and enhancing the quality of life of California’s backstretch workers and their families. It was originally founded by the California Thoroughbred Trainers (CTT) in 1998 and renamed in memory of veteran trainer and past CTT president Edwin J. Gregson, who was the driving force behind its start. Notable among its benefits are the college scholarships it provides annually to family members of backstretch workers. Jenine Sahadi currently heads the foundation. (Contact phone: 626-447-2145; www.gregsonfoundation.com)

California Center for Equine Health and Performance – The Center for Equine Health (CEH) was established at University of California Davis School of Veterinary Medicine in 1973. The primary purpose of CEH is to serve as an administrative and academic umbrella for research into means and methods of improving equine health, welfare and performance. The team brings together research facilities, students, veterinary residents, researchers and veterinarians to tackle important problems affecting horse health. In conjunction with this, it produces a series of publications that disseminate its findings and pertinent information. Additionally, it serves as the West Coast’s quarantine and treatment station for the potentially devastating venereal disease contagious equine metritis. The center’s current Director is Dr. Carrie J. Finno, DVM, cjfinno@ucdavis.edu (Contact phone: 530-752-6433.) Emeriti Directors include renowned veterinarian Gregory L. Ferraro, DVM, as well as Claudia Sonder, DVM.

UC Davis - JD Wheat Veterinary Orthopedics Laboratory Research Laboratory, School of Veterinary Medicine – The JD Wheat Veterinary Orthopedics Laboratory at UC Davis has been in the forefront of the state’s efforts to understand, treat and prevent musculoskeletal injuries in horses. Using research, education and a range of training tools and methods, the JD Wheat Laboratory has been a key cog in stemming catastrophic equine losses and providing means and methods to enhance safety on the racetrack. Contact: Susan M. Stover, DVM, smstover@ucdavis.edu, Rick M. Arthur, DVM, Equine Medical Director (626) 574-6351, rmarthur@ucdavis.edu.

STAFF ANALYSIS
DISCUSSION AND ACTION BY THE BOARD REGARDING THE PROPOSED
AMENDMENT OF CHRB RULE 1843.2, CLASSIFICATION OF DRUG SUBSTANCES,
TO UPDATE THE ALPHABETICAL SUBSTANCES LIST TO ALIGN WITH THE
ASSOCIATION OF RACING COMMISSIONERS INTERNATIONAL (ARCI) UNIFORM
CLASSIFICATION GUIDELINES FOR FOREIGN SUBSTANCES.

Regular Board Meeting
February 17, 2021

ISSUE:

In 2019, California Horse Racing Board (Board) amended [Rule 1843.2, Classification of Drug Substances](#), to update the Board's Classification of Foreign Substance Alphabetical Substance List (Substance List), which is incorporated in the regulation by reference, to align with updates from the Association of Racing Commissioners International (ARCI) Uniform Classification Guidelines. The Board traditionally updates its Substance List annually to align with the most recently published ARCI Uniform Classification Guidelines.

However, the United States Congress passed the Horse Racing Integrity and Safety Act of 2020 (HISA) in December, 2020. The HISA creates the independent Horseracing Anti-Doping and Medication Control Authority (Authority) which is tasked with developing and implementing a horseracing anti-doping and medication control program and racetrack safety program for all "covered horses", "covered persons", and "covered horseraces". The Authority's actions could therefore potentially conflict with the Board's, specifically regarding penalty classification guidelines for foreign substances pursuant to Board Rule 1843.2.

ANALYSIS:

HISA Section 2 subsection (4) defines "covered horse" as any thoroughbred horse, or any other breed made subject to HISA by the election of the applicable State racing commission or breed governing organization, pursuant to Section 5(k). Therefore, the provisions of HISA apply to, at a minimum, thoroughbred horses in California, and may be expanded to further breeds in the state at the election of either the Board or the representative horsemen's organization representing that breed.

Similarly, Section 2 subsection (5) defines "covered horserace" as any race involving covered horses, and subsection 2(6) defines "covered persons" as all persons licensed by the state, in California's case, by the Board, to engage in the care, training or racing of covered horses. Therefore, HISA applies, at present, to all licensees and races involving thoroughbreds in the Board's jurisdiction.

Section 3(a) provides for the creation of the Authority and charges the Authority with developing and implementing a horseracing anti-doping and medication control program and a racetrack safety program for covered horses, covered persons, and covered

horseraces. Section 4(a) further provides that the Authority is under the oversight of the Federal Trade Commission (Commission) and must submit any proposed rule or modification to a rule regarding a description of safety, performance, and anti-doping and medication control rule violations applicable to covered horses and covered persons and a schedule of civil sanctions for violations, to the Commission.

Section 5(a) provides that the Authority shall exercise independent and exclusive national authority over all horseracing, safety, performance, and anti-doping and medication control matters for covered horses, persons, and horseraces, similar to such authority of the State racing commissions before the HISA effective date. *Section 5(b) further provides that rules promulgated by the Authority in accordance with HISA shall preempt any provision of State law or regulation with respect to matters within the jurisdiction of the Authority or the jurisdiction of HISA.* Consequently, any rules or regulations implemented by the Authority that conflict with rules or regulations implemented by the Board will overrule the Board's rules because the Authority's jurisdiction supersedes that of the Board's.

Section 6(a) provides that the Authority shall establish a horseracing anti-doping and medication control program applicable to all covered horses, persons and races. *Section 6(b) provides that in developing the horseracing anti-doping and medication control program, the Authority shall take into consideration that the rules, standards, procedures, and protocols regulating medication and treatment methods for covered entities should be uniform and uniformly administered nationally.*

Section 6(g)(1) provides that the Authority shall implement baseline anti-doping and medication control rules, which are described in subsection 6(g)(2). The baseline anti-doping and medication control rules shall include a list of permitted and prohibited substances and the ARCI penalty and multiple medication violation rules, Model Rules of Racing (version 6.2). Therefore, the HISA penalty guidelines will match exactly the ARCI's Uniform Classification Guidelines. The proposed Substance List in Board Rule 1843.2 very nearly matches the ARCI's most recent Uniform Classification Guidelines, with a few exceptions. Consequently, when HISA becomes effective, those exceptions will be overruled by HISA.

However, Section 6(g)(3) allows for modifications to the baseline anti-doping and medication control rules if the Anti-Doping and Medication Control Standing Committee, a committee within the Authority, submits a recommendation for modification to the penalty guidelines for approval by the Authority. The modifications must be approved by the Authority, and ultimately, the Commission.

The proposed Substance List incorporated in the proposed amendment to Board Rule 1843.2 is consistent with the December 2020 ARCI Uniform Classification Guidelines with the exception of the following substances: Albuterol (Salbutamol), Cannabidiol (CBD), Chorionic Gonadotropin (CG), Clenbuterol, Cobalt, Furosemide, Luteinizing Hormone (LG), Ractopamine, and Zilpaterol hydrochloride.

The proposed Substance List also differs in its special notation regarding Methamphetamine, providing that if the Board, board of stewards, hearing officer, or administrative law judge determines that the finding of methamphetamine or its metabolites was unintentional and not based upon an attempt to affect the outcome of a race, or if testing shows only the presence of levo-methamphetamine in the sample, they may elect to assign a Class B penalty. This notation is a departure from the ARCI guidelines which provide “Recommended Penalty B if testing can prove presence of only levo-methamphetamine is present in sample”.

Similarly, a distinguished special notation applies to both Ractopamine and Zilpaterol hydrochloride. The proposed Substance List provides that if the Board, board of stewards, hearing officer, or administrative law judge determines that the finding of either Zilpaterol or Ractopamine was unintentional and not based upon an attempt to affect the outcome of the race, they may elect to assign a Class B penalty.

The proposed Substance List classification for Albuterol (Salbutamol) and Clenbuterol differ only such that the Substance List recommends a Class 3 B penalty for all breeds, where the ARCI guidelines recommend a Class 3 B penalty for thoroughbreds, and a Class A penalty for Quarter horse races. The proposed Substance List classifies CBD as a Class 3 B substance, and the ARCI guidelines classify it as a Class 2 B substance.

The proposed Substance List classifies Chorionic Gonadotropin (CG) and Luteinizing Hormone (LH) as a Class 3 B substances, but differs from the ARCI guidelines because the Substance List specifies that the Class 3 B penalty is for geldings, colts, adult intact males, and spayed females only, but is a Class 4 D penalty for intact females.

The proposed Substance List and the ARCI guidelines both distinguish between Cobalt violations in excess of 25.0 parts per billion and violations in excess of 50.0 parts per billion. The Substance List proposes a penalty Class 4 C for violations in excess of 25.0 parts per billion and a penalty Class 3 B for violations in excess of 50.0 parts per billion. The ARCI guidelines provide for a written warning and placement on the Veterinarian’s List for a violation in excess of 25.0 parts per billion, and a penalty Class 3 B for violations in excess of 50.0 parts per billion.

The proposed Substance List classifies Furosemide as a Class 4 C substance, whereas the ARCI guidelines provide an “N/A” penalty class for furosemide.

BACKGROUND:

BPC [section 19580](#) provides that the Board shall adopt regulations to establish policies, guidelines, and penalties relating to equine medication to preserve and enhance the integrity of horse racing in this state. BPC [section 19581](#) states that no substance of any kind shall be administered by any means to a horse after it has been entered to race in a horse race, unless the Board has, by regulation, specifically authorized the use of the substance and the quantity and composition thereof. BPC [section 19582](#) provides that violations of BPC section 19581, as determined by the Board, are punishable in

regulations adopted by the Board, and that the Board may classify violations based upon each class of prohibited drug substances, prior violations within the previous three years and prior violations within the violator's lifetime. Board [Rule 1843, Medication, Drugs and Other Substances](#), provides that no horse participating in a race shall carry in its body any drug substance or its metabolites or analogues, foreign to the horse except as hereinafter expressly provided. No drug substance shall be administered to a horse which is entered to compete in a race to be run in this state except for approved and authorized drug substances as provided in these rules.

RECOMMENDATION:

This item is presented for Board discussion and action.

CALIFORNIA HORSE RACING BOARD
TITLE 4., CALIFORNIA CODE OF REGULATIONS
ARTICLE 15. VETERINARY PRACTICES
PROPOSED AMENDMENT OF
RULE 1843.2. CLASSIFICATION OF DRUG SUBSTANCES

Rule 1843.2. Classification of Drug Substances.

The Board, the board of stewards, the hearing officer, or the administrative law judge, when adjudicating a hearing for a violation of Business and Professions Code section 19581, shall consider the classification of the substance as referenced in the California Horse Racing Board (CHRB) Classification of Foreign Substances, Alphabetical Substances List (Rev. 01/4921), hereby incorporated by reference, which is based on the Association of Racing Commissioners International (ARCI) Uniform Classification Guidelines for Foreign Substances (012/4820), as modified by the Board.

Authority cited: Sections 19580, 19581 and 19582,
Business and Professions Code.

Reference: Sections 19580, 19581 and 19582,
Business and Professions Code.

CHRB 1843.2 CLASSIFICATION OF FOREIGN SUBSTANCES

ALPHABETICAL SUBSTANCE LIST

1843.2. Classification of Drug Substances.

The Board, the board of stewards, the hearing officer, or the administrative law judge, when adjudicating a hearing for a violation of Business and Professions Code section 19581, shall consider the classification of the substance as referenced in the California Horse Racing Board (CHRB) Classification of Foreign Substances, Alphabetical Substances List (Rev. 01/~~1921~~), hereby incorporated by reference, which is based on the Association of Racing Commissioners International (ARCI) Uniform Classification Guidelines for Foreign Substances (~~012/1820~~), as modified by the Board.

Authority: Sections 19580, 19581 and 19582,
Business and Professions Code.

Reference: Sections 19580, 19581 and 19582,
Business and Professions Code.

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
<u>Δ-1-androstene-3, 17 diol</u>		<u>3</u>	<u>A</u>	
<u>Δ-1-androstene-3, 17 dione</u>		<u>3</u>	<u>A</u>	
<u>Δ-1-dihydrotestosterone</u>		<u>3</u>	<u>A</u>	
<u>1-androstenediol (5α-androst-1-ene-3β, 17β-diol)</u>		<u>3</u>	<u>B</u>	
<u>1-androstenedione (5α-androst-1-ene-3, 17-dione)</u>		<u>3</u>	<u>B</u>	
<u>1-testosterone (17β-hydroxy-5α-androst-1-en-3-one)</u>		<u>3</u>	<u>A</u>	
<u>19-Norandrostenediol</u>		<u>3</u>	<u>B</u>	
<u>19-Norandrostenedione</u>		<u>3</u>	<u>B</u>	
<u>19-noretiocholanolone</u>		<u>3</u>	<u>B</u>	
<u>2-Aminoheptane</u>	<i>Tuamine</i>	4	B	
<u>3,4-methylenedioxypropylprovalerone</u>	<i>MDPV, "bath salts"</i>	<u>1</u>	<u>A</u>	
<u>3-Methoxytyramine</u>	<i>3-MT</i>	2	A	
<u>3,4-methylenedioxypropylprovalerone</u>	<i>MDPV, "bath salts"</i>	<u>1</u>	<u>A</u>	
<u>4-androstene-3,6,17 trione (6-oxo)</u>		<u>3</u>	<u>B</u>	
<u>4-androstenediol (androst-4-ene-3β,17β-diol)</u>		<u>3</u>	<u>B</u>	
<u>4-Hydroxytestosterone</u>		<u>3</u>	<u>B</u>	
<u>5-androstenedione (androst-5-ene-3,17-dione)</u>		<u>3</u>	<u>B</u>	
<u>5α-androstane-3α,17α-diol</u>		<u>3</u>	<u>B</u>	
<u>5α-androstane-3α,17β-diol</u>		<u>3</u>	<u>B</u>	
<u>5α-androstane-3β,17α-diol</u>		<u>3</u>	<u>B</u>	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
<u>5α-androstane-3β,17β-diol</u>		<u>3</u>	<u>B</u>	
<u>5β-androstane-3 α, 17β-diol, androst-4-ene-3α,17α-diol</u>		<u>3</u>	<u>B</u>	
<u>7-keto-dhea;19-</u>		<u>3</u>	<u>B</u>	
<u>7α-hydroxy-dhea</u>		<u>3</u>	<u>B</u>	
<u>7β-hydroxy-dhea</u>		<u>3</u>	<u>B</u>	
<u>a-Cobratoxin</u>		<u>1</u>	<u>A</u>	
Acebutolol	<i>Sectral</i>	3	B	
Acecarbromal		2	A	
Acenocoumarol		5	C	
Acepromazine	<i>Atrovet, Notensil, PromAce[®]</i>	3	B	
Acetaminophen (Paracetamol)	<i>Tylenol, Tempra, etc.</i>	4	C	
Acetanilid		4	B	
Acetazolamide	<i>Diamox, Vetamox</i>	4	C	
Acetophenazine	<i>Tindal</i>	2	A	
Acetophenetidin (Phenacetin)		4	B	
<u>Acetylcysteine</u>		<u>4</u>	<u>C</u>	
Acetylsalicylic acid (Aspirin)		4	C	
Activators of the AMPactivated protein kinase (AMPK) - E.g., AICAR, and Peroxisome Proliferator Activated Receptor δ (pparδ) agonists (e.g., GW 1516).	<u>AICAR</u>	<u>2</u>	<u>A</u>	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Alclometasone	<i>Aclovate</i>	4	€	
Adinazolam		2	A	
Adrenochrome monosemicarbazone salicylate		4	B	
Alclofenac		2	B	
Albuterol (Salbutamol)	<i>Proventil, Ventolin</i>	3	B	
Alclofenac		2	B	
Alclometasone	<i>Aclovate</i>	4	C	
Alcuronium	<i>Alloferin</i>	2	A	
Aldosterone	<i>Aldocortin, Electrocortin</i>	4	B	
Alfentanil	<i>Alfenta</i>	1	A	
Almotriptan	<i>Axert</i>	3	A	
Alphaprodine	<i>Nisentil</i>	2	A	
<u>Alpha-pyrrolidinovalerophenone (also known as Alpha PVP)</u>	<i>“Bath Salts”</i>	1	A	
Alpidem	<i>Anaxyl</i>	2	A	
Alprazolam	<i>Xanax</i>	2	A	
Alprenolol		2	A	
Althesin	<i>Saffan</i>	2	A	
Altrenogest	<i>Regumate</i>	4	C	<u>Class 4/C is for geldings, colts, adult intact males, spayed females only. Penalty Class 4/D for intact females.</u>
Ambenonium	<i>Mytelase, Myeuran</i>	3	B	
Ambroxol	<i>Ambril, etc.</i>	4	B	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Amcinonide	<i>Cyclocort</i>	4	C	
Amiloride	<i>Moduretic; Midamor</i>	4	B	
Aminocaproic acid	<i>Amicar, Caprocid</i>	4	C	
<u>Aminoglutethimide</u>		<u>3</u>	<u>B</u>	
Amiodarone		4	B	
Aminophylline	<i>Aminophyllin, etc.</i>	3	B	
Aminopyrine		4	B	
<u>Amiodarone</u>		<u>4</u>	<u>B</u>	
Aminorex	<i>Aminoxafen, Aminoxaphen, Apique, McN-742, Menocil</i>	1	A	
Amisometradine	<i>Rolictron</i>	4	B	
Amisulpride	<i>Solian</i>	2	A	
Amitraz	<i>Mitaban</i>	3	B	
Amitriptyline	<i>Elavil, Amitri, Endep</i>	2	A	
Amlodipine	<i>Ammivin, Norvasc</i>	3	B	
Amobarbital	<i>Amytal</i>	2	A	
Amoxapine	<i>Asendin</i>	2	A	
Amperozide		2	A	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Amphetamine		1	A	
Amrinone		4	B	
Amyl nitrite		2	A	
<u>Anastrozole</u>		<u>3</u>	<u>B</u>	
<u>Andarine</u>		<u>2</u>	<u>A</u>	
<u>Androst-4-ene-3α,17β-diol</u>		<u>3</u>	<u>B</u>	
<u>Androst-4-ene-3β,17α-diol</u>		<u>3</u>	<u>B</u>	
<u>Androst-5-ene-3α,17α-diol</u>		<u>3</u>	<u>B</u>	
<u>Androst-5-ene-3α,17β-diol</u>		<u>3</u>	<u>B</u>	
<u>Androst-5-ene-3β,17α-diol</u>		<u>3</u>	<u>B</u>	
<u>Androsta-1,4,6-triene-3,17-dione (androstatrienedione)</u>		<u>3</u>	<u>B</u>	
<u>Androstenediol (androst-5-ene-3β, 17β-diol)</u>		<u>3</u>	<u>B</u>	
<u>Androstenedione (androst-4-ene-3, 17-dione)</u>		<u>3</u>	<u>B</u>	
<u>Androsterone (3 βhydroxy-5 α -androstan-17-one)</u>		<u>3</u>	<u>B</u>	
Anileridine	<i>Leritine</i>	1	A	
Anilopam	<i>Anisine</i>	2	A	
Anisindione		5	D	
Anisotropine	<i>Valpin</i>	4	B	
Antipyrine		4	B	
Apazone (Azapropazone)	<i>Rheumox</i>	4	B	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Apomorphine		1	A	
Aprindine		4	B	
Aprobarbital	<i>Alurate</i>	2	A	
<u>ARA-290</u>		<u>1</u>	<u>A</u>	
Arecoline		3	A	
Arformoterol		3	B	
<u>Aripiprazole</u>	<u>Abilify</u>	<u>2</u>	<u>A</u>	
<u>Arsenic</u>		<u>3</u>	<u>B</u>	<u>Arsenic is present in pressure-treated lumber designated for non-residential use. Cribbing or wood chewing may result in exposure sufficient to result in concentrations in excess of the screening limit. Findings for arsenic warrant investigation into the route of exposure with mitigation to 3/C recommended when there is compelling evidence for environmental exposure rather than deliberate administration.</u>
Articaine	<i>Septocaine; Ultracaine; etc.</i>	2	B	
<u>Asialo EPO</u>		<u>1</u>	<u>A</u>	
Atenolol	<i>Tenormin</i>	3	B	
Atipamazole		2	B	
Atomoxetine	<i>Strattera</i>	2	A	
Atracurium	<i>Tracrium</i>	2	A	
Atropine		3	B	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Azacylonol	<i>Frenque</i>	2	A	
Azaperone	<i>Stresnil, Suicalm, Fentaz (with Fentanyl)</i>	2	A	
Baclofen	<i>Lioresal</i>	4	B	
Barbital	<i>Veronal</i>	2	A	
Barbiturates		2	A	
Beclomethasone	<i>Propaderm</i>	4	C	
Bemegrade	<i>Megimide, Mikedimide</i>	2	A	
Benazepril	<i>Lotrel, Lotensin</i>	3	A	
Bendroflumethiazide	<i>Naturetin</i>	4	B	
Benoxaprofen		2	B	
Benoxinate	<i>Dorsacaine</i>	4	C	
Benperidol	<i>Anquil</i>	2	A	
Bentazepam	<i>Tiadipona</i>	2	A	
Benzactizine	<i>Deprol, Bronchodilett en</i>	2	A	
Benzocaine		4	B	
Benzoctamine		2	A	
Benzodiazepines		2	A	
Benzonatate	<i>Tessalon Perles, Zonatuss</i>	2	A	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Benzphetamine	<i>Didrex</i>	2	A	
Benzthiazide		4	B	
Benztropine	<i>Cogentin</i>	2	A	
Benzylpiperazine (BZP)		1	A	
Bepriidil	<i>Bepadin</i>	4	B	
Betamethasone	<i>Betasone, etc</i>	4	C	
Betaxolol	<i>Kerlone</i>	3	B	
Bethanechol	<i>Urecholine, Duvoid</i>	4	C	
Bethanidine	<i>Esbatal</i>	3	A	
Biperiden	<i>Akineton</i>	3	A	
Biriperone		2	A	
Bisoprolol	<i>Zebeta, Bisobloc, etc.</i>	3	B	
Bisphosphonates (any)		<u>3</u>	<u>A</u>	
Bitolterol	<i>Effectin</i>	3	A	
Bolandiol (estr-4-ene3β, 17β-diol)		<u>3</u>	<u>A</u>	
Bolasterone		3	A	
Boldenone	<i>Equipoise</i>	3	B	
Boldione		3	A	
Botulinum toxin	<i>Botox</i>	<u>12</u>	A	
Bretylum	<i>Bretylol</i>	3	B	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Brimonidine	<i>Alphagan</i>	2	A	
Bromazepam	<i>Lexotan, Lectopam</i>	2	A	
Bromfenac	<i>Duract</i>	3	A	
Bromhexine	<i>Oletor, etc.</i>	4	B	
Bromisovalum	<i>Diffucord, etc.</i>	2	A	
Bromocriptine	<i>Parlodel</i>	2	A	
Bromodiphenhydramine		3	B	
Bromperidol	<i>Bromidol</i>	2	A	
Brompheniramine	<i>Dimetane, Disomer</i>	3	B	
Brotizolam	<i>Brotocol</i>	2	A	
Budesonide	<i>Pulmacort, Rhinocort</i>	4	C	
Bufexamac		3	A	
Bumetanide	<i>Bumex</i>	3	B	
Bupivacaine	<i>Marcaine</i>	2	A	
Buprenorphine	<i>Temgesic</i>	2	A	
Bupropion	<i>Wellbutrin</i>	2	A	
Buspirone	<i>Buspar</i>	2	A	
Butabarbital (Secbutobarbitone)	<i>Butacaps, Butasol, etc.</i>	2	A	
Butacaine	<i>Butyn</i>	2	A	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Butalbital (Talbutal)	<i>Fiorinal</i>	2	A	
Butamben (butyl aminobenzoate)	<i>Butesin</i>	4	C	
Butanilicaine	<i>Hostacain</i>	2	A	
Butaperazine	<i>Repoise</i>	2	A	
Butoctamide	<i>Listomin</i>	2	A	
Butorphanol	<i>Stadol, Torbugesic</i>	3	B	
Butoxycaine	<i>Stadacain</i>	4	B	
N-Butylscopolamine		4	C	
Caffeine		2	B	
Calusterone	<i>Methosorb</i>	3	A	
Camazepam	<i>Paxor</i>	2	A	
Camphor		4	C	
Candesartan	<i>Atcand</i>	3	B	
<u>Cannabidiol (CBD)</u>	<u><i>Anti-epileptic,</i></u> <u><i>analgesic</i></u>	<u>3</u>	<u>B</u>	
<u>Canrenone</u>		<u>4</u>	<u>C</u>	
Capsaicin		2	B	
Captodiame	<i>Covatine</i>	2	A	
Captopril	<i>Capolen</i>	3	B	
Carazolol	<i>Carbacel,</i> <i>Conducton</i>	3	A	
Carbachol	<i>Lentin, Doryl</i>	3	B	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Carbamezapine	<i>Tegretol</i>	3	B	
<u>Carbamylated EPO</u>		<u>1</u>	<u>A</u>	
Carbazochrome		4	B	
Carbidopa + levodopa	<i>Sinemet</i>	2	A	
Carbinoxamine	<i>Clistin</i>	3	B	
Carbromol	<i>Mifudorm</i>	2	A	
<u>Cardarine (GW-501516)</u>		<u>2</u>	<u>A</u>	
Carfentanil		1	A	
Carisoprodol	<i>Rela, Soma</i>	2	B	
Carphenazine	<i>Proketazine</i>	2	A	
<u>Carpipramine</u>	<u><i>Prazinil</i></u>	<u>2</u>	<u>A</u>	
Carprofen	<i>Rimadyl</i>	4	B	
Carteolol	<i>Cartrol</i>	3	B	
Carticaine (see articaine)	<i>Septocaine; Ultracaine, etc.</i>	2	B	
Carvedilol	<i>Coreg</i>	3	B	
Cathinone	<i>khat, kat, qat, quat, chat, catha, Abyssinian tea, African tea</i>	1	A	
Celecoxib	<i>Celebrex</i>	3	B	
Cetirizine	<i>Zyrtec</i>	4	C	
Chloral betaine	<i>Beta-Chlor</i>	2	A	
Chloral hydrate	<i>Nactec, Oridrate, etc.</i>	2	A	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Chloraldehyde (chloral)		2	A	
Chloralose (Alpha-Chloralose)		2	A	
Chlordiazepoxide	<i>Librium</i>	2	A	
Chlorhexidol		2	A	
Chlormerodrin	<i>Neohydrin</i>	4	B	
Chlormezanone	<i>Trancopal</i>	2	A	
Chloroform		2	A	
Chlorophenesin	<i>Maolate</i>	4	C	
Chloroprocaine	<i>Nesacaine</i>	2	A	
Chloroquine	<i>Avloclor</i>	4	C	
Chlorothiazide	<i>Diuril</i>	4	B	
Chlorpheniramine	<i>Chlortriemton, etc.</i>	4	B	
Chlorproethazine	<i>Newiplege</i>	2	A	
Chlorpromazine	<i>Thorazine, Largactil</i>	1	A	
Chlorprothixene	<i>Taractan</i>	2	A	
Chlorthalidone	<i>Hydroton</i>	4	B	
Chlorzoxazone	<i>Paraflex</i>	4	B	
<u>Chorionic Gonadotropin (CG)</u>		<u>3</u>	<u>B</u>	<u>Class 3/B for geldings, colts, adult intact males, spayed females only. Penalty Class 4/D for intact females.</u>
Ciclesonide		4	C	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Cilostazol	<i>Pletal</i>	4	B	
Cimeterol		3	A	
Cimetidine	<i>Tagamet</i>	5	D	
Cinchocaine	<i>Nupercaine</i>	2	B	
Citalopram	<i>Celex</i>	2	A	
Clanobutin		4	B	
Clemastine	<i>Tavist</i>	3	B	
Clenbuterol	<i>Ventipulmin</i>	3	B	
Clibucaine	<i>Batrax</i>	2	A	
Clidinium	<i>Quarezan, Clindex, etc.</i>	3	B	
Clobazam	<i>Urbanyl</i>	2	A	
Clobetasol	<i>Temovate</i>	4	C	
Clocapramine		2	A	
Clocortolone	<i>Cloderm</i>	4	C	
<u>Clodronate</u>		<u>3</u>	<u>A</u>	
Clofenamide		4	B	
Clomethiazole (Chlormethiazole)		2	A	
<u>Clomiphene</u>		<u>3</u>	<u>B</u>	
Clomipramine	<i>Anafranil</i>	2	A	
Clonazepam	<i>Klonopin</i>	2	A	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Clonidine	<i>Catapres</i>	3	B	
Clorazepate	<i>Tranxene</i>	2	A	
Clormecaine	<i>Placacid</i>	2	A	
Clostebol		3	A	
Clothiapine	<i>Entermin</i>	2	A	
Clotiazepam	<i>Trecalmo, Rize</i>	2	A	
Cloxazolam	<i>Enadel, Sepazon, Tolestan</i>	2	A	
Clozapine	<i>Clozaril, Leponex</i>	2	A	
CNTO 530		<u>1</u>	<u>A</u>	
Cobalt (in excess of 25.0 ppb)		4	C	For cobalt concentrations in excess of 25.0 parts per billion (ppb) of blood serum or plasma but at or below 50.0 parts per billion (ppb) of blood serum or plasma or below.
Cobalt (in excess of 50.0 ppb)		3	B	For cobalt concentrations in excess of 50.0 parts per billion (ppb) of blood serum or plasma.
a-Cobratexin		<u>1</u>	A	
Cocaine		1	A	If the Board, the board of stewards, the hearing officer, or the administrative law judge determines that the finding of cocaine or its metabolites was unintentional and not based upon an attempt to affect the outcome of a race, they may elect to assign a Class B penalty
Codeine		1	A	
Colchicine		4	B	
Conorphone		2	A	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Corticaïne	<i>Ultracain</i>	2	A	
<u>Corticotrophind</u>		<u>3</u>	<u>B</u>	
Cortisone	<i>Cortone, etc.</i>	4	C	
Cromolyn	<i>Intel</i>	5	D	
Crotetamide		2	A	
Cyamemazine	<i>Tercian</i>	2	A	
Cyclandelate	<i>Cyclospasmol</i>	3	A	
Cyclizine	<i>Merazine</i>	3	B	
Cyclobarbitol	<i>Phanodorm</i>	2	A	
Cyclobenzaprine	<i>Flexeril</i>	4	B	
<u>Cyclofenil</u>		<u>3</u>	<u>B</u>	
Cyclomethycaine	<i>Surfacaine</i>	4	C	
Cyclothiazide	<i>Anhydron, Renazide</i>	4	B	
Cycrimine	<i>Pagitane</i>	3	B	
Cyproheptadine	<i>Periactin</i>	3	B	
Danazol	<i>Danocrine</i>	3	B	
Dantrolene	<i>Dantrium</i>	4	C	
Darbepoetin	<i>Aranesp</i>	1	A	
<u>Darbepoetin (depo)</u>		<u>1</u>	<u>A</u>	
Decamethonium	<i>Syncurine</i>	2	A	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Dehydrochloromethyltestosterone		3	A	
Dembroxol (Dembrexine)	<i>Sputolysin</i>	4	C	
Demoxepam		2	A	
Deoxycorticosterone	<i>Percortin, DOCA, Descotone, Dorcostrin</i>	4	C	
Deracoxib	<i>Deremaxx</i>	3	B	
Dermorphin		1	A	
Desipramine	<i>Norpromine, Pertofrane</i>	2	A	
Desonide	<i>Des Owen</i>	4	C	
Desoximetasone	<i>Topicort</i>	4	C	
Desoxymethyltestosterone		3	A	
Detomidine	<i>Dormosedan</i>	3	B	
Dexamethasone	<i>Azium, etc.</i>	4	C	
Dextromethorphan		4	B	
Dextromoramide	<i>Palfium, Narcolo</i>	1	A	
Dextropropoxyphene	<i>Darvon</i>	3	B	
Dezocine	<i>Dalgan</i>	2	A	
Diamorphine		1	A	
Diazepam	<i>Valium</i>	3	B	
Diazoxide	<i>Proglycem</i>	3	B	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Dibucaine	<i>Nupercainal, Cinchocaine</i>	2	B	
Dichloralphenazone	<i>Febenol, Isocom</i>	2	A	
Dichlorphenamide	<i>Daramide</i>	4	C	
Diclofenac	<i>Voltaren, Voltarol</i>	4	C	
Dicumarol	<i>Dicumarol</i>	5	D	
Diethylpropion	<i>Tepanil, etc.</i>	2	A	
Diethylthiambutene	<i>Themalon</i>	2	A	
Diflorasone	<i>Florone, Maxiflor</i>	4	C	
Diflucortolone	<i>Flu-Cortinest, etc.</i>	4	C	
Diflunisal		3	B	
Digitoxin	<i>Crytodigin</i>	4	B	
Digoxin	<i>Lanoxin</i>	4	B	
Dihydrocodeine	<i>Parcodin</i>	2	A	
Dihydroergotamine		4	B	
<u>Dihydrotestosterone (17β-hydroxy-5α-androstane-3-one)</u>		<u>3</u>	<u>B</u>	
<u>Di-isopropylamine</u>		<u>2</u>	<u>B</u>	
Dilorazepam	<i>Briantum</i>	2	A	
Diltiazem	<i>Cardizem</i>	4	B	
Dimeflin		3	A	
Dimethisoquin	<i>Quotane</i>	4	B	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Dimethylsulfoxide (DMSO)	<i>Domoso</i>	4	C	
Diphenadione		5	C	
Diphenhydramine	<i>Benadryl</i>	3	B	
Diphenoxylate	<i>Difenoxin, Lomotil</i>	4	B	
Diprenorphine	<i>M50/50</i>	2	A	
Dipyridamole	<i>Persantine</i>	3	B	
Dipyrrone	<i>Novin, Methampyrone</i>	4	<u>BC</u>	
Disopyramide	<i>Norpace</i>	4	B	
Divalproex	<i>Depakote</i>	3	A	
Dixyrazine	<i>Esucos</i>	2	A	
Dobutamine	<i>Dobutrex</i>	3	B	
<u>Donepezil</u>	<u><i>Aricept</i></u>	<u>1</u>	<u>A</u>	
Dopamine	<i>Intropin</i>	2	A	
Donepezil	<i>Aricept</i>	1	A	
Doxacurium	<i>Nuromax</i>	2	A	
Doxapram	<i>Dopram</i>	2	A	
Doxazosin		3	A	
Doxefazepam	<i>Doxans</i>	2	A	
Doxepin	<i>Adapin, Sinequan</i>	2	A	
Doxylamine	<i>Decapryn</i>	3	B	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Dromostanolone	<i>Drolban</i>	3	B	
Droperidol	<i>Inapsine, Droleptan, Innovar-Vet (with Fentanyl)</i>	2	A	
<u>Drostanolone</u>		<u>3</u>	<u>A</u>	
Duloxetine		2	A	
Dyclonine	<i>Dyclone</i>	4	C	
Dyphylline		3	B	
Edrophonium	<i>Tensilon</i>	3	B	
Eletripan	<i>Relpax</i>	3	A	
Eltenac		4	B	
Enalapril (metabolite enalaprilat)	<i>Vasotec</i>	3	A	
Enciprazine		2	A	
Endorphins		1	A	
Enkephalins		1	A	
Ephedrine		2	A	
<u>Epi-dihydrotestosterone</u>		<u>3</u>	<u>B</u>	
Epibatidine		2	A	
Epinephrine		2	A	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
<u>Epitestosterone</u>		<u>3</u>	<u>B</u>	
<u>EPO-Fc</u>		<u>1</u>	<u>A</u>	
<u>EPO-mimetic peptides (EMP)</u>		<u>1</u>	<u>A</u>	
Ergoloid mesylates (dihydroergocornine mesylate, dihydroergocristine mesylate, and dihydroergocryptine mesylate)		2	A	
Ergonovine	<i>Ergotrate</i>	4	C	
Ergotamine	<i>Gynergen, Cafergot, etc.</i>	4	B	
Erthryl tetranitrate	<i>Cardilate</i>	3	A	
Erythropoietin (EPO)	<i>Epogen, Procrit, etc.</i>	1	A	
Esmolol	<i>Brevibloc</i>	3	B	
Esomeprazole	<i>Nexium</i>	5	D	
Estazolam	<i>Domnamid, Eurodin, Nuctalon</i>	2	A	
Eszopiclone		2	A	
<u>Etacrynic acid</u>		<u>3</u>	<u>B</u>	
Etamiphylline		3	B	
Etanercept	<i>Enbrel</i>	4	B	
Ethacrynic acid	<i>Edecrin</i>	3	B	
Ethamivan		2	A	
Ethanol		2	A	
Ethchlorvynol	<i>Placidyl</i>	2	A	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Ethinamate	<i>Valmid</i>	2	A	
Ethoheptazine	<i>Zactane</i>	2	A	
Ethopropazine	<i>Parsidol</i>	2	A	
Ethosuximide	<i>Zarontin</i>	3	A	
Ethotoin	<i>Peganone</i>	4	B	
Ethoxzolamide	<i>Cardrase, Ethamide</i>	4	C	
Ethylaminobenzoate (Benzocaine)	<i>Semets, etc.</i>	4	C	
Ethylestrenol	<i>Maxibolin, Organon</i>	3	B	
Ethylisobutrazine	<i>Diquel</i>	2	A	
Ethylmorphine	<i>Dionin</i>	1	A	
Ethylnorepinephrine	<i>Bronkephrine</i>	3	A	
Ethylphenidate		1	A	
Etidocaine	<i>Duranest</i>	2	A	
Etifoxin	<i>Stresam</i>	2	A	
<u>Etiocholanolone</u>		<u>3</u>	<u>B</u>	
Etizolam	<i>Depas, Pasaden</i>	2	A	
<u>Ethamsylate</u>		<u>4</u>	<u>B</u>	
Etodolac	<i>Lodine</i>	3	B	
Etodroxizine	<i>Indunox</i>	2	A	
Etomidate		2	A	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Etorphine HCl	<i>M99</i>	1	A	
<u>Exemestane</u>	<u><i>Aromatase inhibitors</i></u>	<u>3</u>	<u>B</u>	
Famotidine	<i>Gaster, etc.</i>	5	D	
Felbamate	<i>Felbatol</i>	3	B	
Felodipine	<i>Plendil</i>	4	B	
Fenarbamate	<i>Tymium</i>	2	A	
Fenbufen	<i>Cincopal</i>	3	B	
Fenclozic acid	<i>Myalex</i>	2	B	
Fenfluramine	<i>Pondimin</i>	2	A	
Fenoldopam	<i>Corlopam</i>	3	B	
Fenoprofen	<i>Nalfon</i>	3	B	
Fenoterol	<i>Berotec</i>	3	B	
Fenspiride	<i>Respiride, Respan, etc</i>	3	B	
Fentanyl	<i>Sublimaze</i>	1	A	
Fentiazac		3	B	
Fexofenadine	<i>Allegra</i>	4	C	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
<u>Fibroblast Growth Factors (fgfs), Hepatocyte Growth Factor (HGF), Insulinlike Growth Factor-1 (IGF-1) and its analogues, Mechano Growth Factors (mgfs), Platelet-Derived Growth Factor (PDGF), Vascular-Endothelial Growth Factor (VEGF) and any other growth factor affecting muscle, tendon or ligament protein synthesis/ degradation, vascularization, energy utilization, regenerative capacity or fiber type switching.</u>		<u>3</u>	<u>A</u>	
Firocoxib		4	C	
Flecainide	<i>Idalon</i>	4	B	
Floctafenine	<i>Idalon, Idarac</i>	4	B	
Fluanisone	<i>Sedalande</i>	2	A	
Fludiazepam	<i>Erispam</i>	2	A	
Fludrocortisone	<i>Alforone, etc.</i>	4	C	
Flufenamic acid		3	B	
Flumethasone	<i>Flucort, etc.</i>	4	C	
Flumethiazide	<i>Ademol</i>	4	B	
Flunarizine	<i>Sibelium</i>	4	B	
Flunisolide	<i>Bronilide, etc.</i>	4	C	
Flunitrazepam	<i>Rohypnol, Narcozep, Darkene, Hypnodorm</i>	2	A	
Flunixin	<i>Banamine</i>	4	C*	
Fluocinolone	<i>Synalar</i>	4	C	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Fluocinonide	<i>Licon, Lidex</i>	4	C	
Fluopromazine	<i>Psyquil, Siquil</i>	2	A	
Fluoresone	<i>Caducid</i>	2	A	
Fluorometholone	<i>FML</i>	4	C	
Fluoroprednisolone		4	B	
Fluoxetine	<i>Prozac</i>	2	A	
Fluoxymesterone	<i>Halotestin</i>	3	B	
Flupenthixol	<i>Depixol, Fluanxol</i>	2	A	
Fluphenazine	<i>Prolixin, Permitil, Anatensol, etc.</i>	2	B	
Flupirtine	<i>Katadolone</i>	3	A	
Fluprednisolone	<i>Alphadrol</i>	4	C	
Flurandrenolide	<i>Cordran</i>	4	C	
Flurazepam	<i>Dalmane</i>	2	A	
Flurbiprofen	<i>Froben</i>	3	B	
Fluspirilene	<i>Imap, Redeptin</i>	2	A	
Fluticasone	<i>Flixonase, Flutide</i>	4	C	
Flutoprazepam	<i>Restas</i>	2	A	
Fluvoxamine	<i>Dumirox, Faverin, etc.</i>	2	A	
Formebolone		3	A	
Formestane	<i>Aromatase inhibitors</i>	<u>3</u>	<u>B</u>	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Formoterol	<i>Altram</i>	3	B	
Fosinopril	<i>Monopril</i>	3	A	
Fosphenytoin	<i>Cerebyx</i>	3	B	
<u>Fulvestrant</u>		<u>3</u>	<u>B</u>	
Furazabol		3	A	
Furosemide	<i>Lasix</i>	N/A	<u>C</u>	
Gabapentin	<i>Neurontin</i>	3	B	
Galantamine	<i>Reminyl</i>	2	A	
Gallamine	<i>Flaxedil</i>	2	A	
Gamma Aminobutyric Acid (GABA)	<i>Carolina Gold</i>	3	B	
Gepirone		2	A	
Gestrinone		3	A	
<u>GH-Releasing Peptides (ghrps), e.g., alexamorelin, GHRP-6, hexarelin and pralmorelin (GHRP-2)</u>		<u>3</u>	<u>A</u>	
Glutethimide	<i>Doriden</i>	2	A	
Glycopyrrolate	<i>Robinul</i>	4	C	
<u>Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g., CJC1295, sermorelin and tesamorelin</u>		<u>3</u>	<u>A</u>	
<u>Growth Hormone Secretagogues (GHS), e.g., ghrelin and ghrelin mimetics, e.g., anamorelin and ipamorelin</u>		<u>3</u>	<u>A</u>	
Guaifenesin (glycerol guaiacolate)	<i>Gecolate</i>	4	C	
<u>Guanabenz</u>	<i>Wytensin</i>	<u>3</u>	<u>B</u>	
Guanadrel	<i>Hylorel</i>	3	A	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Guanethidine	<i>Ismelin</i>	3	A	
Guanabenz	<i>Wytensin</i>	3	B	
Halazepam	<i>Paxipam</i>	2	A	
Halcinonide	<i>Halog</i>	4	C	
Halobetasol	<i>Ultravate</i>	4	C	
Haloperidol	<i>Haldol</i>	2	A	
Haloxazolam	<i>Somelin</i>	2	A	
<u>Harpagoside</u>	<u><i>"Devil's Claw"</i></u>	<u>4</u>	<u>B</u>	
Hemoglobin glutamers	<i>Oxyglobin Hemopure</i>	2	A	
Heptaminol	<i>Corofundol</i>	3	B	
Heroin		1	A	
Hexafluorenum	<i>Myalexen</i>	2	A	
Hexobarbital	<i>Evipal</i>	2	A	
Hexocyclium	<i>Tral</i>	4	B	
Hexylcaine	<i>Cyclaine</i>	2	B	
<u>HIF activators (e.g. Argon, xenon)</u>		<u>3</u>	<u>A</u>	
Homatropine	<i>Homapin</i>	3	B	
Homophenazine	<i>Pelvichthol</i>	2	A	
Hydralazine	<i>Apresoline</i>	3	B	
Hydrochlorthiazide	<i>Hydrodiuril</i>	4	B	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Hydrocodone(dihydrocodienone)	<i>Hycodan</i>	1	A	
Hydrocortisone (Cortisol)	<i>Cortef, etc.</i>	4	C	
Hydroflumethiazide	<i>Saluron</i>	4	B	
Hydromorphone	<i>Dilaudid</i>	1	A	
Hydroxyamphetamine	<i>Paradrine</i>	1	A	
4-hydroxytestosterone		3	B	
Hydroxyzine	<i>Atarax</i>	2	B	
<u>Hypoxia-inducible factor (HIF) activators</u>		<u>1</u>	<u>A</u>	
<u>Hypoxia-inducible factor (HIF) stabilizers (e.g. IOX-2)</u>		<u>1</u>	<u>A</u>	
Ibomal	<i>Noctal</i>	2	A	
Ibuprofen	<i>Motrin, Advil, Nurpin, etc.</i>	4	C	
Ibutilide	<i>Corvert</i>	3	B	
Iloprost	<i>Ventavis</i>	3	A	
Imipramine	<i>Imavate, Presamine, Tofranil</i>	2	A	
<u>Indapamide</u>		<u>3</u>	<u>C</u>	
Indomethacin	<i>Indocin</i>	3	B	
Infliximab	<i>Remicade</i>	4	B	
<u>Insulins</u>		<u>3</u>	<u>B</u>	
Ipratropium		3	B	
Irbesarten	<i>Avapro</i>	3	A	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Isapirone		2	A	
Isocarboxazid	<i>Marplan</i>	2	A	
Isoetharine	<i>Bronkosol</i>	3	B	
Isoflupredone	<i>Predef 2x</i>	4	C	
Isomethadone		2	A	
Isometheptene	<i>Octin, Octon</i>	4	B	
Isopropamide	<i>Darbid</i>	4	B	
Isoproterenol	<i>Isoprel</i>	2	A	
Isosorbide dinitrate	<i>Isordil</i>	3	B	
Isoxicam	<i>Maxicam</i>	2	B	
Isoxsuprine	<i>Vasodilan</i>	4	D	
Isradipine	<i>DynaCirc</i>	4	B	
Kebuzone		3	B	
Ketamine	<i>Ketalar, Ketaset, Vetalar</i>	2	B	
Ketazolam	<i>Anxon, Laftram, Solatran, Loftran</i>	2	A	
Ketoprofen	<i>Orudis</i>	4	C*	
Ketorolac	<i>Toradol</i>	3	A	
Labetalol	<i>Normodyne</i>	3	B	
Lamotrigine	<i>Lamictal</i>	3	A	
Lansoprazole		5	D	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Lenperone	<i>Elanone-V</i>	2	A	
Letosteine	<i>Viscotiol, Visiotal</i>	4	B	
Letrozole		3	A	
Levamisole		2	B	
Levobunolol	<i>Betagan</i>	3	B	
Levomethorphan		2	A	
Levorphanol	<i>Levo- Dremoran</i>	1	A	
Lidocaine	<i>Xylocaine</i>	2	B	
<u>Ligandrol</u>		<u>2</u>	<u>A</u>	
Lisinopril	<i>Prinivil, Zestril</i>	3	A	
Lithium	<i>Lithizine, Duralith, etc.</i>	2	A	
Lobeline		2	A	
Lofentanil		1	A	
Loflazepate, Ethyl	<i>Victan</i>	2	A	
Loperamide	<i>Imodium</i>	3	B	
Loprazolam	<i>Dormonort, Havlane</i>	2	A	
Loratidine	<i>Claritin</i>	4	C	
Lorazepam	<i>Ativan</i>	2	A	
Lormetazepam	<i>Noctamid</i>	2	A	
Losartan	<i>Hyzaar</i>	3	B	
Loxapine	<i>Laxitane</i>	2	A	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
<u>Luteinizing Hormone (LH)</u>		<u>3</u>	<u>B</u>	<u>Class 3/B for geldings, colts, adult intact males, spayed females only. Penalty Class 4/D for intact females.</u>
Mabuterol		3	A	
Maprotiline	<i>Ludiomil</i>	2	A	
Mazindol	<i>Sanorex</i>	1	A	
Mebutamate	<i>Axiten, Dormate, Capla</i>	2	A	
Mecamylamine	<i>Inversine</i>	3	B	
Meclizine	<i>Antivert, Bonine</i>	3	B	
Meclofenamic acid	<i>Arquel</i>	4	C	
Meclofenoxate	<i>Lucidril, etc.</i>	2	A	
Medazepam	<i>Nobrium, etc.</i>	2	A	
Medetomidine	<i>Domitor</i>	3	B	
<u>Medroxyprogesterone</u>	<u><i>Depo-Provera</i></u>	4	C	<u>Classification for geldings, colts, adult intact males, spayed females only. Penalty Class 4/D for intact females.</u>
Medrysone	<i>Medriusar, etc.</i>	4	C	
Mefenamic acid	<i>Ponstel</i>	3	B	
Meldonium	<i>Mildronate, et al</i>	1	A	
Meloxicam	<i>Mobic</i>	4	B	
Melperone	<i>Eunerpan</i>	2	A	
Memantine	<i>Namenda</i>	2	A	
Meparfynol	<i>Oblivon</i>	2	A	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Mepazine	<i>Pacatal</i>	2	A	
Mepenzolate	<i>Cantil</i>	3	B	
Meperidine	<i>Demerol</i>	1	A	
Mephenesin	<i>Tolserol</i>	4	B	
Mephenoxalone	<i>Control, etc.</i>	2	A	
Mephentermine	<i>Wyamine</i>	1	A	
Mephénytoin	<i>Mesantoin</i>	2	A	
Mephobarbital (Methylphenobarbital)	<i>Mebaral</i>	2	A	
Mepivacaine	<i>Carbocaine</i>	2	B	
Meproamate	<i>Equanil, Miltown</i>	2	A	
Meralluride	<i>Mercurydrin</i>	4	B	
Merbaphen	<i>Novasural</i>	4	B	
Mercaptomerin	<i>Thiomerin</i>	4	B	
Mercumatilin	<i>Cumertilin</i>	4	B	
Mersalyl	<i>Salyrgan</i>	4	B	
Mesalamine	<i>Asacol</i>	5	C	
Mesoridazine	<i>Serentil</i>	2	A	
Mestanolone		3	A	
Mesterolone		3	A	
Metaclazepam	<i>Talis</i>	2	A	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
<u>Metandienone</u>		<u>3</u>	<u>A</u>	
Metaproterenol	<i>Alupent, Metaprel</i>	3	B	
Metaraminol	<i>Aramine</i>	1	A	
Metaxalone	<i>Skelaxin</i>	4	B	
Metazocine		2	A	
<u>Metenolone</u>		<u>3</u>	<u>A</u>	
Metformin		2	B	
Metenolone		3	A	
Methacholine		3	A	
Methadone	<i>Dolophine</i>	1	A	
Methamphetamine	<i>Desoxyn</i>	1	A	If the Board, the board of stewards, the hearing officer, or the administrative law judge determines that the finding of methamphetamine or its metabolites was unintentional and not based upon an attempt to affect the outcome of a race, or if testing shows only the presence of levo-methamphetamine in the sample, they may elect to assign a Class B penalty. Recommended Penalty B if testing can prove presence of only levo-methamphetamine is present in sample.
Methandrostenolone	<i>Dianobal</i>	3	A	
Methandriol (Methylandrostenediol)	<i>Probolis</i>	3	A	
<u>Methandrostenolone</u>	<u><i>Dianobal</i></u>	<u>3</u>	<u>A</u>	
Methantheline	<i>Banthine</i>	3	B	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Methapyrilene	<i>Histadyl, etc.</i>	3	B	
Methaqualone	<i>Quaalude</i>	1	A	
Metharbital	<i>Gemonil</i>	2	A	
Methasterone		3	A	
Methazolamide	<i>Naptazane</i>	4	C	
Methcathinone		1	A	
Methdilazine	<i>Tacaryl</i>	3	B	
<u>Methenolone</u>	<u><i>Primobolan</i></u>	<u>3</u>	<u>A</u>	
Methixene	<i>Trest</i>	3	A	
Methocarbamol	<i>Robaxin</i>	4	C	
Methohexital	<i>Brevital</i>	2	A	
Methotrexate	<i>Folex, Nexate, etc.</i>	4	B	
Methotrimeprazine	<i>Levoprome, Neurocil, etc.</i>	2	A	
Methoxamine	<i>Vasoxyl</i>	3	A	
Methoxyphenamine	<i>Orthoxide</i>	3	A	
<u>Methoxypolyethylene glycol-epoetin beta (CERA)</u>		<u>1</u>	<u>A</u>	
Methscopolamine	<i>Pamine</i>	4	B	
Methsuximide	<i>Celontin</i>	4	B	
Methylatropine		3	B	
Methyclothiazide	<i>Enduron</i>	4	B	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
<u>Methyl-1-testosterone</u>		<u>3</u>	<u>A</u>	
<u>Methylatropine</u>		<u>3</u>	<u>B</u>	
Methyldienolone		3	A	
Methyldopa	<i>Aldomet</i>	3	A	
Methylhexanaine (Methylhexaneamine)	<i>Geranamine</i>	4	A	
Methylergonovine	<i>Methergine</i>	4	C	
<u>Methylhexanamine (Methylhexaneamine)</u>	<u><i>Geranamine</i></u>	<u>1</u>	<u>A</u>	
Methylnortestosterone (Trestolone)		3	A	
Methylphenidate	<i>Ritalin</i>	1	A	
Methylprednisolone	<i>Medrol</i>	4	C	
Methyltestosterone	<i>Metandren</i>	3	B	
Methyl 1 testosterone		3	A	
Methyprylon	<i>Noludar</i>	2	A	
Methysergide	<i>Sansert</i>	4	B	
Metiamide		4	B	
Metoclopramide	<i>Reglan</i>	4	C	
Metocurine	<i>Metubine</i>	2	A	
Metolazone		3	B	
Metomidate	<i>Hypnodil</i>	2	A	
Metopon (methyldihydromorphinone)		1	A	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Metoprolol	<i>Lopressor</i>	3	B	
<u>Metribolone</u>		<u>3</u>	<u>A</u>	
Mexazolam	<i>Melex</i>	2	A	
Mexiletine	<i>Mexitil</i>	4	B	
Mibefradil	<i>Posicor</i>	3	B	
Mibolerone		3	B	
Midazolam	<i>Versed</i>	3	B	
Midodrine	<i>Pro-Amiline</i>	3	B	
<u>Milrinone</u>		4	B	
Minoxidil	<i>Loniten</i>	3	B	
Mirtazepine	<i>Remeron</i>	2	A	
Misoprostol	<i>Cytotec</i>	5	D	
Mitragynine	<i>Kratom</i>	1	A	
Mivacurium	<i>Mivacron</i>	2	A	
Modafinil	<i>Provigil</i>	2	A	
Moexipril (metabolite, moexiprilat)	<i>Uniretic</i>	3	B	
Molindone	<i>Moban</i>	2	A	
Mometasone	<i>Elocon</i>	4	C	
Montelukast	<i>Singulair</i>	4	C	
Moperone	<i>Luvatren</i>	2	A	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Morphine		1	A6	If the Board, the board of stewards, the hearing officer, or the administrative law judge determines that the finding of morphine was unintentional and not based upon an attempt to affect the outcome of a race, the Stewards or Board may elect to assign a Class B penalty.
Mosaprimine		2	A	
Muscarine		3	A	
myo-inositoltrispyrophosphate (ITPP)		1	A	
<u>N-Butylscopolamine</u>		<u>4</u>	<u>C</u>	
Nabumetone	<i>Anthraxan, Relafen, Reliflex</i>	3	A	
Nadolol	<i>Corgard</i>	3	B	
Naepaine	<i>Amylsine</i>	2	A	
Nalbuphine	<i>Nubain</i>	2	A	
Nalorphine	<i>Nalline</i>	2	A	
Naloxone	<i>Narcan</i>	3	B	
Naltrexone	<i>Revia</i>	3	B	
<u>Nandrolone</u>	<i><u>Nandrolin, Laurabolin, Durabolin</u></i>	<u>3</u>	<u>B</u>	
Naphazoline	<i>Privine</i>	4	B	
Naproxen	<i>Equiproxen, Naprosyn</i>	4	C	
Naratriptan	<i>Amerge</i>	3	B	
Nebivolol		3	A	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Nedocromil	<i>Tilade</i>	5	D	
Nefazodone	<i>Serzone</i>	2	A	
Nefopam		3	A	
Neostigmine	<i>Prostigmine</i>	3	B	
Nicardipine	<i>Cardine</i>	4	B	
Nifedipine	<i>Procardia</i>	4	B	
Niflumic acid	<i>Nifluril</i>	3	B	
Nikethamide	<i>Coramine</i>	1	A	
Nimesulide		3	B	
Nimetazepam	<i>Erimin</i>	2	A	
Nimodipine	<i>Nemotop</i>	4	B	
Nitrazepam	<i>Mogadon</i>	2	A	
Nitroglycerin		2	B	
Nizatidine	<i>Axid</i>	5	D	
19-norandrostenediol		3	B	
19-norandrostenedione		3	B	
<u>Norandrosterone</u>		<u>3</u>	<u>B</u>	
Norbolethone/Norboletone		3	A	
Norclostebol		3	A	
Nordiazepam	<i>Calmday, Nordaz, etc.</i>	2	A	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
<u>Norethisterone (norethindrone)</u>		4	<u>B</u>	Same penalty for all genders.
Norepinephrine		2	A	
Norethandrolone		3	A	
Nortestosterone		3	B	
Nortriptyline	<i>Aventyl, Pamelor</i>	2	A	
Nylidrine	<i>Arlidin</i>	3	A	
Olanzapine	<i>Zyprexa</i>	2	A	
<u>Oliceridine</u>		<u>1</u>	<u>A</u>	
Olmesartan	<i>Benicar</i>	3	A	
Olsalazine	<i>Dipentum</i>	5	C	
Omeprazole	<i>Prilosec, Losec</i>	5	D	
<u>Oripavine</u>		<u>2</u>	<u>A</u>	
Orphenadrine	<i>Norlfex</i>	4	B	
<u>Ostarine</u>		<u>2</u>	<u>A</u>	
Oxabolone		3	A	
Oxandrolone	<i>Anavar</i>	3	B	
Oxaprozin	<i>Daypro, Deflam</i>	4	B	
Oxazepam	<i>Serax</i>	2	A	
Oxazolam	<i>Serenal</i>	2	A	
Oxcarbazepine	<i>Trileptal</i>	3	A	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Oxilofrine (hydroxyephedrine)		2	A	
Oxprenolol	<i>Trasicor</i>	3	A	
Oxycodone	<i>Percodan</i>	1	A	
Oxymesterone		3	A	
Oxymetazoline	<i>Afrin</i>	4	B	
Oxymetholone	<i>Adroyd, Anadrol</i>	3	B	
Oxymorphone	<i>Numorphan</i>	1	A	
Oxyperitine	<i>Forit, Integrin</i>	2	A	
Oxyphenbutazone	<i>Tandearil</i>	4	C	
Oxyphencyclimine	<i>Daricon</i>	4	B	
Oxyphenonium	<i>Antrenyl</i>	4	B	
Paliperidone		2	A	
Pancuronium	<i>Pavulon</i>	2	A	
Pantoprazole	<i>Protonix</i>	5	D	
Papaverine	<i>Pavagen, etc.</i>	3	A	
<u>Parecoxib</u>		<u>4</u>	<u>B</u>	
Paraldehyde	<i>Paral</i>	2	A	
Paramethadione	<i>Paradione</i>	3	A	
Paramethasone	<i>Haldrone</i>	4	C	
Pargyline	<i>Eutonyl</i>	3	A	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Paroxetine	<i>Paxil, Seroxat</i>	2	A	
<u>Peginesatide</u>		<u>1</u>	<u>A</u>	
Pemoline	<i>Cylert</i>	1	A	
Penbutolol	<i>Levitol</i>	3	B	
Penfluridol	<i>Cyperon</i>	2	A	
Pentaerythritol tetranitrate	<i>Duotrate</i>	3	A	
Pentazocine	<i>Talwin</i>	3	B	
Pentobarbital	<i>Nembutal</i>	2	A	
Pentoxifylline	<i>Trental, Vazofirin</i>	4	D	
Pentylene-tetrazol	<i>Metrazol, Nioric</i>	1	A	
Perazine	<i>Taxilan</i>	2	A	
Perfluorodecolin		<u>2</u>	A	
<u>Perfluorocarbons</u>		<u>2</u>	<u>A</u>	
Perfluorodecahydronophthalene		2	A	
<u>Perfluorodecolin</u>		<u>2</u>	<u>A</u>	
Perfluorooctylbromide		2	A	
Perfluorotripropylamine		2	A	
Perfluorocarbons		2	A	
Pergolide	<i>Permax</i>	3	B	
Periciazine	<i>Alodept, etc.</i>	2	A	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Perindopril	<i>Biprel</i>	3	A	
Perlazine	<i>Hypnodin</i>	2	A	
Perphenazine	<i>Trilafon</i>	2	A	
Phenacetamide	<i>Phenurone</i>	4	B	
Phenaglycodol	<i>Acalo, Alcamid, etc.</i>	2	A	
Phenazocine	<i>Narphen</i>	1	A	
Phencyclidine (PCP)	<i>Sernylan</i>	1	A	
Phendimetrazine	<i>Bontril, etc.</i>	1	A	
Phenelzine	<i>Nardelzine, Nardil</i>	2	A	
Phenindione	<i>Hedulin</i>	5	D	
Phenmetrazine	<i>Preludin</i>	1	A	
Phenobarbital	<i>Luminal</i>	2	A	
Phenoxybenzamine	<i>Dibenzyline</i>	3	B	
Phenprocoumon	<i>Liquamar</i>	5	D	
Phensuximide	<i>Milontin</i>	4	B	
Phentermine	<i>Iomamin</i>	2	A	
Phentolamine	<i>Regitine</i>	3	B	
Phenylbutazone	<i>Butazolidin</i>	4	C*	
Phenylephrine	<i>Isophrin, Neo-Synephrine</i>	3	B	
Phenylpropanolamine	<i>Propadrine</i>	3	B	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Phenytoin	<i>Dilantin</i>	4	B	
Physostigmine	<i>Eserine</i>	3	A	
Picrotoxin		1	A	
Piminodine	<i>Alvodine, Cimadon</i>	2	A	
Pimobendan		2	B	
Pimozide	<i>Orap</i>	2	A	
Pinazepam	<i>Domar</i>	2	A	
Pindolol	<i>Viskin</i>	3	B	
Pipamperone	<i>Dipiperon</i>	2	A	
Pipecuronium	<i>Arduan</i>	2	A	
Pipequaline		2	A	
Piperacetazine	<i>Psymod, Quide</i>	2	A	
Piperocaine	<i>Metycaine</i>	2	A	
Pipotiazine	<i>Lonseren, Piportil</i>	2	A	
Pipradrol	<i>Dataril, Gerondyl, etc.</i>	2	A	
Piquindone		2	A	
Pirbuterol	<i>Maxair</i>	3	B	
Pirenzepine	<i>Gastrozepin</i>	5	C	
Piretanide	<i>Arelix, Tauliz</i>	3	B	
Piritramide		1	A	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Piroxicam	<i>Feldene</i>	4	B	
<u>Plasma expanders (e.g. Bycerol; intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol)</u>		<u>3</u>	<u>A</u>	
Polyethylene glycol		5	D	
Polythiazide	<i>Renese</i>	4	B	
Pramoxine	<i>Tronothaine</i>	4	C	
<u>Prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en17-one)</u>		<u>3</u>	<u>B</u>	
Prazepam	<i>Verstran, Centrax</i>	2	A	
Prazosin	<i>Minipress</i>	3	B	
Prednisolone	<i>Delta-Cortef, etc.</i>	4	C	
Prednisone	<i>Meticorten, etc.</i>	4	C	
<u>Pregabalin</u>	<u><i>Lyrica</i></u>	<u>3</u>	<u>B</u>	
Prilocaine	<i>Citanest</i>	2	B	
Primidone	<i>Mysoline</i>	3	B	
Probenecid		4	C	
Procainamide	<i>Pronestyl</i>	4	B	
Procaine		3	B	
Procaterol	<i>Pro Air</i>	3	A	
Prochlorperazine	<i>Darbazine, Compazine</i>	2	A	
Procyclidine	<i>Kemadrin</i>	3	B	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Promazine	<i>Sparine</i>	3	B	
Promethazine	<i>Phenergan</i>	3	B	
Propafenone	<i>Rythmol</i>	4	B	
Propanidid		2	A	
Propantheline	<i>Pro-Banthine</i>	3	B	
Proparacaine	<i>Ophthaine</i>	4	C	
Propentophylline	<i>Karsivan</i>	3	B	
Propiomazine	<i>Largon</i>	2	A	
Propionylpromazine	<i>Tranvet</i>	2	A	
Propiram		2	A	
Propofol	<i>Diprivan, Disoprivan</i>	2	A	
Propoxycaine	<i>Ravocaine</i>	2	A	
Propranolol	<i>Inderal</i>	3	B	
Propylhexedrine	<i>Benzedrex</i>	4	B	
Prostanazol		3	A	
Prothipendyl	<i>Dominal</i>	2	A	
Protokylol	<i>Ventaire</i>	3	A	
Protriptyline	<i>Concordin, Triptil</i>	2	A	
Proxibarbital	<i>Axeen, Centralgol</i>	2	A	
Pseudoephedrine	<i>Cenafed, Novafed</i>	3	B	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Pyridostigmine	<i>Mestinon, Regonol</i>	3	B	
Pyrilamine	<i>Neoantergan, Equihist</i>	3	B	
Pyrithyldione	<i>Hybersulfan, Sonodor</i>	2	A	
Quazipam	<i>Doral</i>	2	A	
Quetiapine	<i>Seroquel</i>	2	A	
Quinbolone		3	A	
Quinapril, Quinaprilat	<i>Accupril</i>	3	A	
<u>Quinbolone</u>		<u>3</u>	<u>A</u>	
Quinidine	<i>Quinidex, Quinocardine</i>	4	B	
Rabeprazole	<i>Aciphex</i>	5	D	
Racemethorphan		2	A	
Racemorphan		2	A	
Raclopride		2	A	
Ractopamine	<i>Paylean</i>	2	A	If the Board, the board of stewards, the hearing officer, or the administrative law judge determines that the finding of ractopamine was unintentional and not based upon an attempt to affect the outcome of a race, they may elect to assign a Class B penalty.
<u>Raloxifene</u>		<u>3</u>	<u>B</u>	
Ramipril, metabolite Ramiprilat	<i>Altace</i>	3	A	
Ranitidine	<i>Zantac</i>	5	D	
Remifentanil	<i>Ultiva</i>	1	A	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Remoxipride	<i>Roxiam</i>	2	A	
Reserpine	<i>Serpasil</i>	2	B	
Rilmazafone		2	A	
Risperidone		2	A	
Ritanserlin		2	A	
Ritodrine	<i>Yutopar</i>	3	B	
Rivastigmine	<i>Exelon</i>	2	A	
Rizatriptan	<i>Maxalt</i>	3	B	
Rocuronium	<i>Zemuron</i>	2	A	
Rofecoxib	<i>Vioxx</i>	2	B	
Romifidine	<i>Sedivet</i>	3	B	
Ropivacaine	<i>Naropin</i>	2	A	
<u>Roxadustat (FG-4592)</u>		<u>1</u>	<u>A</u>	
Salicylamide		4	C	
Salicylate		4	C	
Salmeterol		3	B	
Scopolamine (Hyoscine)	<i>Triptone</i>	4	C	
Secobarbital (Quinalbarbitone)	<i>Seconal</i>	2	A	
<u>Selective Androgen Receptor Modulators (SARMs)</u>		<u>2</u>	<u>A</u>	
Selegiline	<i>Eldepryl, Jumex, etc.</i>	2	A	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Sertraline	<i>Lustral, Zoloft</i>	2	A	
Sibutramine	<i>Meridia</i>	3	B	
Sildenafil	<i>Viagra</i>	3	A	
<u>Snake Venoms</u>		<u>1</u>	<u>A</u>	
Somatropin	<i>Nutropin</i>	2	A	
Somatrem	<i>Protropin</i>	2	A	
<u>Somatropin</u>	<u><i>Nutropin</i></u>	<u>2</u>	<u>A</u>	
Sotalol	<i>Betapace, Sotacor</i>	3	B	
Spiclomazine		2	A	
Spiiperone		2	A	
Spirapril, metabolite Spiraprilat	<i>Renomax</i>	3	A	
Spironalactone	<i>Aldactone</i>	4	B	
<u>Spiironolactone</u>	<u><i>Diuretic</i></u>	<u>3</u>	<u>C</u>	
Stanozolol	<i>Winstrol-V</i>	3	B	
Stenbolone		3	A	
Strychnine		1	A	
Succinylcholine	<i>Sucostrin, Quelin, etc.</i>	2	A	
Sufentanil	<i>Sufenta</i>	1	A	
Sulfasalazine	<i>Azulfidine, Azaline</i>	4	C	
Sulfondiethylmethane		2	A	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Sulfonmethane		2	A	
Sulforidazine	<i>Inofal</i>	2	A	
Sulindac	<i>Clinoril</i>	3	B	
Sulpiride	<i>Aiglonyl, Sulpitil</i>	2	A	
Sultopride	<i>Barnetil</i>	2	A	
Sumatriptan	<i>Imitrex</i>	3	B	
Synthetic cannabis	<i>Spice, K2, Kronic</i>	1	A	
Tadalafil	<i>Cialis</i>	3	A	
Talbutal	<i>Lotusate</i>	2	A	
<u>Tamoxifen</u>		<u>3</u>	<u>B</u>	
Tandospirone		2	A	
<u>Tapentadol</u>	<u><i>Nucynta</i></u>	<u>1</u>	<u>A</u>	
TCO2		3	B	
Telmisartan	<i>Micardis</i>	3	B	
Temazepam	<i>Restoril</i>	2	A	
Tenoxicam	<i>Alganex, etc.</i>	3	B	
Tepoxalin		3	B	
Terazosin	<i>Hytrin</i>	3	A	
Terbutaline	<i>Brethine, Bricanyl</i>	3	B	
Terfenadine	<i>Seldane, Triludan</i>	4	C	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Testolactone	<i>Teslac</i>	3	B	
<u>Testolone</u>		<u>2</u>	<u>A</u>	
Testosterone		3	B	
Tetrabenazine	<i>Nitoman</i>	2	A	
Tetracaine	<i>Pontocaine</i>	2	A	
Tetrahydrogestrinone		3	A	
Tetrahydrozoline	<i>Tyzine</i>	4	B	
Tetrazepam	<i>Musaril, Myolastin</i>	2	A	
<u>THC (tetrahydrocannabinol)</u>	<u>Drug of human abuse</u>	<u>1</u>	<u>A</u>	
Thebaine		2	A	
Theobromine		4	B	
Theophylline	<i>Aqualphyllin, etc.</i>	3	B	
Thialbarbital	<i>Kemithal</i>	2	A	
Thiamylal	<i>Surital</i>	2	A	
Thiethylperazine	<i>Torecan</i>	2	A	
Thiopental	<i>Pentothal</i>	2	A	
Thiopropazate	<i>Dartal</i>	2	A	
Thiopropazine	<i>Majeptil</i>	2	A	
Thioridazine	<i>Mellaril</i>	2	A	
Thiosalicylate		4	B	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Thiothixene	<i>Navane</i>	2	A	
Thiphenamil	<i>Trocinate</i>	4	B	
<u>Thyroxine and thyroid modulators/hormones, including but not limited to those containing T4 (tetraiodothyronine/thyroxine), T3 (triiodothyronine), or combinations thereof.</u>	<i>Levothyroxine</i>	<u>3</u>	<u>C</u>	
Tiapride	<i>Italprid, Luxoben, etc.</i>	2	A	
Tiaprofenic acid	<i>Surgam</i>	3	B	
<u>Tibolone</u>		<u>3</u>	<u>A</u>	
<u>Tildronate Sodium</u>		<u>3</u>	<u>A</u>	
Tiletamine	<i>Component of Telazol</i>	2	A	
Timiperone	<i>Tolopelon</i>	2	A	
Timolol	<i>Blocardrin</i>	3	B	
Tocainide	<i>Tonocard</i>	4	B	
Tofisopam	<i>Grandaxain, Seriel</i>	2	A	
Tolazoline	<i>Priscoline</i>	3	B	
Tolfenamic Acid		4	B	
Tolmetin	<i>Tolectin</i>	3	B	
Topirimate	<i>Topamax</i>	2	A	
<u>Toremifene</u>		<u>3</u>	<u>B</u>	
Torseamide (Torasemide)	<i>Demadex</i>	3	A	
Tramadol	<i>Ultram</i>	2	B	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Trandolapril (and metabolite, trandolaprilat)	<i>Tarka</i>	3	B	
Tranexamic acid		4	C	
Tranlycypromine	<i>Parnate</i>	2	A	
Trazodone	<i>Desyrel</i>	2	A	
Trenbolone	<i>Finoplix</i>	3	B	
Tretoquinol	<i>Inolin</i>	2	A	
Triamcinolone	<i>Vetalog, etc.</i>	4	C	
Triamterene	<i>Dyrenium</i>	4	B	
Triazolam	<i>Halcion</i>	2	A	
Tribromethanol		2	A	
Tricaine methanesulfonate	<i>Finquel</i>	2	A	
Trichlormethiazide	<i>Naqua, Naquasone</i>	4	C	
Trichloroethanol		2	A	
Trichloroethylene	<i>Trilene, Trimar</i>	2	A	
Triclofos	<i>Triclos</i>	2	A	
Tridihexethyl	<i>Pathilon</i>	4	B	
Trifluomeprazine	<i>Nortran</i>	2	A	
Trifluoperazine	<i>Stelazine</i>	2	A	
Trifluoperidol	<i>Triperidol</i>	2	A	
Triflupromazine	<i>Vetame, Vesprin</i>	2	A	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Trihexylphenidyl	<i>Artane</i>	3	A	
Trimeprazine	<i>Temaril</i>	4	B	
<u>Trimetazidine</u>		<u>3</u>	<u>B</u>	
Trimethadione	<i>Tridione</i>	3	B	
Trimethaphan	<i>Arfonad</i>	3	A	
Trimipramine	<i>Surmontil</i>	2	A	
Tripelennamine	<i>PBZ</i>	3	B	
Triprolidine	<i>Actidil</i>	3	B	
<u>Trometamol (Also known as tris hydroxymethyl aminomethane [THAM])</u>	<u><i>Tris (hydroxymethyl) aminomethane</i></u>	<u>3</u>	<u>B</u>	
Tubocurarine (Curare)	<i>Metubin</i>	2	A	
Tybamate	<i>Benvil, Nospan, etc.</i>	2	A	
Urethane		2	A	
Valdecoxib		2	B	
Valerenic acid		3	A	
Valnoctamide	<i>Nirvanyl</i>	2	A	
Valsartan	<i>Diovan</i>	3	B	
Vardenafil	<i>Levitra</i>	3	A	
Vedaprofen		4	B	
Venlafaxine	<i>Efflexor</i>	2	A	
Veralipride	<i>Accional, Veralipril</i>	2	A	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Verapamil	<i>Calan, Isoptin</i>	4	B	
Vercuronium	<i>Norcuron</i>	2	A	
Viloxazine	<i>Catatrol, Vivalan, etc.</i>	2	A	
Vinbarbital	<i>Delvinol</i>	2	A	
Vinylbital	<i>Optanox, Speda</i>	2	A	
Warfarin	<i>Coumadin, Coufarin</i>	5	D	
Xylazine	<i>Rompun, Bay Va 1470</i>	3	B	
Xylometazoline	<i>Otrivin</i>	4	B	
Yohimbine		2	B	
Zafirlukast	<i>Accolate</i>	4	C	
Zaleplon	<i>Sonata</i>	2	A	
Zeranol	<i>Ralgro</i>	4	C	
Ziconotide		1	A	
Zileuton	<i>Zyflo</i>	4	C	
Zilpaterol hydrochloride	<i>Zilpaterol</i>	2	A	If the Board, the board of stewards, the hearing officer, or the administrative law judge determines that the finding of Zilpaterol was unintentional and not based upon an attempt to affect the outcome of a race, they may elect to assign a Class B penalty.
Ziprasidone	<i>Geoden</i>	2	A	
Zolazepam		2	A	

CHRB CLASSIFICATION OF FOREIGN SUBSTANCES

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation
Zolmitriptan	<i>Zomig</i>	3	B	
Zolpidem	<i>Ambien, Stilnox</i>	2	A	
Zomepirac	<i>Zomax</i>	2	B	
Zonisamide	<i>Zonegran</i>	3	B	
Zopiclone	<i>Imovan</i>	2	A	
Zotepine	<i>Lodopin</i>	2	A	
Zuclopenthixol	<i>Ciatyl, Cesordinol</i>	2	A	
A-1 androstene 3, 17 diol		3	A	
A-1 androstene 3, 17 dione		3	A	
A-1 dihydrotestosterone		3	A	



**DRUG TESTING STANDARDS AND
PRACTICES PROGRAM.**

**Uniform Classification Guidelines for Foreign Substances
And Recommended Penalties Model Rule.**
December, 2020 (V.14.4)

© ASSOCIATION OF RACING COMMISSIONERS INTERNATIONAL – 2020.

Association of Racing Commissioners International
2365 Harrodsburg Road, Suite B-450, Lexington, Kentucky USA 40504 www.arci.com

Preamble to the Uniform Classification Guidelines of Foreign Substances

The Preamble to the Uniform Classification Guidelines was approved by the RCI Drug Testing and Quality Assurance Program Committee (now the Drug Testing Standards and Practices Program Committee) on August 26, 1991. Minor revisions to the Preamble were made by the Drug Classification subcommittee (now the Veterinary Pharmacologists Subcommittee) on September 3, 1991.

"The Uniform Classification Guidelines printed on the following pages are intended to assist stewards, hearing officers and racing commissioners in evaluating the seriousness of alleged violations of medication and prohibited substance rules in racing jurisdictions. Practicing equine veterinarians, state veterinarians, and equine pharmacologists are available and should be consulted to explain the pharmacological effects of the drugs listed in each class prior to any decisions with respect to penalties to be imposed. The ranking of drugs is based on their pharmacology, their ability to influence the outcome of a race, whether or not they have legitimate therapeutic uses in the racing horse, or other evidence that they may be used improperly. These classes of drugs are intended only as guidelines and should be employed only to assist persons adjudicating facts and opinions in understanding the seriousness of the alleged offenses. The facts of each case are always different and there may be mitigating circumstances which should always be considered. These drug classifications will be reviewed frequently and new drugs will be added when appropriate."

Notes Regarding Classification Guidelines

- Where the use of a drug is specifically permitted by a jurisdiction, then the jurisdiction's rule supersedes these penalty guidelines.
- Regulators should be aware that a laboratory report may identify a drug only by the name of its metabolite. The metabolite might not be listed here, but the parent compound may be.
- These classes of drugs are intended only as guidelines and should be employed only to assist persons adjudicating facts and opinions in understanding the seriousness of the alleged offenses.
- The facts of each case are different and there may be mitigating circumstances that should be considered.
- These drug classifications will be reviewed periodically. New drugs will be added or some drugs may be reclassified when appropriate.
- [Racing Commissioners International \(RCI\) and/or the Racing Medication and Testing Consortium \(RMTC\) should be consulted for found substances or drugs not included in these guidelines and treated as Class 1 violations warranting a Class A penalty unless otherwise advised.](#)

Classification Criteria

The RCI Drug Classification Scheme is based on 1) pharmacology, 2) drug use patterns, and 3) the appropriateness of a drug for use in the racing horse. Categorization is decided using the following general guidelines:

- **Pharmacology.** Drugs that are known to be potent stimulants or depressants are placed in higher classes, while those that have (or would be expected to have) little effect on the outcome of a race are placed in lower classes.

- **Drug Use Patterns.** Some consideration is given to placement of drugs based on practical experience with their use and the nature of positive tests. For example, procaine positives have in the past been associated primarily with the administration of procaine penicillin, and this has been taken into consideration in the placement of procaine into Class 3 instead of Class 2 with other injectable local anesthetics.
- **Appropriateness of Drug Use.** Drugs that clearly are intended for use in equine therapeutics are placed in lower classes. Drugs that clearly are not intended for use in the horse are placed in higher classes, particularly if they might affect the outcome of a race. Drugs that are recognized as legitimately useful in equine therapeutics but could affect the outcome of a race are placed in the middle or higher classes.

The list includes most drugs that have been reported as detected by racing authority laboratories in the United States, Canada, the United Kingdom and other Association of Official Racing Chemists (AORC) laboratories, but does not include those which would seem to have no effect on the performance of the horse or drug detectability. For example, it does not include antibiotics, sulfonamides, vitamins, anthelmintics, or pangamic acid, all of which have been reported.

The list contains many drugs that have never been reported as detected. Usually, these are representatives of chemical classes that have the potential for producing an effect, and in many cases, for which at least one drug in that chemical class has been reported.

Most drugs have numerous effects, and each was judged on an individual basis. There are instances where there is a rather fine distinction between drugs in one category and those in the next. This is a reflection of a nearly continuous spectrum of effects from the most innocuous drug on the list to the drug that is the most offensive.

Classification Definitions

- **Class 1:** Stimulant and depressant drugs that have the highest potential to affect performance and that have no generally accepted medical use in the racing horse. Many of these agents are Drug Enforcement Agency (DEA) schedule II substances. These include the following drugs and their metabolites: Opiates, opium derivatives, synthetic opioids and psychoactive drugs, amphetamines and amphetamine-like drugs as well as related drugs, including but not limited to apomorphine, nikethamide, mazindol, pemoline, and pentylenetetrazol. Though not used as therapeutic agents, all DEA Schedule 1 agents are included in Class 1 because they are potent stimulant or depressant substances with psychotropic and often habituating actions. This class also includes all erythropoietin stimulating substances and their analogues.
- **Class 2:** Drugs that have a high potential to affect performance, but less of a potential than drugs in Class 1. These drugs are 1) not generally accepted as therapeutic agents in racing horses, or 2) they are therapeutic agents that have a high potential for abuse. Drugs in this class include: psychotropic drugs, certain nervous system and cardiovascular system stimulants, depressants, and neuromuscular blocking agents. Injectable local anesthetics are included in this class because of their high potential for abuse as nerve blocking agents.
- **Class 3:** Drugs that may or may not have generally accepted medical use in the racing horse, but the pharmacology of which suggests less potential to affect performance than drugs in Class 2. Drugs in this class include bronchodilators, anabolic steroids and other drugs with primary effects on the autonomic nervous system, procaine, antihistamines with sedative properties and the high-ceiling diuretics.

- **Class 4:** This class includes therapeutic medications that would be expected to have less potential to affect performance than those in Class 3. Drugs in this class includes less potent diuretics; corticosteroids; antihistamines and skeletal muscle relaxants without prominent central nervous system (CNS) effects; expectorants and mucolytics; hemostatics; cardiac glycosides and anti-arrhythmics; topical anesthetics; antidiarrheals and mild analgesics. This class also includes the non-steroidal anti-inflammatory drugs (NSAIDs), at concentrations greater than established limits.
- **Class 5:** This class includes those therapeutic medications that have very localized actions only, such as anti-ulcer drugs, and certain anti-allergic drugs. The anticoagulant drugs are also included.
- **Prohibited Practices:**
 - A) The possession and/or use of a drug, substance or medication, specified below, on the premises of a facility under the jurisdiction of the regulatory body for which a recognized analytical method has not been developed to detect and confirm the administration of such substance; or the use of which may endanger the health and welfare of the horse or endanger the safety of the rider or driver; or the use of which may adversely affect the integrity of racing:
 - 1) Erythropoietin
 - 2) Darbepoetin
 - 3) Oxyglobin
 - 4) Hemopure
 - B) The possession and/or use of a drug, substance, or medication on the premises of a facility under the jurisdiction of the regulatory body that has not been approved by the United States Food and Drug Administration (FDA) for use in the United States.
 - C) The practice, administration, or application of a treatment, procedure, therapy or method identified below, which is performed on the premises of a facility under jurisdiction of a regulatory body and which may endanger the health and welfare of the horse or endanger the safety of the rider or driver, or the use of which may adversely affect the integrity of racing:

Drug Classification Scheme

- **Class 1:** Opiates, opium derivatives, synthetic opioids, psychoactive drugs, amphetamines, and all DEA Schedule I substances (see <http://www.deadiversion.usdoj.gov/schedules/#list>), and many DEA Schedule II drugs. Also found in this class are drugs that are potent stimulants of the CNS. Drugs in this class have no generally accepted medical use in the racing horse and their pharmacologic potential for altering the performance of a racing horse is very high. This class also includes all erythropoietin stimulating substances and their analogues.

 - **Class 2:** Drugs placed in this category have a high potential for affecting the outcome of a race. Most are not generally accepted as therapeutic agents in the racing horse. Many are products intended to alter consciousness or the psychic state of humans, and have no approved or indicated use in the horse. Some, such as injectable local anesthetics, have legitimate use in equine medicine, but should not be found in a racing horse. The following groups of drugs are placed in this class:
 - A) Opiate partial agonists, or agonist-antagonists.
 - B) Non-opiate psychotropic drugs. These drugs may have stimulant, depressant, analgesic or neuroleptic effects.
 - C) Miscellaneous drugs, which might have a stimulant effect on the CNS.
 - D) Drugs with prominent CNS depressant action.
 - E) Anti-depressant and antipsychotic drugs, with or without prominent CNS stimulatory or depressant effects.
 - F) Muscle blocking drugs - those that have a direct neuromuscular blocking action.
 - G) Local anesthetics that have a reasonable potential for use as nerve-blocking agents (except procaine).
 - H) Snake venoms and other biologic substances that may be used as nerve-blocking agents.

 - **Class 3:** Drugs placed in this class may or may not have an accepted therapeutic use in the horse. Many are drugs that affect the cardiovascular, pulmonary and autonomic nervous systems. They all have the potential of affecting the performance of a racing horse. The following groups of drugs are placed in this class:
 - A) Drugs affecting the autonomic nervous system that do not have prominent CNS effects, but which do have prominent cardiovascular or respiratory system effects. Bronchodilators are included in this class.
 - B) A local anesthetic that has nerve-blocking potential but also has a high potential for producing urine residue levels from a method of use not related to the anesthetic effect of the drug (procaine).
 - C) Miscellaneous drugs with mild sedative action, such as the sleep-inducing antihistamines.
 - D) Primary vasodilating/hypotensive agents.
 - E) Potent diuretics affecting renal function and body fluid composition.
 - F) Anabolic and/or androgenic steroids and other drugs.
-
- **Class 4:** Drugs in this category comprise primarily therapeutic medications routinely used in racehorses. These may influence performance, but generally have a more limited ability to do so. Groups of drugs assigned to this category include the following:

- A) Non-opiate drugs that have a mild central antipyretic effect.
- B) Drugs affecting the autonomic nervous system that do not have prominent CNS, cardiovascular, or respiratory effects:
 - 1) Drugs used solely as topical vasoconstrictors or decongestants.
 - 2) Drugs used as gastrointestinal antispasmodics.
 - 3) Drugs used to void the urinary bladder.
 - 4) Drugs with a major effect on CNS vasculature or smooth muscle of visceral organs.
- C) Antihistamines that do not have a significant CNS depressant effect. This does not include the H2 blocking agents, which are in Class 5.
- D) Mineralocorticoid drugs.
- E) Skeletal muscle relaxants.
- F) Anti-inflammatory drugs. These drugs may reduce pain as a consequence of their anti-inflammatory action.
 - 1) Non-steroidal anti-inflammatory drugs (NSAIDs). (Aspirin-like drugs).
 - 2) Corticosteroids (glucocorticoids).
 - 3) Miscellaneous anti-inflammatory agents. G. Less potent diuretics.
- H. Cardiac glycosides and antiarrhythmic agents.
 - 1. Cardiac glycosides.
 - 2. Antiarrhythmic agents (exclusive of lidocaine, bretylium, and propranolol).
 - 3. Miscellaneous cardiotonic drugs.
- I. Topical Anesthetics - agents not available in injectable formulations.
- J. Antidiarrheal drugs.
- K. Miscellaneous drugs:
 - 1. Expectorants with little or no other pharmacologic action.
 - 2. Stomachics.
 - 3. Mucolytic agents.

- **Class 5:** Drugs in this category are therapeutic medications that have very localized actions only, such as anti-ulcer drugs, and certain antiallergic drugs. The anticoagulant drugs are also included.

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
----------------	---------------	------------	---------------	------------------	-------

Δ-1-androstene-3, 17diol		3	A		
Δ-1-androstene-3, 17dione		3	A		
Δ-1-dihydrotestosterone		3	A		
1-androstenediol (5αandrost-1-ene-3β, 17βdiol)		3	B	Steroid - endogenous weak androgen steroid hormone and intermediate in the biosynthesis of testosterone from dehydroepiandrosterone (DHEA) and of estrone.	Endogenous AAS
1-androstenedione (5αandrost-1-ene-3, 17dione)		3	B	Steroid - endogenous weak androgen steroid hormone and intermediate in the biosynthesis of testosterone from dehydroepiandrosterone (DHEA) and of estrone.	Endogenous AAS
1-testosterone (17βhydroxy-5α-androst-1en-3-one)		3	A	Steroid - chemically related to anabolic steroids.	AAS lacking FDA approval
19-Norandrostenediol		3	B		
19-Norandrostenedione		3	B		
19-noretiocholanolone.		3	B	Nandrolene Link - a metabolite of nandrolone (19-nortestosterone) and bolandione (19norandrostenedione).	Metabolite of a B substance
2-Aminoheptane	<i>Tuamine</i>	4	B		
3-Methoxytyramine	<i>3-MT</i>	2	A		
3,4-methylenedioxypropylamphetamine	<i>MDPV, "bath salts"</i>	1	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
-----------------------	----------------------	-------------------	----------------------	-------------------------	--------------

4-androstene-3,6,17-trione (6-oxo)		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - Aromatase inhibitors.	Testolactone has B classification
4-androstenediol (androst-4-ene-3β,17βdiol)				-	
4-Hydroxytestosterone		3	B		
5-androstenedione (androst-5-ene-3,17dione)				-	
5α-androstane-3α,17αdiol		3	B	Testosterone Link - testosterone metabolite.	Metabolite of a B substance
5α-androstane-3α,17βdiol				-	
5α-androstane-3β,17αdiol		3	B	Testosterone Link - testosterone metabolite.	Metabolite of a B substance
5α-androstane-3β,17βdiol				-	
5β-androstane-3α,17βdiol, androst-4-ene-3α,17α-diol		3	B	Testosterone Link - androstenediol that is converted to testosterone.	Metabolized to a B substance
7-keto-dhea;19-				-	
7α-hydroxy-dhea		3	B	DHEA Link - naturally occurring steroid and a major metabolite of dehydroepiandrosterone (DHEA).	Metabolite of a B substance
7β-hydroxy-dhea		3	B	DHEA Link - naturally occurring steroid and a major metabolite of dehydroepiandrosterone (DHEA).	Metabolite of a B substance
a-Cobratoxin		1	A		
Acebutolol	<i>Sectral</i>	3	B		

Accecarbromal		2	A		
Acenocoumarol					
Acepromazine	<i>Atrovet, Notensil, PromAce®</i>	3	B		
Acetaminophen (Paracetamol)					
Acetanilid		4	B		
Acetazolamide					
Acetophenazine	<i>Tindal</i>	2	A		
Acetophenetidin (Phenacetin)					
Acetylcysteine		4	C		
Acetylsalicylic acid (Aspirin)		4	C		
Activators of the AMPactivated protein kinase (AMPK) - E.g., AICAR, and Peroxisome Proliferator Activated Receptor δ (pparδ) agonists (e.g., GW 1516).					
Adinazolam		2	A		
Adrenochrome monosemicarbazone salicylate					
Albuterol (Salbutamol)	<i>Proventil, Ventolin</i>	3	B	NOTE: "A" penalty for quarter horse races.	
Alclofenac		2	B		
Alclometasone	<i>Aclovate</i>	4	C		
Alcuronium	<i>Alloferin</i>	2	A		

Aldosterone	<i>Aldocortin, Electro cortin</i>	4	B		
--------------------	-----------------------------------	---	---	--	--

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Alfentanil	<i>Alfenta</i>	1	A		
Almotriptan	<i>Axert</i>	3	A		
Alphaprodine	<i>Nisentil</i>	2	A		
Alpha-pyrrolidinovalerophenone (also known as Alpha PVP)		1	A	Known as bath salts in humans	
Alpidem	<i>Anaxyl</i>	2	A		
Alprazolam	<i>Xanax</i>	2	A		
Alprenolol		2	A		
Althesin	<i>Saffan</i>	2	A		
Altrenogest	<i>Regumate</i>	4	C	*Classification for geldings, colts, adult intact males, spayed females only.	
Ambenonium	<i>Mytelase, Myeuran</i>	3	B		
Ambroxol	<i>Ambril, etc.</i>	4	B		
Amcinonide	<i>Cyclocort</i>	4	C		
Amiloride	<i>Moduretic; Midamor</i>	4	B		
Aminocaproic acid	<i>Amicar, Caprocid</i>	4	C		
Aminoglutethimide		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines.	Testolactone has B classification
Aminophylline	<i>Aminophyllin, etc.</i>	3	B		
Aminopyrine		4	B		
Aminorex	<i>Aminoxafen, Aminoxaphen, Apiquel, McN-742, Menocil</i>	1	A		

Amiodarone		4	B		
Amisometradine					
Amisulpride	<i>Solian</i>	2	A		
Amitraz					

Amitriptyline	<i>Elavil, Amitril, Endep</i>	2	A		
Amlodipine					
Amobarbital	<i>Amytal</i>	2	A		
Amoxapine					
Amperozide		2	A		
Amphetamine					
Amrinone		4	B		
Amyl nitrite					
Anastrozole		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - Aromatase inhibitors.	Testolactone has B classification
Andarine					
Androst-4-ene-3α,17βdiol					
Androst-4-ene-3β,17αdiol		3	B	Testosterone Link - an androstenediol that is converted to testosterone.	Metabolized to a B substance
Androst-5-ene-3α,17αdiol		3	B	Testosterone Link - androstenediol that is converted to testosterone.	Metabolized to a B substance

<i>Androst-5-ene-3α,17βdiol</i>		3	B	Testosterone Link - prohormone of testosterone.	Metabolized to a B substance
<i>Androst-5-ene-3β,17βdiol</i>		3	B	Testosterone Link - prohormone of testosterone.	Metabolized to a B substance
<i>Androsta-1,4,6-triene-3,17-dione (androstatrienedione)</i>		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - Aromatase inhibitors.	Testolactone has B classification

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Androstenediol (androst-5-ene-3β,17βdiol)		3	B	Steroid: weak androgen and estrogen steroid hormone and intermediate in the biosynthesis of testosterone from dehydropiandrosterone (DHEA)	Metabolite of a B substance
Androstenedione (androst-4-ene-3,17dione)		3	B	Steroid: endogenous weak androgen steroid hormone and intermediate in the biosynthesis of testosterone from dehydroepiandrosterone (DHEA) and of estrone.	Endogenous AAS
<i>Androsterone (3βhydroxy-5α-androstan-17-one)</i>		3	B	Testosterone Link - a metabolite of testosterone and dihydrotestosterone (DHT).	Metabolite of a B substance
Anileridine	<i>Leritine</i>	1	A		
Anilopam	<i>Anisine</i>	2	A		
Anisindione		5	D		
Anisotropine	<i>Valpin</i>	4	B		
Antipyrine		4	B		
Apazone (Azapropazone)	<i>Rheumox</i>	4	B		

Apomorphine		1	A		
Aprindine					
Aprobarbital	<i>Alurate</i>	2	A		
ARA-290					
Arecoline		3	A		
Arformoterol					
Aripiprazole					
Arsenic		3	B	Arsenic is present in pressure-treated lumber designated for non-residential use. Cribbing or wood chewing may result in exposure sufficient to result in concentrations in excess of the screening limit. Findings for arsenic warrant investigation into the route of exposure with mitigation to 3/C recommended when there is compelling evidence for environmental exposure rather than deliberate administration.	

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
<i>Aromatase inhibitors listed:</i>					
Articaine	<i>Septocaine; Ultracaine,</i>	2	B		

<i>Asialo EPO</i>		1	A	Erythropoietin Link - desialylated form of human glycoprotein hormone erythropoietin (EPO), which has been reported to be neuro-, cardio-, and renoprotective in animal models of organ injuries.	Blood doping agent
Atenolol					
Atipamazole		2	B		
Atomoxetine					
Atracurium	<i>Tracrium</i>	2	A		
Atropine					
Azacylonol	<i>Frenque</i>	2	A		
Azaperone					
Baclofen	<i>Lioresal</i>	4	B		
Barbital					
Barbiturates		2	A		
Beclomethasone					
Bemegride	<i>Megimide, Mikedimide</i>	2	A		
Benazepril					
Bendroflumethiazide	<i>Naturetin</i>	4	B		
Benoxaprofen		2	B		
Benoxinate	<i>Dorsacaine</i>	4	C		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Benperidol	<i>Anquil</i>	2	A		

Bentazepam	<i>Tiadipona</i>	2	A		
Benzactizine					
Benzocaine		4	B		
Benzoctamine					
Benzodiazepines		2	A		
Benzonatate					
Benzphetamine	<i>Didrex</i>	2	A		
Benzthiazide					
Benztropine	<i>Cogentin</i>	2	A		
Benzylpiperazine (BZP)		1	A		
Bepriidil	<i>Bepadil</i>	4	B		
Betamethasone	<i>Betasone, etc.</i>	4	C		
Betaxolol	<i>Kerlone</i>	3	B		
Bethanechol	<i>Urecholine, Duvoid</i>	4	C		
Bethanidine	<i>Esbatal</i>	3	A		
Biperiden	<i>Akineton</i>	3	A		
Biriperone		2	A		
Bisoprolol	<i>Zebeta, Bisobloc, etc.</i>	3	B		
Bisphosphonates (any)		3	A		
Bitolterol	<i>Effectin</i>	3	A		

Bolandiol (estr-4-ene3β, 17β-diol)		3	A	Steroid	AAS lacking FDA approval
---	--	---	---	---------	--------------------------

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Bolasterone		3	A		
Boldenone	<i>Equipoise</i>	3	B		
Boldione		3	A		
Botulinum toxin		2	A		
Bretylum	<i>Bretylol</i>	3	B		
Brimonidine	<i>Alphagan</i>	2	A		
Bromazepam	<i>Lexotan, Lectopam</i>	2	A		
Bromfenac	<i>Duract</i>	3	A		
Bromhexine	<i>Oletor, etc.</i>	4	B		
Bromisovalum	<i>Diffucord, etc.</i>	2	A		
Bromocriptine	<i>Parlodel</i>	2	A		
Bromodiphenhydramine		3	B		
Bromperidol	<i>Bromidol</i>	2	A		
Brompheniramine	<i>Dimetane, Disomer</i>	3	B		
Brotizolam	<i>Brotocol</i>	2	A		
Budesonide	<i>Pulmacort, Rhinocort</i>	4	C		
Bufexamac		3	A		
Bumetanide	<i>Bumex</i>	3	B		
Bupivacaine	<i>Marcaine</i>	2	A		

Buprenorphine	<i>Temgesic</i>	2	A		
Bupropion					
Buspirone	<i>Buspar</i>	2	A		

Butabarbital (Secbutobarbitone)					
Butacaine	<i>Butyn</i>	2	A		
Butalbital (Talbutal)					
Butamben (butyl aminobenzoate)	<i>Butesin</i>	4	C		
Butanilicaine					
Butaperazine	<i>Repoise</i>	2	A		
Butoctamide					
Butorphanol	<i>Stadol, Torbugesic</i>	3	B		
Butoxycaine					
Caffeine		2	B		
Calusterone					
Camazepam	<i>Paxor</i>	2	A		
Camphor					
Candesartan	<i>Atcand</i>	3	B		
Cannabidiol (CBD)¹					
Canrenone		4	C	Metabololite of a C substance - steroidal antimineralocorticoid, active metabolite of spironolactone (a diuretic).	
Capsaicin		2	B		

Captodiamine	<i>Covatine</i>	2	A		
Captopril					
Carazolol	<i>Carbacel, Conducton</i>	3	A		
Carbachol					
Carbamezapine	<i>Tegretol</i>	3	B		

Carbamylated EPO					
Carbazochrome		4	B		
Carbidopa + levodopa					
Carbinoxamine	<i>Clistin</i>	3	B		
Carbromol					
Cardarine (GW-501516)		2	A	No legit use in the racehorse. Lacks FDA approval	
Carfentanil		1	A		
Carisoprodol	<i>Rela, Soma</i>	2	B		
Carphenazine	<i>Proketazine</i>	2	A		
Carpipramine	<i>Prazinil</i>	2	A		
Carprofen	<i>Rimadyl</i>	4	B		
Carteolol	<i>Cartrol</i>	3	B		
Carticaine (see articaïne)	<i>Septocaine; Ultracaine, etc.</i>	2	B		
Carvedilol	<i>Coreg</i>	3	B		
Cathinone	<i>khat, kat, qat, quat, chat, catha, Abyssinian tea, African tea</i>	1	A		

Celecoxib	<i>Celebrex</i>	3	B		
Cetirizine					
Chloral betaine	<i>Beta-Chlor</i>	2	A		
Chloral hydrate					
Chloraldehyde (chloral)		2	A		
Chloralose (AlphaChloralose)					

Chlordiazepoxide	<i>Librium</i>	2	A		
Chlorhexidol		2	A		
Chlormerodrin	<i>Neohydrin</i>	4	B		
Chlormezanone	<i>Trancopal</i>	2	A		
Chloroform		2	A		
Chlorophenesin	<i>Maolate</i>	4	C		
Chloroprocaine	<i>Nesacaine</i>	2	A		
Chloroquine	<i>Avloclor</i>	4	C		
Chlorothiazide	<i>Diuril</i>	4	B		
Chlorpheniramine	<i>Chlortrimeton, etc.</i>	4	B		
Chlorproethazine	<i>Newiplege</i>	2	A		
Chlorpromazine	<i>Thorazine, Largactil</i>	1	A		
Chlorprothixene	<i>Taractan</i>	2	A		

Chlorthalidone					
Chlorzoxazone	<i>Paraflex</i>	4	B		
Chorionic Gonadotropin (CG)					
Ciclesonide		4	C		
Cilostazol					
Cimeterol		3	A		
Cimetidine					
Cinchocaine	<i>Nupercaine</i>	2	B		

Citalopram					
Clanobutin		4	B		
Clemastine					
Clenbuterol	<i>Ventipulmin</i>	3	B	NOTE: "A" penalty for quarter horse races.	
Clibucaine					
Clidinium	<i>Quarezan, Clindex, etc.</i>	3	B		
Clobazam					
Clobetasol	<i>Temovate</i>	4	C		
Clocapramine		2	A		
Clocortolone	<i>Cloderm</i>	4	C		
Clodronate	<i>OsPhos</i>	3	A	Bisphosphonate	

Clofenamide					
Clomethiazole (Chlormethiazole)		2	A		
Clomiphene					
Clomipramine	<i>Anafranil</i>	2	A		
Clonazepam					
Clonidine	<i>Catapres</i>	3	B		
Clorazepate					
Clormecaine	<i>Placacid</i>	2	A		
Clostebol		3	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Clothiapine	<i>Entermin</i>	2	A		
Clotiazepam	<i>Trecalmo, Rize</i>	2	A		
Cloxazolam	<i>Enadel, Sepazon, Tolestan</i>	2	A		
Clozapine	<i>Clozaril, Leponex</i>	2	A		
CNTO 530		1	A	Erythropoietin Link - a biopharmaceutical consisting of a novel peptide that mimics the actions of erythropoietin, CNTO 530 produced sustained increases in red blood cell parameters.	Blood doping agent

Cobalt (check note)					
Cocaine		1	A3	If it is determined by the State Veterinarian/Equine Medical Director; the Stewards, or the Racing Authority that the finding of cocaine or morphine was unintentional and not based upon an attempt to affect the outcome of a race, the Stewards or Racing Authority may elect to assign a Class B penalty to the trainer.	
Codeine					
Colchicine		4	B		
Conorphone					
Corticaine	<i>Ultracain</i>	2	A		
Corticotrophind		3	B	Peptide hormone involved in the stress response.	
Cortisone	<i>Cortone, etc.</i>	4	C		
Cromolyn	<i>Intel</i>	5	D		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Crotetamide		2	A		
Cyamemazine	<i>Tercian</i>	2	A		
Cyclandelate	<i>Cyclospasmol</i>	3	A		
Cyclizine	<i>Merazine</i>	3	B		
Cyclobarbital	<i>Phanodorm</i>	2	A		
Cyclobenzaprine	<i>Flexeril</i>	4	B		

Cyclofenil		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - selective estrogen receptor modulator (SERM).	Testolactone has B classification
Cyclomethycaine					
Cyclothiazide	<i>Anhydron, Renazide</i>	4	B		
Cycrimine					
Cyproheptadine	<i>Periactin</i>	3	B		
Danazol					
Dantrolene	<i>Dantrium</i>	4	C		
Darbepoetin					
Darbepoetin (depo)		1	A	Erythropoietin Link - Bone marrow stimulant (Erythropoiesisstimulating agents are medications which stimulates the bone marrow to make red blood cells).	Blood doping agent
Decamethonium					
Dehydrochloromethyltestosterone		3	A		

Dembroxol (Dembrexine)					
Demoxepam		2	A		
Deoxycorticosterone					
Deracoxib	<i>Deremaxx</i>	3	B		
Dermorphin		1	A		

Desipramine	<i>Norpromine, Pertofrane</i>	2	A		
Desonide					
Desoximetasone	<i>Topicort</i>	4	C		
Desoxymethyltestosterone		3	A		
Detomidine	<i>Dormosedan</i>	3	B		
Dexamethasone	<i>Azium, etc.</i>	4	C		
Dextromethorphan		4	B		
Dextromoramide	<i>Palfium, Narcolo</i>	1	A		
Dextropropoxyphene	<i>Darvon</i>	3	B		
Dezocine	<i>Dalgan</i>	2	A		
Diamorphine		1	A		
Diazepam	<i>Valium</i>	2	B		
Diazoxide	<i>Proglycem</i>	3	B		
Dibucaine	<i>Nupercainal, Cinchocaine</i>	2	B		
Dichloralphenazone	<i>Febenol, Isocom</i>	2	A		
Dichlorphenamide	<i>Daramide</i>	4	C		
Diclofenac	<i>Voltaren, Voltarol</i>	4	C		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Dicumarol	<i>Dicumarol</i>	5	D		
Diethylpropion	<i>Tepanil, etc.</i>	2	A		
Diethylthiambutene	<i>Themalon</i>	2	A		

Diflorasone	<i>Florone, Maxiflor</i>	4	C		
Diflucortolone					
Diflunisal		3	B		
Digitoxin					
Digoxin	<i>Lanoxin</i>	4	B		
Diisopropylamine					
Dihydrocodeine					
Dihydroergotamine		4	B		
Dihydrotestosterone (17β-hydroxy-5αandrostan-3-one)					
Dilorazepam	<i>Briantum</i>	2	A		
Diltiazem					
Dimeflin		3	A		
Dimethisoquin					
Dimethylsulfoxide (DMSO)	<i>Domoso</i>	4	C		
Diphenadione		5	C		
Diphenhydramine	<i>Benadryl</i>	3	B		
Diphenoxylate	<i>Difenoxin, Lomotil</i>	4	B		
Diprenorphine	<i>M50/50</i>	2	A		
Dipyridamole	<i>Persantine</i>	3	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
-----------------------	----------------------	-------------------	----------------------	-------------------------	--------------

Dipyron	<i>Novin, Methampyrone</i>	4	C		
Disopyramide					
Divalproex	<i>Depakote</i>	3	A		
Dixyrazine					
Dobutamine	<i>Dobutrex</i>	3	B		
Donepezil					
Dopamine	<i>Intropin</i>	2	A		
Doxacurium					
Doxapram	<i>Dopram</i>	2	A		
Doxazosin					
Doxefazepam	<i>Doxans</i>	2	A		
Doxepin					
Doxylamine	<i>Decapryn</i>	3	B		
Dromostanolone					
Droperidol	<i>Inapsine, Droleptan, Innovar-Vet (with Fentanyl)</i>	2	A		
Drostanolone		3	A	Steroid	AAS lacking FDA approval
Duloxetine		2	A		
Dyclonine	<i>Dyclone</i>	4	C		
Dyphylline		3	B		
Edrophonium	<i>Tensilon</i>	3	B		
Eletripan	<i>Relpax</i>	3	A		

Eltenac					
Enalapril (metabolite enalaprilat)	<i>Vasotec</i>	3	A		
Enciprazine					
Endorphins		1	A		
Enkephalins					
Ephedrine		2	A		
Epi-dihydrotestosterone					
Epibatidine		2	A		
Epinephrine					
Epitestosterone		3	B	Testosterone Link - endogenous steroid and an epimer of the androgen sex hormone testosterone.	Endogenous, stereoisomer of a B substance.
EPO-Fc					
<i>EPO-mimetic peptides (EMP):</i>		1	A		
Ergoloid mesylates (dihydroergocornine mesylate, dihydroergocristine mesylate, and dihydroergocryptine mesylate)		2	A		
Ergonovine	<i>Ergostrate</i>	4	C		
Ergotamine	<i>Gynergen, Cafergot, etc.</i>	4	B		
Erthrityl tetranitrate	<i>Cardilate</i>	3	A		

Erythropoietin (EPO)					
Esmolol	<i>Brevibloc</i>	3	B		

Esomeprazole					
Estazolam	<i>Domnamid, Eurodin, Nuctalon</i>	2	A		
Eszopiclone					
Etacrynic acid		3	C		
Etamiphylline					
Etanercept	<i>Enbrel</i>	4	B		
Ethacrynic acid					
Ethamivan		2	A		
Ethanol		2	A		
Ethchlorvynol	<i>Placidyl</i>	2	A		
Ethinamate	<i>Valmid</i>	2	A		
Ethoheptazine	<i>Zactane</i>	2	A		
Ethopropazine	<i>Parsidol</i>	2	A		
Ethosuximide	<i>Zarontin</i>	3	A		
Ethotoin	<i>Peganone</i>	4	B		
Ethoxzolamide	<i>Cardrase, Ethamide</i>	4	C		
Ethylaminobenzoate (Benzocaine)	<i>Semets, etc.</i>	4	C		
Ethylestrenol	<i>Maxibolin, Organon</i>	3	B		

Ethylisobutrazine					
Ethylmorphine	<i>Dionin</i>	1	A		
Ethylnorepinephrine					
Ethylphenidate		1	A		

Etidocaine					
Etifoxin	<i>Stresam</i>	2	A		
Etiocholanolone					
Etizolam	<i>Depas, Pasaden</i>	2	A		
Ethamsylate					
Etodolac					
Etodroxizine	<i>Indunox</i>	2	A		
Etofenamate					
Etomidate		2	A		
Etorphine HCl	<i>M99</i>	1	A		
Exemestane	Aromatase inhibitors	3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - Aromatase inhibitors.	Testolactone has B classification
Famotidine	<i>Gaster, etc.</i>	5	D		
Felbamate	<i>Felbatol</i>	3	B		

Felodipine	<i>Plendil</i>	4	B		
Fenarbamate	<i>Tymium</i>	2	A		
Fenbufen	<i>Cincopal</i>	3	B		
Fenclozic acid	<i>Myalex</i>	2	B		
Fenfluramine	<i>Pondimin</i>	2	A		
Fenoldopam	<i>Corlopam</i>	3	B		
Fenoprofen	<i>Nalfon</i>	3	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Fenoterol	<i>Berotec</i>	3	B		
Fenspiride	<i>Respiride, Respan, etc</i>	3	B		
Fentanyl	<i>Sublimaze</i>	1	A		
Fentiazac		3	B		
Fexofenadine	<i>Allegra</i>	4	C		

Fibroblast Growth Factors (fgfs), Hepatocyte Growth Factor (HGF), Insulin-like Growth Factor-1 (IGF-1) and its analogues, Mechano Growth Factors (mgfs), Platelet-Derived Growth Factor (PDGF), Vascular-Endothelial Growth Factor (VEGF) and any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularization, energy utilization, regenerative capacity or fiber type switching.		3	A	Cardiac, Muscle effects - a family of peptide cytokines that are important in the regulation of many tissues.	Lack FDA approval; no legitimate use in race horse.
Firocoxib					
Flecainide	<i>Idalon</i>	4	B		
Floctafenine					
Fluanisone	<i>Sedalande</i>	2	A		
Fludiazepam					
Fludrocortisone	<i>Alforone, etc.</i>	4	C		
Flufenamic acid		4	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Flumethasone	<i>Flucort, etc.</i>	4	C		
Flumethiazide	<i>Ademol</i>	4	B		

Flunarizine	<i>Sibelium</i>	4	B		
Flunisolide					
Flunitrazepam	<i>Rohypnol, Narcozep, Darkene, Hypnodorm</i>	2	A		
Flunixin					
Fluocinolone	<i>Synalar</i>	4	C		
Fluocinonide					
Fluopromazine	<i>Psyquil, Siquil</i>	2	A		
Fluoresone					
Fluorometholone	<i>FML</i>	4	C		
Fluoroprednisolone		4	B		
Fluoxetine	<i>Prozac</i>	2	A		
Fluoxymesterone	<i>Halotestin</i>	3	B		
Flupenthixol	<i>Depixol, Fluanxol</i>	2	A		
Fluphenazine	<i>Prolixin, Permitil, Anatensol, etc.</i>	2	B		
Flupirtine	<i>Katadolone</i>	3	A		
Fluprednisolone	<i>Alphadrol</i>	4	C		
Flurandrenolide	<i>Cordran</i>	4	C		
Flurazepam	<i>Dalmane</i>	2	A		
Flurbiprofen	<i>Froben</i>	3	B		
Fluspirilene	<i>Imap, Redeptin</i>	2	A		

Fluticasone	<i>Flixonase, Flutide</i>	4	C		
Flutoprazepam					
Fluvoxamine	<i>Dumirox, Faverin, etc.</i>	2	A		
Formebolone					
Formestane	Aromatase inhibitors	3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - Aromatase inhibitors.	Testolactone has B classification
Formoterol					
Fosinopril	<i>Monopril</i>	3	A		
Fosphenytoin					
Fulvestrant		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - Estrogen receptor antagonist antineoplastic agent.	Testolactone has B classification
Furazabol					
Furosemide	<i>Lasix</i>	N/A			
Gabapentin					
Galantamine	<i>Reminyl</i>	2	A		
Gallamine					
Gamma Aminobutyric Acid (GABA)	<i>Carolina Gold</i>	3	B		
Gepirone		2	A		
Gestrinone		3	A		

<i>GH-Releasing Peptides (ghrps), e.g., alexamorelin, GHRP-6, hexarelin and pralmorelin (GHRP-2)</i>					
Glutethimide	<i>Doriden</i>	2	A		
Glycopyrrolate					
<i>Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g., CJC-1295, sermorelin and tesamorelin</i>		3	A	Anabolic Effects - peptide analogue of growth hormone-releasing hormone which is used as a diagnostic agent to assess growth hormone secretion for the purpose of diagnosing growth hormone deficiency.	Anabolic agent lacking FDA approval
<i>Growth Hormone Secretagogues (GHS), e.g., ghrelin and ghrelin mimetics, e.g., anamorelin and ipamorelin</i>		3	A	Anabolic Effects - hunger hormone, appetiteenhancing and anabolic effects.	Anabolic agent lacking FDA approval
Guaifenesin (glycerol guaiacolate)	<i>Gecolate</i>	4	C		
Guanabenz	<i>Wyntensin</i>	3	B		
Guanadrel	<i>Hylorel</i>	3	A		
Guanethidine	<i>Ismelin</i>	3	A		
Halazepam	<i>Paxipam</i>	2	A		
Halcinonide	<i>Halog</i>	4	C		
Halobetasol	<i>Ultravate</i>	4	C		

Haloperidol					
Haloxazolam	<i>Somelin</i>	2	A		
Harpagoside		4	B	Devil's Claw Plant	

Hemoglobin glutamers					
Heptaminol	<i>Corofundol</i>	3	B		
Heroin		1	A		
Hexafluorenum	<i>Myalexen</i>	2	A		
Hexobarbital	<i>Evipal</i>	2	A		
Hexocyclium	<i>Tral</i>	4	B		
Hexylcaine	<i>Cyclaine</i>	2	B		
HIF activators (e.g. Argon, xenon)		3	A	Cardiovascular Effects - a key mediator of oxygen homeostasis that was first identified as a transcription factor that is induced and activated by decreased oxygen tension.	Blood doping agent
Homatropine	<i>Homapin</i>	3	B		
Homophenazine	<i>Pelvichthol</i>	2	A		
Hydralazine	<i>Apresoline</i>	3	B		
Hydrochlorthiazide	<i>Hydrodiuril</i>	4	B		
Hydrocodone (dihydrocodienone)	<i>Hycodan</i>	1	A		
Hydrocortisone (Cortisol)	<i>Cortef, etc.</i>	4	C		

Hydroflumethiazide					
Hydromorphone	<i>Dilaudid</i>	1	A		
Hydroxyamphetamine					
Hydroxyzine	<i>Atarax</i>	2	B		
Hypoxia-inducible factor (HIF) activators					
Hypoxia-inducible factor (HIF) stabilizers (e.g. IOX-2)					
Ibomal					

Ibuprofen	<i>Motrin, Advil, Nurpin, etc.</i>	4	C		
Ibutilide					
Iloprost	<i>Ventavis</i>	3	A		
Imipramine					
Indapamide	Diuretic	3	C		
Indomethacin					
Infliximab	<i>Remicade</i>	4	B		
Insulins		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - protein hormone that is used as a medication to treat high blood sugar.	
Ipratropium		3	B		
Irbesarten	<i>Avapro</i>	3	A		
Isapirone		2	A		
Isocarboxazid	<i>Marplan</i>	2	A		
Isoetharine	<i>Bronkosol</i>	3	B		

Isoflupredone					
Isomethadone		2	A		
Isometheptene					
Isopropamide	<i>Darbid</i>	4	B		
Isoproterenol					
Isosorbide dinitrate	<i>Isordil</i>	3	B		
Isoxicam					
Isoxsuprine	<i>Vasodilan</i>	4	D		
Isradipine					

Kebuzone		3	B		
Ketamine					
Ketazolam	<i>Anxon, Laftram, Solatran, Loftran</i>	2	A		
Ketoprofen					
Ketorolac	<i>Toradol</i>	3	A		
Labetalol					
Lamotrigine	<i>Lamictal</i>	3	A		
Lansoprazole		5	D		
Lenperone	<i>Elanone-V</i>	2	A		
Letosteine	<i>Viscotiol, Visiotal</i>	4	B		
Letrozole		3	A		

Levamisole					
Levobunolol	<i>Betagan</i>	3	B		
Levomethorphan					
Levorphanol	<i>Levo-Dremoran</i>	1	A		
Lidocaine					
Ligandrol		2	A		SARM
Lisinopril	<i>Prinivil, Zestril</i>	3	A		
Lithium					
Lobeline		2	A		
Lofentanil		1	A		
Loflazepate, Ethyl	<i>Victan</i>	2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Loperamide	<i>Imodium</i>	3	B		
Loprazolam	<i>Dormonort, Havlane</i>	2	A		
Loratidine	<i>Claritin</i>	4	C		
Lorazepam	<i>Ativan</i>	2	A		
Lormetazepam	<i>Noctamid</i>	2	A		
Losartan	<i>Hyzaar</i>	3	B		
Loxapine	<i>Laxitane</i>	2	A		
Luteinizing Hormone (LH)		3	B		Hormone and behavioral effects - a hormone produced by gonadotropic cells in the anterior pituitary gland. In females, an acute rise of LH triggers ovulation and development of the corpus luteum. Used for behavior modification in colts / horses. There should be no restriction/regulation in fillies and mares.

Mabuterol		3	A		
Maprotiline	<i>Ludiomil</i>	2	A		
Mazindol	<i>Sanorex</i>	1	A		
Mebutamate	<i>Axiten, Dormate, Capla</i>	2	A		
Mecamylamine	<i>Inversine</i>	3	B		
Meclizine	<i>Antivert, Bonine</i>	3	B		
Meclofenamic acid	<i>Arquel</i>	4	C		
Meclofenoxate	<i>Lucidiril, etc.</i>	2	A		
Medazepam	<i>Nobrium, etc.</i>	2	A		
Medetomidine	<i>Damintor</i>	3	B		
Medroxyprogesterone		3	B	Classification for all genders	
Medrysone	<i>Medriusar, etc.</i>	4	C		
Mefenamic acid	<i>Ponstel</i>	3	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Meldonium	<i>Mildronate, et al</i>	1	A		
Meloxicam	<i>Mobic</i>	4	B		
Melperone	<i>Eunerpan</i>	2	A		
Memantine	<i>Namenda</i>	2	A		
Meparfynol	<i>Oblivon</i>	2	A		
Mepazine	<i>Pacatal</i>	2	A		
Mepenzolate	<i>Cantil</i>	3	B		

Meperidine	<i>Demerol</i>	1	A		
Mephesisin	<i>Tolserol</i>	4	B		
Mephenoqualone	<i>Control, etc.</i>	2	A		
Mephentermine	<i>Wyamine</i>	1	A		
Mephentoin	<i>Mesantoin</i>	2	A		
Mephobarbital (Methylphenobarbital)	<i>Mebaral</i>	2	A		
Mepivacaine	<i>Carbocaine</i>	2	B		
Meprobamate	<i>Equanil, Miltown</i>	2	A		
Meralluride	<i>Mercuryhydrin</i>	4	B		
Merbaphen	<i>Novasural</i>	4	B		
Mercaptomerin	<i>Thiomerin</i>	4	B		
Mercumatinin	<i>Cumertilin</i>	4	B		
Mersalyl	<i>Salyrgan</i>	4	B		
Mesalamine	<i>Asacol</i>	5	C		
Mesoridazine	<i>Serentil</i>	2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Mestanolone		3	A		
Mesterolone		3	A		
Metaclazepam	<i>Talis</i>	2	A		
Metandienone		3	A	Steroid	AAS lacking FDA approval
Metaproterenol	<i>Alupent, Metaprel</i>	3	B		

Metaraminol	<i>Aramine</i>	1	A		
Metaxalone					
Metazocine		2	A		
Metenolone					
Metformin		2	B		
Methacholine		3	A		
Methadone	<i>Dolophine</i>	1	A		
Methamphetamine	<i>Desoxyn</i>	1	A4	Recommended Penalty B if testing can prove presence of only levo-methamphetamine is present in sample.	
Methandriol (Methylandrostenediol)	<i>Probolis</i>	3	A		
Methandrostenolone	<i>Dianobal</i>	3	A		
Methantheline	<i>Banthine</i>	3	B		
Methapyrilene	<i>Histadyl, etc.</i>	3	B		
Methaqualone	<i>Quaalude</i>	1	A		
Metharbital	<i>Gemonil</i>	2	A		
Methasterone		3	A		
Methazolamide	<i>Naptazane</i>	4	C		
Methcathinone		1	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Methdilazine	<i>Tacaryl</i>	3	B		
Methenolone	<i>Primobolan</i>	3	A		
Methixene	<i>Trest</i>	3	A		

Methocarbamol	<i>Robaxin</i>	4	C		
Methohexital					
Methotrexate	<i>Folex, Nexate, etc.</i>	4	B		
Methotrimeprazine					
Methoxamine	<i>Vasoxyl</i>	3	A		
Methoxyphenamine					
<i>Methoxypolyethylene glycol-epoetin beta (CERA)</i>		1	A	Erythropoietin Link - an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia associated with chronic kidney disease (CKD in adult patients on dialysis and patients not on dialysis.	Blood doping agent
Methscopolamine					
Methsuximide	<i>Celontin</i>	4	B		
Methyclothiazide					
Methyl-1-testosterone		3	A		
Methylatropine		3	B		
Methyldienolone		3	A		
Methyldopa	<i>Aldomet</i>	3	A		
Methylergonovine	<i>Methergine</i>	4	C		
Methylhexanamine (Methylhexanamine)	<i>Geranamine</i>	1	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Methylnortestosterone (Trestolone)		3	A		

Methylphenidate					
Methylprednisolone	<i>Medrol</i>	4	C		
Methyltestosterone					
Methyprylon	<i>Noludar</i>	2	A		
Methysergide					
Metiamide		4	B		
Metoclopramide					
Metocurine	<i>Metubine</i>	2	A		
Metolazone					
Metomidate	<i>Hypnodil</i>	2	A		
Metopon (methyldihydromorphin one)					
Metoprolol	<i>Lopressor</i>	3	B		
Metribolone					
Mexazolam	<i>Melex</i>	2	A		
Mexiletine					
Mibefradil	<i>Posicor</i>	3	B		
Mibolerone		3	B		
Midazolam	<i>Versed</i>	3	B		
Midodrine	<i>Pro-Amiline</i>	3	B		
Milrinone		4	B		

Minoxidil					
Mirtazepine	<i>Remeron</i>	2	A		
Misoprostol					
Mitragynine	<i>Kratom</i>	1	A		
Mivacurium					
Modafinil	<i>Provigil</i>	2	A		
Moexipril (metabolite, moexiprilat)					
Molidustat		1	A	Blood doping agent	
Molindone	<i>Moban</i>	2	A		
Mometasone					
Montelukast	<i>Singulair</i>	4	C		
Moperone					
Morphine		1	A6	If it is determined by the State Veterinarian/Equine Medical Director; the Stewards, or the Racing Authority that the finding of cocaine or morphine was unintentional and not based upon an attempt to affect the outcome of a race, the Stewards or Racing Authority may elect to assign a Class B penalty to the trainer.	
Mosaprimine					
Muscarine		3	A		
myo-inositol trispyrophosphate (ITPP)		1	A		
N-Butylscopolamine		4	C		
Nabumetone	<i>Anthraxan, Relafen, Reliflex</i>	3	A		

Nadolol	<i>Corgard</i>	3	B		
Naepaine					
Nalbuphine	<i>Nubain</i>	2	A		

Nalorphine					
Naloxone	<i>Narcan</i>	3	B		
Naltrexone					
Nandrolone	<i>Nandrolin, Laurabolin, Durabolin</i>	3	B		
Naphazoline					
Naproxen	<i>Equiproxen, Naprosyn</i>	4	C		
Naratriptan					
Nebivolol		3	A		
Nedocromil					
Nefazodone	<i>Serzone</i>	2	A		
Nefopam		3	A		
Neostigmine	<i>Prostigmine</i>	3	B		
Nicardipine	<i>Cardine</i>	4	B		
Nifedipine	<i>Procardia</i>	4	B		
Niflumic acid	<i>Nifluril</i>	3	B		
Nikethamide	<i>Coramine</i>	1	A		

Nimesulide					
Nimetazepam	<i>Erimin</i>	2	A		
Nimodipine					
Nitrazepam	<i>Mogadon</i>	2	A		
Nitroglycerin					
Nizatidine	<i>Axid</i>	5	D		

<i>Norandrosterone</i>					
Norbolethone/Norboletone		3	A		
Norclostebol					
Nordiazepam	<i>Calmday, Nordaz, etc.</i>	2	A		
Norethisterone (norethindrone)					
Norepinephrine					
Norethandrolone		3	A		
Nortestosterone					
Nortriptyline	<i>Aventyl, Pamelor</i>	2	A		
Nylidrine					
Olanzapine	<i>Zyprexa</i>	2	A		
Oliceridine		1	A	FDA approved opioid for humans	
Olmesartan	<i>Benicar</i>	3	A		

Olsalazine	<i>Dipentum</i>	5	C		
Omeprazole					
Oripavine		2	A		
Orphenadrine	<i>Norlfex</i>	4	B		
Ostarine					
Oxabolone					
Oxandrolone	<i>Anavar</i>	3	B		
Oxaprozin					
Oxazepam	<i>Serax</i>	2	A		
Oxazolam					
Oxcarbazepine	<i>Trileptal</i>	3	A		

Oxilofrine (hydroxyephedrine)					
Oxprenolol	<i>Trasicor</i>	3	A		
Oxycodone	<i>Percodan</i>	1	A		
Oxymesterone		3	A		
Oxymetazoline	<i>Afrin</i>	4	B		
Oxymetholone	<i>Adroyd, Anadrol</i>	3	B		
Oxymorphone	<i>Numorphan</i>	1	A		
Oxyperitine	<i>Forit, Integrin</i>	2	A		

Oxyphenbutazone	<i>Tandearil</i>	4	C		
Oxyphencyclimine	<i>Daricon</i>	4	B		
Oxyphenonium	<i>Antrenyl</i>	4	B		
Paliperidone		2	A		
Pancuronium	<i>Pavulon</i>	2	A		
Pantoprazole	<i>Protonix</i>	5	D		
Papaverine	<i>Pavagen, etc.</i>	3	A		
Parecoxib		4	B		
Paraldehyde	<i>Paral</i>	2	A		
Paramethadione	<i>Paradione</i>	3	A		
Paramethasone	<i>Haldrone</i>	4	C		
Pargyline	<i>Eutonyl</i>	3	A		
Paroxetine	<i>Paxil, Seroxat</i>	2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Peginesatide		1	A	Erythropoietin Link - an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis.	Blood doping agent
Pemoline	<i>Cylert</i>	1	A		
Penbutolol	<i>Levatol</i>	3	B		
Penfluridol	<i>Cyperon</i>	2	A		

Pentaerythritol tetranitrate					
Pentazocine	<i>Talwin</i>	3	B		
Pentobarbital					
Pentoxyfylline	<i>Trental, Vazofirin</i>	4	D		
Pentylene-tetrazol					
Perazine	<i>Taxilan</i>	2	A		
Perfluorocarbons					
Perfluorodecahydronaphthalene		2	A		
Perfluorodecolin					
Perfluorooctylbromide		2	A		
Perfluorotripropylamine		2	A		
Pergolide	<i>Permax</i>	3	B		
Periciazine	<i>Alodept, etc.</i>	2	A		
Perindopril	<i>Biprel</i>	3	A		
Perlapine	<i>Hypnodin</i>	2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Perphenazine	<i>Trilafon</i>	2	A		
Phenacemide	<i>Phenurone</i>	4	B		
Phenaglycodol	<i>Acalo, Alcamid, etc.</i>	2	A		
Phenazocine	<i>Narphen</i>	1	A		

Phencyclidine (PCP)	<i>Sernylan</i>	1	A		
Phendimetrazine	<i>Bontril, etc.</i>	1	A		
Phenelzine	<i>Nardelzine, Nardil</i>	2	A		
Phenindione	<i>Hedulin</i>	5	D		
Phenmetrazine	<i>Preludin</i>	1	A		
Phenobarbital	<i>Luminal</i>	2	A		
Phenoxybenzamine	<i>Dibenzyline</i>	3	B		
Phenprocoumon	<i>Liquamar</i>	5	D		
Phensuximide	<i>Milontin</i>	4	B		
Phentermine	<i>Iomamin</i>	2	A		
Phentolamine	<i>Regitine</i>	3	B		
Phenylbutazone	<i>Butazolidin</i>	4	C*		
Phenylephrine	<i>Isophrin, Neo-Synephrine</i>	3	B		
Phenylpropanolamine	<i>Propadrine</i>	3	B		
Phenytoin	<i>Dilantin</i>	4	B		
Physostigmine	<i>Eserine</i>	3	A		
Picrotoxin		1	A		
Piminodine	<i>Alvodine, Cimadon</i>	2	A		

Pimobendan		2	B		
Pimozide					
Pinazepam	<i>Domar</i>	2	A		
Pindolol					
Pipamperone	<i>Dipiperon</i>	2	A		
Pipecuronium					
Pipequaline		2	A		
Piperacetazine					
Piperocaine	<i>Metycaine</i>	2	A		
Pipotiazine					
Pipradrol	<i>Dataril, Gerondyl, etc.</i>	2	A		
Piquindone					
Pirbuterol	<i>Maxair</i>	3	B		
Pirenzepine					
Piretanide	<i>Arelix, Tauliz</i>	3	B		
Pirtramide		1	A		
Piroxicam	<i>Feldene</i>	4	B		

Plasma expanders (e.g. Bycerol; intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol)					
Polyethylene glycol		5	D		
Polythiazide					

Pramoxine	<i>Tronothaine</i>	4	C		
Prasterone (dehydroepiandrosterone, DHEA, 3βhydroxyandrost-5-en17-one)		3	B	Steroid - inactive endogenous steroid.	Endogenous AAS
Prazepam	<i>Verstran, Centrax</i>	2	A		
Prazosin	<i>Minipress</i>	3	B		
Prednisolone	<i>Delta-Cortef, etc.</i>	4	C		
Prednisone	<i>Meticorten, etc.</i>	4	C		
Pregabalin	<i>Lyrica</i>	3	B	Gabapentanoid	
Prilocaine	<i>Citanest</i>	2	B		
Primidone	<i>Mysoline</i>	3	B		
Probenecid		4	C		
Procainamide	<i>Pronestyl</i>	4	B		
Procaine		3	B		

Procaterol					
Prochlorperazine	<i>Darbazine, Compazine</i>	2	A		
Procyclidine					
Promazine	<i>Sparine</i>	3	B		
Promethazine					
Propafenone	<i>Rythmol</i>	4	B		
Propanidid					
Propantheline	<i>Pro-Banthine</i>	3	B		
Proparacaine					

Propentophylline	<i>Karsivan</i>	3	B		
Propiomazine					
Propionylpromazine	<i>Tranvet</i>	2	A		
Propiram		2	A		
Propofol	<i>Diprivan, Disoprivan</i>	2	A		
Propoxycaine	<i>Ravocaine</i>	2	A		
Propranolol	<i>Inderal</i>	3	B		
Propylhexedrine	<i>Benzedrex</i>	4	B		
Prostanazol		3	A		

Prothipendyl					
Protokylol	<i>Ventaire</i>	3	A		
Protriptyline					
Proxibarbital	<i>Axeen, Centralgol</i>	2	A		
Pseudoephedrine					
Pyridostigmine	<i>Mestinon, Regonol</i>	3	B		
Pyrilamine					
Pyrithyldione	<i>Hybersulfan, Sonodor</i>	2	A		
Quazipam					
Quetiapine	<i>Seroquel</i>	2	A		
Quinapril, Quinaprilat					
Quinbolone		3	A		
Quinidine					

Rabeprazole	<i>Aciphex</i>	5	D		
Racemethorphan					
Racemorphan		2	A		
Raclopride		2	A		
Ractopamine	<i>Paylean</i>	2	A		

Raloxifene					
Ramipril, metabolite Ramiprilat	<i>Altace</i>	3	A		
Ranitidine					
Remifentanil	<i>Ultiva</i>	1	A		
Remoxipride					
Reserpine	<i>Serpasil</i>	2	B		
Rilmazafone					
Risperidone		2	A		
Ritanserin		2	A		
Ritodrine	<i>Yutopar</i>	3	B		
Rivastigmine	<i>Exelon</i>	2	A		
Rizatriptan	<i>Maxalt</i>	3	B		
Rocuronium	<i>Zemuron</i>	2	A		
Rofecoxib	<i>Vioxx</i>	2	B		
Romifidine	<i>Sedivet</i>	3	B		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Ropivacaine	<i>Naropin</i>	2	A		

Roxadustat (FG-4592)					
Salicylamide		4	C		
Salicylate					
Salmeterol		3	B		
Scopolamine (Hyoscine)					
Secobarbital (Quinalbarbitone)	<i>Seconal</i>	2	A		
Selective Androgen Receptor Modulators (SARMs)					
Selegiline					
Sertraline	<i>Lustral, Zoloft</i>	2	A		
Sibutramine					
Sildenafil	<i>Viagra</i>	3	A		
Snake Venoms					
Somatrem	<i>Protropin</i>	2	A		
Somatropin					
Sotalol	<i>Betapace, Sotacor</i>	3	B		
Spiclomazine		2	A		
Spiperone		2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
-----------------------	----------------------	-------------------	----------------------	-------------------------	--------------

Spirapril, metabolite Spiraprilat					
Spironolactone	<i>Aldactone</i>	4	B		
Spironolactone					
Stanozolol	<i>Winstrol-V</i>	3	B		
Stenbolone					
Strychnine		1	A		
Succinylcholine					
Sufentanil	<i>Sufenta</i>	1	A		
Sulfasalazine					
Sulfondiethylmethane		2	A		
Sulfonmethane		2	A		
Sulforidazine	<i>Inofal</i>	2	A		
Sulindac	<i>Clinoril</i>	3	B		
Sulpiride	<i>Aiglonyl, Sulpitil</i>	2	A		
Sultopride	<i>Barnetil</i>	2	A		
Sumatriptan	<i>Imitrex</i>	3	B		
Synthetic cannabis	<i>Spice, K2, Kronic</i>	1	A		
Tadalafil	<i>Cialis</i>	3	A		
Talbutal	<i>Lotusate</i>	2	A		
Tamoxifen		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - Estrogen receptor antagonist antineoplastic agent.	Testolactone has B classification

Tandospirone					
Tapentadol	<i>Nucynta</i>	1	A		
TCO2		3	B		
Telmisartin					
Temazepam	<i>Restoril</i>	2	A		
Tenoxicam					
Tepoxalin		3	B		
Terazosin					
Terbutaline	<i>Brethine, Bricanyl</i>	3	B		
Terfenadine					
Testolactone	<i>Teslac</i>	3	B		
Testolone					
Testosterone					
Tetrabenazine	<i>Nitoman</i>	2	A		
Tetracaine					
Tetrahydrogestrinone		3	A		
Tetrahydrozoline					
Tetrazepam	<i>Musaril, Myolastin</i>	2	A		
THC (tetrahydrocannabinol) ²					
Thebaine		2	A		
Theobromine		4	B		

Theophylline	<i>Aqualphyllin, etc.</i>	3	B		
Thialbarbital	<i>Kemithal</i>	2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Thiamylal	<i>Surital</i>	2	A		
Thiethylperazine	<i>Torecan</i>	2	A		
Thiopental	<i>Pentothal</i>	2	A		
Thiopropazate	<i>Dartal</i>	2	A		
Thiopropazine	<i>Majeptil</i>	2	A		
Thioridazine	<i>Mellaril</i>	2	A		
Thiosalicylate		4	B		
Thiothixene	<i>Navane</i>	2	A		
Thiphenamil	<i>Trocinate</i>	4	B		
Thyroxine and thyroid modulators/hormones, including but not limited to those containing T4 (tetraiodothyronine/thyroxine), T3 (triiodothyronine), or combinations thereof.	Levothyroxine	3	C		FDA approved but has (limited) legitimate use in care of racehorses.
Tiapride	<i>Italprid, Luxoben, etc.</i>	2	A		
Tiaprofenic acid	<i>Surgam</i>	3	B		
Tibolone		3	A	Steroid - synthetic steroid.	AAS lacking FDA approval
Tildronate Sodium	<i>Tildren</i>	3	A	Bisphosphonate	
Tiletamine	<i>Component of Telazol</i>	2	A		

Timiperone	<i>Tolopelon</i>	2	A		
Timolol					
Tocainide	<i>Tonocard</i>	4	B		
Tofisopam					

Tolazoline	<i>Priscoline</i>	3	B		
Tolfenamic Acid		4	B		
Tolmetin	<i>Tolectin</i>	3	B		
Topirimate	<i>Topamax</i>	2	A		
Toremifene		3	B	Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - Selective estrogen receptor modulator.	
Torseamide (Torasemide)	<i>Demadex</i>	3	A		
Tramadol	<i>Ultram</i>	2	B		
Trandolapril (and metabolite, trandolaprilat)	<i>Tarka</i>	3	B		
Tranexamic acid		4	C		
Tranlycypromine	<i>Parnate</i>	2	A		
Trazodone	<i>Desyrel</i>	2	A		
Trenbolone	<i>Finoplix</i>	3	B		
Tretoquinol	<i>Inolin</i>	2	A		
Triamcinolone	<i>Vetalog, etc.</i>	4	C		
Triamterene	<i>Dyrenium</i>	4	B		
Triazolam	<i>Halcion</i>	2	A		

Tribromethanol		2	A		
Tricaine methanesulfonate					
Trichlormethiazide	<i>Naqua, Naquasone</i>	4	C		
Trichloroethanol		2	A		
Trichloroethylene	<i>Trilene, Trimar</i>	2	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Triclofos	<i>Triclos</i>	2	A		
Tridihexethyl	<i>Pathilon</i>	4	B		
Trifluomeprazine	<i>Nortran</i>	2	A		
Trifluoperazine	<i>Stelazine</i>	2	A		
Trifluperidol	<i>Triperidol</i>	2	A		
Triflupromazine	<i>Vetame, Vesprin</i>	2	A		
Trihexylphenidyl	<i>Artane</i>	3	A		
Trimeprazine	<i>Temaril</i>	4	B		
Trimetazidine		3	B		Hormone and Metabolic effects, same classification as Testolactone on Human Olympic Guidelines - a drug for angina pectoris, the first cytoprotective anti- ischemic agent.
Trimethadione	<i>Tridione</i>	3	B		
Trimethaphan	<i>Arfonad</i>	3	A		
Trimipramine	<i>Surmontil</i>	2	A		
Tripeleppamine	<i>PBZ</i>	3	B		
Tripolidine	<i>Actidil</i>	3	B		
Trometamol (Also known as tris hydroxymethyl aminomethane [THAM])		3	B		

Tubocurarine (Curare)	<i>Metubin</i>	2	A		
Tybamate	<i>Benvil, Nospan, etc.</i>	2	A		
Urethane		2	A		
Valdecoxib		4	B	Corrected to be consistent with all NSAIDS	
Valerenic acid		3	A		
Valnoctamide	<i>Nirvanyl</i>	2	A		
Valsartan	<i>Diovan</i>	3	B		
Vardenafil	<i>Levitra</i>	3	A		

Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Vedaprofen		4	B		
Venlafaxine	<i>Efflexor</i>	2	A		
Veralipride	<i>Accional, Veralipril</i>	2	A		
Verapamil	<i>Calan, Isoptin</i>	4	B		
Vercuronium	<i>Norcuron</i>	2	A		
Viloxazine	<i>Catatrol, Vivalan, etc.</i>	2	A		
Vinbarbital	<i>Delvinol</i>	2	A		
Vinylbital	<i>Optanox, Speda</i>	2	A		
Warfarin	<i>Coumadin, Coufarin</i>	5	D		
Xylazine	<i>Rompun, Bay Va 1470</i>	3	B		
Xylometazoline	<i>Otrivin</i>	4	B		
Yohimbine		2	B		

Zafirlukast	<i>Accolate</i>	4	C		
Zaleplon	<i>Sonata</i>	2	A		
Zeranol	<i>Ralgro</i>	4	C		
Ziconotide		1	A		
Zileuton	<i>Zyflo</i>	4	C		
Zilpaterol hydrochloride	<i>Zilpaterol</i>	2	A		
Ziprasidone	<i>Geoden</i>	2	A		
Zolazepam		2	A		
Zolmitriptan	<i>Zomig</i>	3	B		
Zolpidem	<i>Ambien, Stilnox</i>	2	A		
Drug/Substance	Trade Name(s)	Drug Class	Penalty Class	Special Notation	Note.
Zomepirac	<i>Zomax</i>	2	B		
Zonisamide	<i>Zonegran</i>	3	B		
Zopiclone	<i>Imovan</i>	2	A		
Zotepine	<i>Lodopin</i>	2	A		
Zuclopenthixol	<i>Ciatyl, Cesordinol</i>	2	A		

UNIFORM CLASSIFICATION OF FOREIGN SUBSTANCES
Version 14.4 (December, 2020)

PENALTY GUIDELINES

© ASSOCIATION OF RACING COMMISSIONERS INTERNATIONAL – 2020.

Association of Racing Commissioners International
2365 Harrodsburg Road, B-450, Lexington, Kentucky, United States
www.arci.com

PENALTY CATEGORY “A”

The following are recommended penalties for violations due to the presence of a drug carrying a Category “A” penalty and for violations of ARCI-011-015 and ARCI-025-015: Prohibited Practices:

LICENSED TRAINER:		
1st Offense	2nd LIFETIME offense in any jurisdiction	3rd LIFETIME offense in any jurisdiction
<ul style="list-style-type: none"> Minimum one-year suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of a three-year suspension <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Minimum fine of \$10,000 or 10% of total purse (greater of the two) absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of \$25,000 or 25% of purse (greater of the two). <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> May be referred to the Commission for any further action deemed necessary by the Commission. 	<ul style="list-style-type: none"> Minimum three-year suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of license revocation with no reapplication for a three-year period. <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Minimum fine of \$25,000 or 25% of total purse (greater of the two) absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of \$50,000 or 50% purse (greater of the two). <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> May be referred to the Commission for any further action deemed necessary by the Commission. 	<ul style="list-style-type: none"> Minimum five-year suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of license revocation with no reapplication for a five-year period. <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Minimum fine of \$50,000 or 50% of total purse (greater of the two) absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of \$100,000 or 100% purse (greater of the two). <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> May be referred to the Commission for any further action deemed necessary by the Commission.
LICENSED OWNER:		
1st Offense	2nd LIFETIME offense in owner’s stable any jurisdiction	3rd LIFETIME offense in owner’s stable in any jurisdiction
<ul style="list-style-type: none"> Disqualification and loss of purse <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Horse shall be placed on the Veterinarian’s List for 180 days and must pass a commission-approved examination before becoming eligible to be entered. 	<ul style="list-style-type: none"> Disqualification and loss of purse <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Horse shall be placed on the Veterinarian’s List for 180 days and must pass a commission-approved examination before becoming eligible to be entered. 	<ul style="list-style-type: none"> Disqualification, loss of purse and \$50,000 fine <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Horse shall be placed on the Veterinarian’s List for 180 days and must pass a commission-approved examination before becoming eligible to be entered. <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Referral to the Commission with a recommendation of a suspension for a minimum of 90 days.

PENALTY CATEGORY “B”

The following are recommended penalties for violations due to the presence of a drug carrying Category “B” penalty, for the detection of two or more NSAIDs in a plasma/serum and/or urine sample, the detection of two or more corticosteroids in a plasma/serum and/or urine sample subject to the provisions set forth in ARCI-011-020(E) and ARCI-025-020(E) and for violations of the established levels for total carbon dioxide:

LICENSED TRAINER:		
1st Offense	2nd offense (365-day period) in any jurisdiction	3rd offense (365-day period) in any jurisdiction
<ul style="list-style-type: none"> Minimum 15-day suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of a 60-day suspension <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Minimum fine of \$500 absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum fine of \$1,000. 	<ul style="list-style-type: none"> Minimum 30-day suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of a 180-day suspension <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Minimum fine of \$1,000 absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum fine of \$2,500. 	<ul style="list-style-type: none"> Minimum 60-day suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of a one-year suspension. <ul style="list-style-type: none"> Minimum fine of \$2,500 absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of \$5,000 or 5% purse (greater of the two). <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> May be referred to the Commission for any further action deemed necessary by the Commission.
LICENSED OWNER:		
1st Offense	2nd offense (365-day period) in owner's stable any jurisdiction	3rd offense (365-day period) in owner's stable in any jurisdiction
<ul style="list-style-type: none"> Disqualification and loss of purse [in the absence of mitigating circumstances]* <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Horse must pass a commission-approved examination before becoming eligible to be entered. 	<ul style="list-style-type: none"> Disqualification and loss of purse [in the absence of mitigating circumstances]* <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Horse must pass a commission-approved examination before becoming eligible to be entered. 	<ul style="list-style-type: none"> Disqualification, loss of purse, and in the absence of mitigating circumstances a \$5,000 fine.* <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Horse shall be placed on the Veterinarian's List for 45 days and must pass a commission-approved examination before becoming eligible to be entered.

PENALTY CATEGORY "C"

The following are recommended penalties for violations due to the presence of a drug carrying a Category "C" penalty and overages for permitted NSAIDs and furosemide: **(All concentrations are for measurements in serum or plasma.)**

LICENSED TRAINER	Furosemide (>100 ng/ml) and/or no furosemide when identified as administered	Phenylbutazone (>0.3 mcg/ml) Flunixin (> 5.0 ng/ml) Ketoprofen (> 2.0 ng/ml) and CLASS C Violations
1 st Offense (365-day period) in any jurisdiction	Minimum of a written warning to maximum fine of \$500	Minimum fine of \$1,000 absent mitigating circumstances
2 nd Offense (365-day period) in any jurisdiction	Minimum of a written warning to maximum fine of \$750	Minimum fine of \$1,500 and 15-day suspension absent mitigating circumstances
3 rd Offense (365-day period) in any jurisdiction	Minimum fine of \$500 to a maximum fine of \$1,000	Minimum fine of \$2,500 and 30-day suspension absent mitigating circumstances
LICENSED OWNER	Furosemide (>100 ng/ml) and/or no furosemide when identified as administered	Phenylbutazone (>0.3 mcg/ml) Flunixin (> 5.0 ng/ml) Ketoprofen (> 2.0 ng/ml) and CLASS C Violations
1 st Offense (365-day period) in any jurisdiction	Horse may be required to pass commission-approved examination before being eligible to run	Disqualification and loss of purse in the absence of mitigating circumstances. Horse must pass commission-approved examination before being eligible to run.
2 nd Offense (365-day period) in any jurisdiction	Horse may be required to pass commission-approved examination before being eligible to run	Disqualification and loss of purse in the absence of mitigating circumstances. If same horse, placed on veterinarian's list for 45 days, must pass commission-approved examination before being eligible to run
3 rd Offense (365-day period) in any jurisdiction	Disqualification and loss of purse. Horse must pass commission-approved examination before being eligible to run	Disqualification and loss of purse in the absence of mitigating circumstances. Minimum \$5,000 fine. If same horse, placed on veterinarian's list for 60 days, must pass commission-approved examination before being eligible to run

After a two-year period, if the licensee has had no further violations, any penalty due to an overage in the 2.0-5.0 category will be expunged from the licensee's record for penalty purposes.

PENALTY CATEGORY "D"

The recommended penalty for a violation involving a drug that carries a Category "D" penalty is a written warning to the trainer and owner. Multiple violations may result in fines and/or suspension.



MMV Point System

Multiple Medication Violation Model Rule. ARCI-011-020

(B)(13)

Officials are advised to check a licensee's ARCI regulatory record to see if multiple medication violations should be considered as an aggravating factor in the determination of an appropriate penalty.

(1) Multiple Medication Violations (MMV)

- (a) A trainer who receives a penalty for a medication violation based upon a horse testing positive for a Class 1-5 medication with Penalty Class A-C, as provided in the most recent version of the ARCI Uniform Classification Guidelines for Foreign Substances, or similar state regulatory guidelines, shall be assigned points as follows:

Penalty Class	Points If Controlled Therapeutic Substance	Points If Non-Controlled Substance
Class A	N/A	6
Class B	2	4
Class C	½ for first violation with an additional ½ point for each additional violation within 365 days ¹	1 for first violation with an additional ½ point for each additional violation within 365 days
Class D	0	0

¹ Points for NSAID violations only apply when the primary threshold of the NSAID is exceeded. Points are not to be separately assigned for a stacking violation.

If the Stewards or Commission determine that the violation is due to environmental contamination, they may assign lesser or no points against the trainer based upon the specific facts of the case.

- (b) The points assigned to a medication violation by the Stewards or Commission ruling shall be included in the ARCI official database. The ARCI shall record points consistent with Section 13(a) including when appropriate, a designation that points have been suspended for the medication violation. Points assigned by such regulatory ruling shall reflect, in the case of multiple

positive tests as described in paragraph (d), whether they constitute a single violation. The Stewards' or Commission Ruling shall be posted on the official website of the Commission and within the official database of the Association of Racing Commissioners International. If an appeal is pending, that fact shall be noted in such Ruling. No points shall be applied until a final adjudication of the enforcement of any such violation.

- (c) A trainer's cumulative points for violations in all racing jurisdictions shall be maintained by the ARCI. Once all appeals are waived or exhausted, the points shall immediately become part of the trainer's official ARCI record and shall be considered by the Commission in its determination to subject the trainer to the mandatory enhanced penalties by the Stewards or Commission as provided in this regulation.
- (d) Multiple positive tests for the same medication incurred by a trainer prior to delivery of official notice by the commission may be treated as a single violation. In the case of a positive test indicating multiple substances found in a single post-race sample, the Stewards may treat each substance found as an individual violation for which points will be assigned, depending upon the facts and circumstances of the case.
- (e) The official ARCI record shall be used to advise the Stewards or Commission of a trainer's past record of violations and cumulative points. Nothing in this administrative regulation shall be construed to confer upon a licensed trainer the right to appeal a violation for which all remedies have been exhausted or for which the appeal time has expired as provided by applicable law.
- (f) The Stewards or Commission shall consider all points for violations in all racing jurisdictions as contained in the trainer's official ARCI record when determining whether the mandatory enhancements provided in this regulation shall be imposed.
- (g) In addition to the penalty for the underlying offense, the following enhancements shall be imposed upon a licensed trainer based upon the cumulative points contained in his/her official ARCI record:

Points	Suspension in days
5-5.5	15 to 30
6-8.5	30 to 60
9-10.5	90 to 180
11 or more	180 to 360

MMV penalties are not a substitute for the current penalty system and are intended to be an additional uniform penalty when the licensee:

- (i) Has had more than one medication violation for the relevant time period, and (ii) Exceeds the permissible number of points.

The Stewards and Commission shall consider aggravating and mitigating circumstances, including the trainer’s prior record for medication violations, when determining the appropriate penalty for the underlying offense. The MMP is intended to be a separate and additional penalty for a pattern of violations.

- (h) The suspension periods as provided in Section 13(g) shall run consecutive to any suspension imposed for the underlying offense.
- (i) The Stewards’ or Commission Ruling shall distinguish between the penalty for the underlying offense and any enhancement based upon a Stewards or Commission review of the trainer’s cumulative points and regulatory record, which may be considered an aggravating factor in a case.
- (j) Points shall expire as follows:

Penalty Classification	Time to Expire
A	3 years
B	2 years
C	1 year

In the case of a medication violation that results in a suspension, any points assessed expire on the anniversary date of the date the suspension is completed.

#####

REVISIONS TO ARCI UNIFORM CLASSIFICATION GUIDELINES FOR FOREIGN SUBSTANCES

Version	Date	Drug/Substance	Notes
14.2	September 2020	Medroxyprogesterone	Replaced methoxyprogesterone as probable typo
14.2	September 2020	Medroxyprogesterone	Added as Drug Class 3, Penalty Class B.
14.2	September 2020	Methoxyprogesterone	Removed as drug does not exist 14.2
		Methoxyprogesterone	Removed Asterisk Language on Permitted Nsaids
<p>“*If the trainer has not had more than one violation within the previous two years, the Stewards/Judges are encouraged to issue a warning in lieu of a fine provided the reported level is below 3.0 mcg/ml absent of aggravating factors.”</p>			
14.3	September 2020	Medroxyprogesterone	Moved to correct location alphabetically
14.4	December 2020	Alpha pyrrolidinovalerophenone	Added as Drug Class 1, Penalty Class A
14.4	December 2020	Aripiprazole	Added as Drug Class 2, Penalty Class A
14.4	December 2020	Arsenic	Added as Drug Class 3, Penalty Class B
14.4	December 2020	Diisopropylamine	Added as Drug Class 2, Penalty Class B
14.4	December 2020	Etofenamate	Added as Drug Class 4, Penalty Class B
14.4	December 2020	Flufenamic Acid	Changed to Drug Class 4, Penalty B
14.4	December 2020	Harpagoside	Added as Drug Class 4, Penalty B
14.4	December 2020	Hypoxia-inducible factor (HIF) activators	Changed from Drug Class 3, Penalty A to Drug Class 1, Penalty A
14.4	December 2020	Hypoxia-inducible factor (HIF) stabilizers (e.g. IOX-2)	Added as Drug Class 1, Penalty A
14.4	December 2020	Molidustat	Added as Drug Class 1, Penalty A
14.4	December 2020	Norethisterone(norethindrone)	Added as Drug Class 4, Penalty B
14.4	December 2020	Oliceridine	Added as Drug Class 1, Penalty A
14.4	December 2020	Oripavine	Added as Drug Class 2, Penalty A
14.4	December 2020	Parecoxib	Added as Drug Class 4, Penalty B
14.4	December 2020	Pregabalin	Added as Drug Class 3, Penalty B
14.4	December 2020	Tapentadol	Added as Drug Class 1, Penalty A
14.4	December 2020	Trometamol (Also known as THAM)	Added as Drug Class 3, Penalty B
14.4	December 2020	Valdecoxib	Changed from Drug Class 2, Penalty B to Drug Class 4, Penalty B

116TH CONGRESS
2D SESSION

H. R. 1754

IN THE SENATE OF THE UNITED STATES

SEPTEMBER 30 (legislative day, SEPTEMBER 29), 2020

Received

AN ACT

To improve the integrity and safety of horseracing by requiring a uniform anti-doping and medication control program to be developed and enforced by an independent Horseracing Anti-Doping and Medication Control Authority.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLE.**

2 This Act may be cited as the “Horseracing Integrity
3 and Safety Act of 2020”.

4 **SEC. 2. DEFINITIONS.**

5 In this Act the following definitions apply:

6 (1) **AUTHORITY.**—The term “Authority” means
7 the Horseracing Integrity and Safety Authority des-
8 ignated by section 3(a).

9 (2) **BREEDER.**—The term “breeder” means a
10 person who is in the business of breeding covered
11 horses.

12 (3) **COMMISSION.**—The term “Commission”
13 means the Federal Trade Commission.

14 (4) **COVERED HORSE.**—The term “covered
15 horse” means any Thoroughbred horse, or any other
16 horse made subject to this Act by election of the ap-
17 plicable State racing commission or the breed gov-
18 erning organization for such horse under section
19 5(k), during the period—

20 (A) beginning on the date of the horse’s
21 first timed and reported workout at a racetrack
22 that participates in covered horseraces or at a
23 training facility; and

24 (B) ending on the date on which the Au-
25 thority receives written notice that the horse
26 has been retired.

1 (5) COVERED HORSERACE.—The term “covered
2 horserace” means any horserace involving covered
3 horses that has a substantial relation to interstate
4 commerce, including any Thoroughbred horserace
5 that is the subject of interstate off-track or advance
6 deposit wagers.

7 (6) COVERED PERSONS.—The term “covered
8 persons” means all trainers, owners, breeders, jock-
9 eys, racetracks, veterinarians, persons (legal and
10 natural) licensed by a State racing commission and
11 the agents, assigns, and employees of such persons
12 and other horse support personnel who are engaged
13 in the care, training, or racing of covered horses.

14 (7) EQUINE CONSTITUENCIES.—The term
15 “equine constituencies” means, collectively, owners,
16 breeders, trainers, racetracks, veterinarians, State
17 racing commissions, and jockeys who are engaged in
18 the care, training, or racing of covered horses.

19 (8) EQUINE INDUSTRY REPRESENTATIVE.—The
20 term “equine industry representative” means an or-
21 ganization regularly and significantly engaged in the
22 equine industry, including organizations that rep-
23 resent the interests of, and whose membership con-
24 sists of, owners, breeders, trainers, racetracks, vet-
25 erinarians, State racing commissions, and jockeys.

1 (9) HORSERACING ANTI-DOPING AND MEDICA-
2 TION CONTROL PROGRAM.—The term “horseracing
3 anti-doping and medication control program” means
4 the anti-doping and medication program established
5 under section 6(a).

6 (10) IMMEDIATE FAMILY MEMBER.—The term
7 “immediate family member” shall include a spouse,
8 domestic partner, mother, father, aunt, uncle, sib-
9 ling, or child.

10 (11) INTERSTATE OFF-TRACK WAGER.—The
11 term “interstate off-track wager” has the meaning
12 given such term in section 3 of the Interstate Horse-
13 racing Act of 1978 (15 U.S.C. 3002).

14 (12) JOCKEY.—The term “jockey” means a
15 rider or driver of a covered horse in covered
16 horseraces.

17 (13) OWNER.—The term “owner” means a per-
18 son who holds an ownership interest in one or more
19 covered horses.

20 (14) PROGRAM EFFECTIVE DATE.—The term
21 “program effective date” means July 1, 2022.

22 (15) RACETRACK.—The term “racetrack”
23 means an organization licensed by a State racing
24 commission to conduct covered horseraces.

1 (16) RACETRACK SAFETY PROGRAM.—The term
2 “racetrack safety program” means the program es-
3 tablished under section 7(a).

4 (17) STAKES RACE.—The term “stakes race”
5 means any race so designated by the racetrack at
6 which such race is run, including, without limitation,
7 the races comprising the Breeders’ Cup World
8 Championships and the races designated as graded
9 stakes by the American Graded Stakes Committee of
10 the Thoroughbred Owners and Breeders Association.

11 (18) STATE RACING COMMISSION.—The term
12 “State racing commission” means an entity des-
13 ignated by State law or regulation that has jurisdic-
14 tion over the conduct of horseracing within the ap-
15 plicable State.

16 (19) TRAINER.—The term “trainer” means an
17 individual engaged in the training of covered horses.

18 (20) TRAINING FACILITY.—The term “training
19 facility” means a location that is not a racetrack li-
20 censed by a State racing commission that operates
21 primarily to house covered horses and conduct offi-
22 cial timed workouts.

23 (21) VETERINARIAN.—The term “veterinarian”
24 means a licensed veterinarian who provides veteri-
25 nary services to covered horses.

1 (22) WORKOUT.—The term “workout” means a
2 timed running of a horse over a predetermined dis-
3 tance not associated with a race or its first quali-
4 fying race, if such race is made subject to this Act
5 by election under section 5(k) of the horse’s breed
6 governing organization or the applicable State racing
7 commission.

8 **SEC. 3. RECOGNITION OF THE HORSERACING INTEGRITY**
9 **AND SAFETY AUTHORITY.**

10 (a) IN GENERAL.—The private, independent, self-
11 regulatory, nonprofit corporation, to be known as the
12 “Horseracing Integrity and Safety Authority”, is recog-
13 nized for purposes of developing and implementing a
14 horseracing anti-doping and medication control program
15 and a racetrack safety program for covered horses, cov-
16 ered persons, and covered horseraces.

17 (b) BOARD OF DIRECTORS.—

18 (1) MEMBERSHIP.—The Authority shall be gov-
19 erned by a board of directors (in this section re-
20 ferred to as the “Board”) comprised of nine mem-
21 bers as follows:

22 (A) INDEPENDENT MEMBERS.—Five mem-
23 bers of the Board shall be independent mem-
24 bers selected from outside the equine industry.

25 (B) INDUSTRY MEMBERS.—

1 (i) IN GENERAL.—Four members of
2 the Board shall be industry members se-
3 lected from among the various equine con-
4 stituencies.

5 (ii) REPRESENTATION OF EQUINE
6 CONSTITUENCIES.—The industry members
7 shall be representative of the various
8 equine constituencies, and shall include not
9 more than one industry member from any
10 one equine constituency.

11 (2) CHAIR.—The chair of the Board shall be an
12 independent member described in paragraph (1)(A).

13 (3) BYLAWS.—The Board of the Authority shall
14 be governed by bylaws for the operation of the Au-
15 thority with respect to—

16 (A) the administrative structure and em-
17 ployees of the Authority;

18 (B) the establishment of standing commit-
19 tees;

20 (C) the procedures for filling vacancies on
21 the Board and the standing committees;

22 (D) term limits for members and termi-
23 nation of membership; and

24 (E) any other matter the Board considers
25 necessary.

1 (c) STANDING COMMITTEES.—

2 (1) ANTI-DOPING AND MEDICATION CONTROL
3 STANDING COMMITTEE.—

4 (A) IN GENERAL.—The Authority shall es-
5 tablish an anti-doping and medication control
6 standing committee, which shall provide advice
7 and guidance to the Board on the development
8 and maintenance of the horseracing anti-doping
9 and medication control program.

10 (B) MEMBERSHIP.—The anti-doping and
11 medication control standing committee shall be
12 comprised of seven members as follows:

13 (i) INDEPENDENT MEMBERS.—A ma-
14 jority of the members shall be independent
15 members selected from outside the equine
16 industry.

17 (ii) INDUSTRY MEMBERS.—A minority
18 of the members shall be industry members
19 selected to represent the various equine
20 constituencies, and shall include not more
21 than one industry member from any one
22 equine constituency.

23 (iii) QUALIFICATION.—A majority of
24 individuals selected to serve on the anti-
25 doping and medication control standing

1 committee shall have significant, recent ex-
2 perience in anti-doping and medication
3 control rules.

4 (C) CHAIR.—The chair of the anti-doping
5 and medication control standing committee
6 shall be an independent member of the Board
7 described in subsection (b)(1)(A).

8 (2) RACETRACK SAFETY STANDING COM-
9 MITTEE.—

10 (A) IN GENERAL.—The Authority shall es-
11 tablish a racetrack safety standing committee,
12 which shall provide advice and guidance to the
13 Board on the development and maintenance of
14 the racetrack safety program.

15 (B) MEMBERSHIP.—The racetrack safety
16 standing committee shall be comprised of seven
17 members as follows:

18 (i) INDEPENDENT MEMBERS.—A ma-
19 jority of the members shall be independent
20 members selected from outside the equine
21 industry.

22 (ii) INDUSTRY MEMBERS.—A minority
23 of the members shall be industry members
24 selected to represent the various equine
25 constituencies.

1 (C) CHAIR.—The chair of the racetrack
2 safety standing committee shall be an industry
3 member of the Board described in subsection
4 (b)(1)(B).

5 (d) NOMINATING COMMITTEE.—

6 (1) MEMBERSHIP.—

7 (A) IN GENERAL.—The nominating com-
8 mittee of the Authority shall be comprised of
9 seven independent members selected from busi-
10 ness, sports, and academia.

11 (B) INITIAL MEMBERSHIP.—The initial
12 nominating committee members shall be set
13 forth in the governing corporate documents of
14 the Authority.

15 (C) VACANCIES.—After the initial com-
16 mittee members are appointed in accordance
17 with subparagraph (B), vacancies shall be filled
18 by the Board pursuant to rules established by
19 the Authority.

20 (2) CHAIR.—The chair of the nominating com-
21 mittee shall be selected by the nominating committee
22 from among the members of the nominating com-
23 mittee.

24 (3) SELECTION OF MEMBERS OF THE BOARD
25 AND STANDING COMMITTEES.—

1 (A) INITIAL MEMBERS.—The nominating
2 committee shall select the initial members of
3 the Board and the standing committees de-
4 scribed in subsection (c).

5 (B) SUBSEQUENT MEMBERS.— The nomi-
6 nating committee shall recommend individuals
7 to fill any vacancy on the Board or on such
8 standing committees.

9 (e) CONFLICTS OF INTEREST.—To avoid conflicts of
10 interest, the following individuals may not be selected as
11 a member of the Board or as an independent member of
12 a nominating or standing committee under this section:

13 (1) An individual who has a financial interest
14 in, or provides goods or services to, covered horses.

15 (2) An official or officer—

16 (A) of an equine industry representative;
17 or

18 (B) who serves in a governance or policy-
19 making capacity for an equine industry rep-
20 resentative.

21 (3) An employee of, or an individual who has a
22 business or commercial relationship with, an indi-
23 vidual described in paragraph (1) or (2).

24 (4) An immediate family member of an indi-
25 vidual described in paragraph (1) or (2).

1 (f) FUNDING.—

2 (1) INITIAL FUNDING.—

3 (A) IN GENERAL.—Initial funding to es-
4 tablish the Authority and underwrite its oper-
5 ations before the program effective date shall be
6 provided by loans obtained by the Authority.

7 (B) BORROWING.—The Authority may bor-
8 row funds toward the funding of its operations.

9 (C) ANNUAL CALCULATION OF AMOUNTS
10 REQUIRED.—

11 (i) IN GENERAL.—Not later than the
12 date that is 90 days before the program ef-
13 fective date, and not later than November
14 1 each year thereafter, the Authority shall
15 determine and provide to each State racing
16 commission the estimated amount required
17 from the State—

18 (I) to fund the State's propor-
19 tionate share of the horseracing anti-
20 doping and medication control pro-
21 gram and the racetrack safety pro-
22 gram for the next calendar year; and

23 (II) to liquidate the State's pro-
24 portionate share of any loan or fund-

1 ing shortfall in the current calendar
2 year and any previous calendar year.

3 (ii) BASIS OF CALCULATION.—The
4 amounts calculated under clause (i) shall—

5 (I) be based on—

6 (aa) the annual budget of
7 the Authority for the following
8 calendar year, as approved by the
9 Board; and

10 (bb) the projected amount of
11 covered racing starts for the year
12 in each State; and

13 (II) take into account other
14 sources of Authority revenue.

15 (iii) REQUIREMENTS REGARDING
16 BUDGETS OF AUTHORITY.—

17 (I) INITIAL BUDGET.—The initial
18 budget of the Authority shall require
19 the approval of $\frac{2}{3}$ of the Board.

20 (II) SUBSEQUENT BUDGETS.—
21 Any subsequent budget that exceeds
22 the budget of the preceding calendar
23 year by more than 5 percent shall re-
24 quire the approval of $\frac{2}{3}$ of the Board.

25 (iv) RATE INCREASES.—

1 (I) IN GENERAL.—A proposed in-
2 crease in the amount required under
3 this subparagraph shall be reported to
4 the Commission.

5 (II) NOTICE AND COMMENT.—
6 The Commission shall publish in the
7 Federal Register such a proposed in-
8 crease and provide an opportunity for
9 public comment.

10 (2) ASSESSMENT AND COLLECTION OF FEES BY
11 STATES.—

12 (A) NOTICE OF ELECTION.—Any State
13 racing commission that elects to remit fees pur-
14 suant to this subsection shall notify the Author-
15 ity of such election not later than 60 days be-
16 fore the program effective date.

17 (B) REQUIREMENT TO REMIT FEES.—
18 After a State racing commission makes a notifi-
19 cation under subparagraph (A), the election
20 shall remain in effect and the State racing com-
21 mission shall be required to remit fees pursuant
22 to this subsection according to a schedule estab-
23 lished in rule developed by the Authority and
24 approved by the Commission.

1 (C) WITHDRAWAL OF ELECTION.—A State
2 racing commission may cease remitting fees
3 under this subsection not earlier than one year
4 after notifying the Authority of the intent of
5 the State racing commission to do so.

6 (D) DETERMINATION OF METHODS.—Each
7 State racing commission shall determine, sub-
8 ject to the applicable laws, regulations, and con-
9 tracts of the State, the method by which the
10 requisite amount of fees, such as foal registra-
11 tion fees, sales contributions, starter fees, and
12 track fees, and other fees on covered persons,
13 shall be allocated, assessed, and collected.

14 (3) ASSESSMENT AND COLLECTION OF FEES BY
15 THE AUTHORITY.—

16 (A) CALCULATION.—If a State racing com-
17 mission does not elect to remit fees pursuant to
18 paragraph (2) or withdraws its election under
19 such paragraph, the Authority shall, not less
20 frequently than monthly, calculate the applica-
21 ble fee per racing start multiplied by the num-
22 ber of racing starts in the State during the pre-
23 ceding month.

24 (B) ALLOCATION.—The Authority shall al-
25 locate equitably the amount calculated under

1 subparagraph (A) collected among covered per-
2 sons involved with covered horseraces pursuant
3 to such rules as the Authority may promulgate.

4 (C) ASSESSMENT AND COLLECTION.—

5 (i) IN GENERAL.—The Authority shall
6 assess a fee equal to the allocation made
7 under subparagraph (B) and shall collect
8 such fee according to such rules as the Au-
9 thority may promulgate.

10 (ii) REMITTANCE OF FEES.—Covered
11 persons described in subparagraph (B)
12 shall be required to remit such fees to the
13 Authority.

14 (D) LIMITATION.—A State racing commis-
15 sion that does not elect to remit fees pursuant
16 to paragraph (2) or that withdraws its election
17 under such paragraph shall not impose or col-
18 lect from any person a fee or tax relating to
19 anti-doping and medication control or racetrack
20 safety matters for covered horseraces.

21 (4) FEES AND FINES.—Fees and fines imposed
22 by the Authority shall be allocated toward funding
23 of the Authority and its activities.

24 (5) RULE OF CONSTRUCTION.—Nothing in this
25 Act shall be construed to require—

1 (A) the appropriation of any amount to the
2 Authority; or

3 (B) the Federal Government to guarantee
4 the debts of the Authority.

5 (g) QUORUM.—For all items where Board approval
6 is required, the Authority shall have present a majority
7 of independent members.

8 **SEC. 4. FEDERAL TRADE COMMISSION OVERSIGHT.**

9 (a) IN GENERAL.—The Authority shall submit to the
10 Commission, in accordance with such rules as the Com-
11 mission may prescribe under section 553 of title 5, United
12 States Code, any proposed rule, or proposed modification
13 to a rule, of the Authority relating to—

14 (1) the bylaws of the Authority;

15 (2) a list of permitted and prohibited medica-
16 tions, substances, and methods, including allowable
17 limits of permitted medications, substances, and
18 methods;

19 (3) laboratory standards for accreditation and
20 protocols;

21 (4) standards for racing surface quality mainte-
22 nance;

23 (5) racetrack safety standards and protocols;

24 (6) a program for injury and fatality data anal-
25 ysis;

1 (7) a program of research and education on
2 safety, performance, and anti-doping and medication
3 control;

4 (8) a description of safety, performance, and
5 anti-doping and medication control rule violations
6 applicable to covered horses and covered persons;

7 (9) a schedule of civil sanctions for violations;

8 (10) a process or procedures for disciplinary
9 hearings; and

10 (11) a formula or methodology for determining
11 assessments described in section 3(f).

12 (b) PUBLICATION AND COMMENT.—

13 (1) IN GENERAL.—The Commission shall—

14 (A) publish in the Federal Register each
15 proposed rule or modification submitted under
16 subsection (a); and

17 (B) provide an opportunity for public com-
18 ment.

19 (2) APPROVAL REQUIRED.—A proposed rule, or
20 a proposed modification to a rule, of the Authority
21 shall not take effect unless the proposed rule or
22 modification has been approved by the Commission.

23 (c) DECISION ON PROPOSED RULE OR MODIFICA-
24 TION TO A RULE.—

1 (1) IN GENERAL.—Not later than 60 days after
2 the date on which a proposed rule or modification is
3 published in the Federal Register, the Commission
4 shall approve or disapprove the proposed rule or
5 modification.

6 (2) CONDITIONS.—The Commission shall ap-
7 prove a proposed rule or modification if the Commis-
8 sion finds that the proposed rule or modification is
9 consistent with—

10 (A) this Act; and

11 (B) applicable rules approved by the Com-
12 mission.

13 (3) REVISION OF PROPOSED RULE OR MODI-
14 FICATION.—

15 (A) IN GENERAL.—In the case of dis-
16 approval of a proposed rule or modification
17 under this subsection, not later than 30 days
18 after the issuance of the disapproval, the Com-
19 mission shall make recommendations to the Au-
20 thority to modify the proposed rule or modifica-
21 tion.

22 (B) RESUBMISSION.—The Authority may
23 resubmit for approval by the Commission a pro-
24 posed rule or modification that incorporates the

1 modifications recommended under subpara-
2 graph (A).

3 (d) PROPOSED STANDARDS AND PROCEDURES.—

4 (1) IN GENERAL.—The Authority shall submit
5 to the Commission any proposed rule, standard, or
6 procedure developed by the Authority to carry out
7 the horseracing anti-doping and medication control
8 program or the racetrack safety program.

9 (2) NOTICE AND COMMENT.—The Commission
10 shall publish in the Federal Register any such pro-
11 posed rule, standard, or procedure and provide an
12 opportunity for public comment.

13 (e) INTERIM FINAL RULES.—The Commission may
14 adopt an interim final rule, to take effect immediately,
15 under conditions specified in section 553(b)(B) of title 5,
16 United States Code, if the Commission finds that such a
17 rule is necessary to protect—

18 (1) the health and safety of covered horses; or

19 (2) the integrity of covered horseraces and wa-
20 gering on those horseraces.

21 **SEC. 5. JURISDICTION OF THE COMMISSION AND THE**
22 **HORSERACING INTEGRITY AND SAFETY AU-**
23 **THORITY.**

24 (a) IN GENERAL.—Beginning on the program effec-
25 tive date, the Commission, the Authority, and the anti-

1 doping and medication control enforcement agency, each
2 within the scope of their powers and responsibilities under
3 this Act, as limited by subsection (j), shall—

4 (1) implement and enforce the horseracing anti-
5 doping and medication control program and the
6 racetrack safety program;

7 (2) exercise independent and exclusive national
8 authority over—

9 (A) the safety, welfare, and integrity of
10 covered horses, covered persons, and covered
11 horseraces; and

12 (B) all horseracing safety, performance,
13 and anti-doping and medication control matters
14 for covered horses, covered persons, and covered
15 horseraces; and

16 (3) have safety, performance, and anti-doping
17 and medication control authority over covered per-
18 sons similar to such authority of the State racing
19 commissions before the program effective date.

20 (b) PREEMPTION.—The rules of the Authority pro-
21 mulgated in accordance with this Act shall preempt any
22 provision of State law or regulation with respect to mat-
23 ters within the jurisdiction of the Authority under this
24 Act, as limited by subsection (j). Nothing contained in this

1 Act shall be construed to limit the authority of the Com-
2 mission under any other provision of law.

3 (c) DUTIES.—

4 (1) IN GENERAL.—The Authority—

5 (A) shall develop uniform procedures and
6 rules authorizing—

7 (i) access to offices, racetrack facili-
8 ties, other places of business, books,
9 records, and personal property of covered
10 persons that are used in the care, treat-
11 ment, training, and racing of covered
12 horses;

13 (ii) issuance and enforcement of sub-
14 poenas and subpoenas duces tecum; and

15 (iii) other investigatory powers of the
16 nature and scope exercised by State racing
17 commissions before the program effective
18 date; and

19 (B) with respect to an unfair or deceptive
20 act or practice described in section 10, may rec-
21 ommend that the Commission commence an en-
22 forcement action.

23 (2) APPROVAL OF COMMISSION.—The proce-
24 dures and rules developed under paragraph (1)(A)

1 shall be subject to approval by the Commission in
2 accordance with section 4.

3 (d) REGISTRATION OF COVERED PERSONS WITH AU-
4 THORITY.—

5 (1) IN GENERAL.—As a condition of partici-
6 pating in covered races and in the care, ownership,
7 treatment, and training of covered horses, a covered
8 person shall register with the Authority in accord-
9 ance with rules promulgated by the Authority and
10 approved by the Commission in accordance with sec-
11 tion 4.

12 (2) AGREEMENT WITH RESPECT TO AUTHORITY
13 RULES, STANDARDS, AND PROCEDURES.—Registra-
14 tion under this subsection shall include an agree-
15 ment by the covered person to be subject to and
16 comply with the rules, standards, and procedures de-
17 veloped and approved under subsection (c).

18 (3) COOPERATION.—A covered person reg-
19 istered under this subsection shall, at all times—

20 (A) cooperate with the Commission, the
21 Authority, the anti-doping and medication con-
22 trol enforcement agency, and any respective
23 designee, during any civil investigation; and

24 (B) respond truthfully and completely to
25 the best of the knowledge of the covered person

1 if questioned by the Commission, the Authority,
2 the anti-doping and medication control enforce-
3 ment agency, or any respective designee.

4 (4) FAILURE TO COMPLY.—Any failure of a
5 covered person to comply with this subsection shall
6 be a violation of section 8(a)(2)(G).

7 (e) ENFORCEMENT OF PROGRAMS.—

8 (1) ANTI-DOPING AND MEDICATION CONTROL
9 ENFORCEMENT AGENCY.—

10 (A) AGREEMENT WITH USADA.—The Au-
11 thority shall seek to enter into an agreement
12 with the United States Anti-Doping Agency
13 under which the Agency acts as the anti-doping
14 and medication control enforcement agency
15 under this Act for services consistent with the
16 horseracing anti-doping and medication control
17 program.

18 (B) AGREEMENT WITH OTHER ENTITY.—If
19 the Authority and the United States Anti-
20 Doping Agency are unable to enter into the
21 agreement described in subparagraph (A), the
22 Authority shall enter into an agreement with an
23 entity that is nationally recognized as being a
24 medication regulation agency equal in qualifica-
25 tion to the United States Anti-Doping Agency

1 to act as the anti-doping and medication control
2 enforcement agency under this Act for services
3 consistent with the horseracing anti-doping and
4 medication control program.

5 (C) NEGOTIATIONS.—Any negotiations
6 under this paragraph shall be conducted in
7 good faith and designed to achieve efficient, ef-
8 fective best practices for anti-doping and medi-
9 cation control and enforcement on commercially
10 reasonable terms.

11 (D) ELEMENTS OF AGREEMENT.—Any
12 agreement under this paragraph shall include a
13 description of the scope of work, performance
14 metrics, reporting obligations, and budgets of
15 the United States Anti-Doping Agency while
16 acting as the anti-doping and medication con-
17 trol enforcement agency under this Act, as well
18 as a provision for the revision of the agreement
19 to increase in the scope of work as provided for
20 in subsection (k), and any other matter the Au-
21 thority considers appropriate.

22 (E) DUTIES AND POWERS OF ENFORCE-
23 MENT AGENCY.—The anti-doping and medica-
24 tion control enforcement agency under an
25 agreement under this paragraph shall—

1 (i) serve as the independent anti-
2 doping and medication control enforcement
3 organization for covered horses, covered
4 persons, and covered horseraces, imple-
5 menting the anti-doping and medication
6 control program on behalf of the Author-
7 ity;

8 (ii) ensure that covered horses and
9 covered persons are deterred from using or
10 administering medications, substances, and
11 methods in violation of the rules estab-
12 lished in accordance with this Act;

13 (iii) implement anti-doping education,
14 research, testing, compliance and adjudica-
15 tion programs designed to prevent covered
16 persons and covered horses from using or
17 administering medications, substances, and
18 methods in violation of the rules estab-
19 lished in accordance with this Act;

20 (iv) exercise the powers specified in
21 section 6(c)(4) in accordance with that sec-
22 tion; and

23 (v) implement and undertake any
24 other responsibilities specified in the agree-
25 ment.

1 (F) TERM AND EXTENSION.—

2 (i) TERM OF INITIAL AGREEMENT.—

3 The initial agreement entered into by the
4 Authority under this paragraph shall be in
5 effect for the 5-year period beginning on
6 the program effective date.

7 (ii) EXTENSION.—At the end of the 5-
8 year period described in clause (i), the Au-
9 thority may—

10 (I) extend the term of the initial
11 agreement under this paragraph for
12 such additional term as is provided by
13 the rules of the Authority and con-
14 sistent with this Act; or

15 (II) enter into an agreement
16 meeting the requirements of this para-
17 graph with an entity described by sub-
18 paragraph (B) for such term as is
19 provided by such rules and consistent
20 with this Act.

21 (2) AGREEMENTS FOR ENFORCEMENT BY
22 STATE RACING COMMISSIONS.—

23 (A) STATE RACING COMMISSIONS.—

24 (i) RACETRACK SAFETY PROGRAM.—

25 The Authority may enter into agreements

1 with State racing commissions for services
2 consistent with the enforcement of the
3 racetrack safety program.

4 (ii) ANTI-DOPING AND MEDICATION
5 CONTROL PROGRAM.—The anti-doping and
6 medication control enforcement agency
7 may enter into agreements with State rac-
8 ing commissions for services consistent
9 with the enforcement of the anti-doping
10 and medication control program.

11 (B) ELEMENTS OF AGREEMENTS.—Any
12 agreement under this paragraph shall include a
13 description of the scope of work, performance
14 metrics, reporting obligations, budgets, and any
15 other matter the Authority considers appro-
16 priate.

17 (3) ENFORCEMENT OF STANDARDS.—The Au-
18 thority may coordinate with State racing commis-
19 sions and other State regulatory agencies to monitor
20 and enforce racetrack compliance with the standards
21 developed under paragraphs (1) and (2) of section
22 7(c).

23 (f) PROCEDURES WITH RESPECT TO RULES OF AU-
24 THORITY.—

1 (1) ANTI-DOPING AND MEDICATION CON-
2 TROL.—

3 (A) IN GENERAL.—Recommendations for
4 rules regarding anti-doping and medication con-
5 trol shall be developed in accordance with sec-
6 tion 6.

7 (B) CONSULTATION.—The anti-doping and
8 medication control enforcement agency shall
9 consult with the anti-doping and medication
10 control standing committee and the Board of
11 the Authority on all anti-doping and medication
12 control rules of the Authority.

13 (2) RACETRACK SAFETY.—Recommendations
14 for rules regarding racetrack safety shall be devel-
15 oped by the racetrack safety standing committee of
16 the Authority.

17 (g) ISSUANCE OF GUIDANCE.—

18 (1) The Authority may issue guidance that—

19 (A) sets forth—

20 (i) an interpretation of an existing
21 rule, standard, or procedure of the Author-
22 ity; or

23 (ii) a policy or practice with respect to
24 the administration or enforcement of such

1 an existing rule, standard, or procedure;
2 and

3 (B) relates solely to—

4 (i) the administration of the Author-
5 ity; or

6 (ii) any other matter, as specified by
7 the Commission, by rule, consistent with
8 the public interest and the purposes of this
9 subsection.

10 (2) SUBMITTAL TO COMMISSION.—The Author-
11 ity shall submit to the Commission any guidance
12 issued under paragraph (1).

13 (3) IMMEDIATE EFFECT.—Guidance issued
14 under paragraph (1) shall take effect on the date on
15 which the guidance is submitted to the Commission
16 under paragraph (2).

17 (h) SUBPOENA AND INVESTIGATORY AUTHORITY.—
18 The Authority shall have subpoena and investigatory au-
19 thority with respect to civil violations committed under its
20 jurisdiction.

21 (i) CIVIL PENALTIES.—The Authority shall develop
22 a list of civil penalties with respect to the enforcement of
23 rules for covered persons and covered horseraces under its
24 jurisdiction.

25 (j) CIVIL ACTIONS.—

1 (1) IN GENERAL.—In addition to civil sanctions
2 imposed under section 8, the Authority may com-
3 mence a civil action against a covered person or
4 racetrack that has engaged, is engaged, or is about
5 to engage, in acts or practices constituting a viola-
6 tion of this Act or any rule established under this
7 Act in the proper district court of the United States,
8 the United States District Court for the District of
9 Columbia, or the United States courts of any terri-
10 tory or other place subject to the jurisdiction of the
11 United States, to enjoin such acts or practices, to
12 enforce any civil sanctions imposed under that sec-
13 tion, and for all other relief to which the Authority
14 may be entitled.

15 (2) INJUNCTIONS AND RESTRAINING ORDERS.—
16 With respect to a civil action commenced under
17 paragraph (1), upon a proper showing, a permanent
18 or temporary injunction or restraining order shall be
19 granted without bond.

20 (k) LIMITATIONS ON AUTHORITY.—

21 (1) PROSPECTIVE APPLICATION.—The jurisdic-
22 tion and authority of the Authority and the Commis-
23 sion with respect to the horseracing anti-doping and
24 medication control program and the racetrack safety
25 program shall be prospective only.

1 (2) PREVIOUS MATTERS.—

2 (A) IN GENERAL.—The Authority and the
3 Commission may not investigate, prosecute, ad-
4 judicate, or penalize conduct in violation of the
5 horseracing anti-doping and medication control
6 program and the racetrack safety program that
7 occurs before the program effective date.

8 (B) STATE RACING COMMISSION.—With re-
9 spect to conduct described in subparagraph (A),
10 the applicable State racing commission shall re-
11 tain authority until the final resolution of the
12 matter.

13 (3) OTHER LAWS UNAFFECTED.—This Act
14 shall not be construed to modify, impair or restrict
15 the operation of the general laws or regulations, as
16 may be amended from time to time, of the United
17 States, the States and their political subdivisions re-
18 lating to criminal conduct, cruelty to animals, mat-
19 ters unrelated to antidoping, medication control and
20 racetrack and racing safety of covered horses and
21 covered races, and the use of medication in human
22 participants in covered races.

23 (1) ELECTION FOR OTHER BREED COVERAGE UNDER
24 ACT.—

1 (1) IN GENERAL.—A State racing commission
2 or a breed governing organization for a breed of
3 horses other than Thoroughbred horses may elect to
4 have such breed be covered by this Act by the filing
5 of a designated election form and subsequent ap-
6 proval by the Authority. A State racing commission
7 may elect to have a breed covered by this Act for the
8 applicable State only.

9 (2) ELECTION CONDITIONAL ON FUNDING
10 MECHANISM.—A commission or organization may
11 not make an election under paragraph (1) unless the
12 commission or organization has in place a mecha-
13 nism to provide sufficient funds to cover the costs of
14 the administration of this Act with respect to the
15 horses that will be covered by this Act as a result
16 of the election.

17 (3) APPORTIONMENT.—The Authority shall ap-
18 portion costs described in paragraph (2) in connec-
19 tion with an election under paragraph (1) fairly
20 among all impacted segments of the horseracing in-
21 dustry, subject to approval by the Commission in ac-
22 cordance with section 4. Such apportionment may
23 not provide for the allocation of costs or funds
24 among breeds of horses.

1 **SEC. 6. HORSERACING ANTI-DOPING AND MEDICATION**
2 **CONTROL PROGRAM.**

3 (a) PROGRAM REQUIRED.—

4 (1) IN GENERAL.—Not later than the program
5 effective date, and after notice and an opportunity
6 for public comment in accordance with section 4, the
7 Authority shall establish a horseracing anti-doping
8 and medication control program applicable to all
9 covered horses, covered persons, and covered
10 horseraces in accordance with the registration of
11 covered persons under section 5(d).

12 (2) CONSIDERATION OF OTHER BREEDS.—In
13 developing the horseracing anti-doping and medica-
14 tion control program with respect to a breed of horse
15 that is made subject to this Act by election of a
16 State racing commission or the breed governing or-
17 ganization for such horse under section 5(k), the
18 Authority shall consider the unique characteristics of
19 such breed.

20 (b) CONSIDERATIONS IN DEVELOPMENT OF PRO-
21 GRAM.—In developing the horseracing anti-doping and
22 medication control program, the Authority shall take into
23 consideration the following:

24 (1) Covered horses should compete only when
25 they are free from the influence of medications,

1 other foreign substances, and methods that affect
2 their performance.

3 (2) Covered horses that are injured or unsound
4 should not train or participate in covered races, and
5 the use of medications, other foreign substances, and
6 treatment methods that mask or deaden pain in
7 order to allow injured or unsound horses to train or
8 race should be prohibited.

9 (3) Rules, standards, procedures, and protocols
10 regulating medication and treatment methods for
11 covered horses and covered races should be uniform
12 and uniformly administered nationally.

13 (4) To the extent consistent with this Act, con-
14 sideration should be given to international anti-
15 doping and medication control standards of the
16 International Federation of Horseracing Authorities
17 and the Principles of Veterinary Medical Ethics of
18 the American Veterinary Medical Association.

19 (5) The administration of medications and
20 treatment methods to covered horses should be
21 based upon an examination and diagnosis that iden-
22 tifies an issue requiring treatment for which the
23 medication or method represents an appropriate
24 component of treatment.

1 (6) The amount of therapeutic medication that
2 a covered horse receives should be the minimum nec-
3 essary to address the diagnosed health concerns
4 identified during the examination and diagnostic
5 process.

6 (7) The welfare of covered horses, the integrity
7 of the sport, and the confidence of the betting public
8 require full disclosure to regulatory authorities re-
9 garding the administration of medications and treat-
10 ments to covered horses.

11 (c) ACTIVITIES.—The following activities shall be car-
12 ried out under the horseracing anti-doping and medication
13 control program:

14 (1) STANDARDS FOR ANTI-DOPING AND MEDI-
15 CATION CONTROL.—Not later than 120 days before
16 the program effective date, the Authority shall issue,
17 by rule—

18 (A) uniform standards for—

19 (i) the administration of medication to
20 covered horses by covered persons; and

21 (ii) laboratory testing accreditation
22 and protocols; and

23 (B) a list of permitted and prohibited
24 medications, substances, and methods, including

1 allowable limits of permitted medications, sub-
2 stances, and methods.

3 (2) REVIEW PROCESS FOR ADMINISTRATION OF
4 MEDICATION.—The development of a review process
5 for the administration of any medication to a cov-
6 ered horse during the 48-hour period preceding the
7 next racing start of the covered horse.

8 (3) AGREEMENT REQUIREMENTS.—The devel-
9 opment of requirements with respect to agreements
10 under section 5(e).

11 (4) ANTI-DOPING AND MEDICATION CONTROL
12 ENFORCEMENT AGENCY.—

13 (A) CONTROL RULES, PROTOCOLS, ETC.—
14 Except as provided in paragraph (5), the anti-
15 doping and medication control program enforce-
16 ment agency under section 5(e) shall, in con-
17 sultation with the anti-doping and medication
18 control standing committee of the Authority
19 and consistent with international best practices,
20 develop and recommend anti-doping and medi-
21 cation control rules, protocols, policies, and
22 guidelines for approval by the Authority.

23 (B) RESULTS MANAGEMENT.—The anti-
24 doping and medication control enforcement
25 agency shall conduct and oversee anti-doping

1 and medication control results management, in-
2 cluding independent investigations, charging
3 and adjudication of potential medication control
4 rule violations, and the enforcement of any civil
5 sanctions for such violations. Any final decision
6 or civil sanction of the anti-doping and medica-
7 tion control enforcement agency under this sub-
8 paragraph shall be the final decision or civil
9 sanction of the Authority, subject to review in
10 accordance with section 9.

11 (C) TESTING.—The anti-doping enforce-
12 ment agency shall perform and manage test dis-
13 tribution planning (including intelligence-based
14 testing), the sample collection process, and in-
15 competition and out-of-competition testing (in-
16 cluding no-advance-notice testing).

17 (D) TESTING LABORATORIES.—The anti-
18 doping and medication control enforcement
19 agency shall accredit testing laboratories based
20 upon the standards established under this Act,
21 and shall monitor, test, and audit accredited
22 laboratories to ensure continuing compliance
23 with accreditation standards.

24 (5) ANTI-DOPING AND MEDICATION CONTROL
25 STANDING COMMITTEE.—The anti-doping and medi-

1 cation control standing committee shall, in consulta-
2 tion with the anti-doping and medication control en-
3 forcement agency, develop lists of permitted and pro-
4 hibited medications, methods, and substances for
5 recommendation to, and approval by, the Authority.
6 Any such list may prohibit the administration of any
7 substance or method to a horse at any time after
8 such horse becomes a covered horse if the Authority
9 determines such substance or method has a long-
10 term degrading effect on the soundness of a horse.

11 (d) PROHIBITION.—Except as provided in sub-
12 sections (e) and (f), the horseracing anti-doping and medi-
13 cation control program shall prohibit the administration
14 of any prohibited or otherwise permitted substance to a
15 covered horse within 48 hours of its next racing start, ef-
16 fective as of the program effective date.

17 (e) ADVISORY COMMITTEE STUDY AND REPORT.—

18 (1) IN GENERAL.—Not later than the program
19 effective date, the Authority shall convene an advi-
20 sory committee comprised of horseracing anti-doping
21 and medication control industry experts, including a
22 member designated by the anti-doping and medica-
23 tion control enforcement agency, to conduct a study
24 on the use of furosemide on horses during the 48-
25 hour period before the start of a race, including the

1 effect of furosemide on equine health and the integ-
2 rity of competition and any other matter the Author-
3 ity considers appropriate.

4 (2) REPORT.—Not later than three years after
5 the program effective date, the Authority shall direct
6 the advisory committee convened under paragraph
7 (1) to submit to the Authority a written report on
8 the study conducted under that paragraph that in-
9 cludes recommended changes, if any, to the prohibi-
10 tion in subsection (d).

11 (3) MODIFICATION OF PROHIBITION.—

12 (A) IN GENERAL.—After receipt of the re-
13 port required by paragraph (2), the Authority
14 may, by unanimous vote of the Board of the
15 Authority, modify the prohibition in subsection
16 (d) and, notwithstanding subsection (f), any
17 such modification shall apply to all States be-
18 ginning on the date that is three years after the
19 program effective date.

20 (B) CONDITION.—In order for a unani-
21 mous vote described in subparagraph (A) to ef-
22 fect a modification of the prohibition in sub-
23 section (d), the vote must include unanimous
24 adoption of each of the following findings:

1 (i) That the modification is war-
2 ranted.

3 (ii) That the modification is in the
4 best interests of horse racing.

5 (iii) That furosemide has no perform-
6 ance enhancing effect on individual horses.

7 (iv) That public confidence in the in-
8 tegrity and safety of racing would not be
9 adversely affected by the modification.

10 (f) EXEMPTION.—

11 (1) IN GENERAL.—Except as provided in para-
12 graph (2), only during the three-year period begin-
13 ning on the program effective date, a State racing
14 commission may submit to the Authority, at such
15 time and in such manner as the Authority may re-
16 quire, a request for an exemption from the prohibi-
17 tion in subsection (d) with respect to the use of
18 furosemide on covered horses during such period.

19 (2) EXCEPTIONS.—An exemption under para-
20 graph (1) may not be requested for—

21 (A) two-year-old covered horses; or

22 (B) covered horses competing in stakes
23 races.

24 (3) CONTENTS OF REQUEST.—A request under
25 paragraph (1) shall specify the applicable State rac-

1 ing commission’s requested limitations on the use of
2 furosemide that would apply to the State under the
3 horseracing anti-doping and medication control pro-
4 gram during such period. Such limitations shall be
5 no less restrictive on the use and administration of
6 furosemide than the restrictions set forth in State’s
7 laws and regulations in effect as of September 1,
8 2020.

9 (4) GRANT OF EXEMPTION.—Subject to sub-
10 section (e)(3), the Authority shall grant an exemp-
11 tion requested under paragraph (1) for the remain-
12 der of such period and shall allow the use of
13 furosemide on covered horses in the applicable State,
14 in accordance with the requested limitations.

15 (g) BASELINE ANTI-DOPING AND MEDICATION CON-
16 TROL RULES.—

17 (1) IN GENERAL.—Subject to paragraph (3),
18 the baseline anti-doping and medication control rules
19 described in paragraph (2) shall—

20 (A) constitute the initial rules of the horse-
21 racing anti-doping and medication control pro-
22 gram; and

23 (B) except as exempted pursuant to sub-
24 sections (e) and (f), remain in effect at all
25 times after the program effective date.

1 (2) BASELINE ANTI-DOPING MEDICATION CON-
2 TROL RULES DESCRIBED.—

3 (A) IN GENERAL.—The baseline anti-
4 doping and medication control rules described
5 in this paragraph are the following:

6 (i) The lists of permitted and prohib-
7 ited substances (including drugs, medica-
8 tions, and naturally occurring substances
9 and synthetically occurring substances) in
10 effect for the International Federation of
11 Horseracing Authorities, including the
12 International Federation of Horseracing
13 Authorities International Screening Limits
14 for urine, dated May 2019, and the Inter-
15 national Federation of Horseracing Au-
16 thorities International Screening Limits for
17 plasma, dated May 2019.

18 (ii) The World Anti-Doping Agency
19 International Standard for Laboratories
20 (version 10.0), dated November 12, 2019.

21 (iii) The Association of Racing Com-
22 missioners International out-of-competition
23 testing standards, Model Rules of Racing
24 (version 9.2).

1 (iv) The Association of Racing Com-
2 missioners International penalty and mul-
3 tiple medication violation rules, Model
4 Rules of Racing (version 6.2).

5 (B) CONFLICT OF RULES.—In the case of
6 a conflict among the rules described in subpara-
7 graph (A), the most stringent rule shall apply.

8 (3) MODIFICATIONS TO BASELINE RULES.—

9 (A) DEVELOPMENT BY ANTI-DOPING AND
10 MEDICATION CONTROL STANDING COM-
11 MITTEE.—The anti-doping and medication con-
12 trol standing committee, in consultation with
13 the anti-doping and medication control enforce-
14 ment agency, may develop and submit to the
15 Authority for approval by the Authority pro-
16 posed modifications to the baseline anti-doping
17 and medication control rules.

18 (B) AUTHORITY APPROVAL.—If the Au-
19 thority approves a proposed modification under
20 this paragraph, the proposed modification shall
21 be submitted to and considered by the Commis-
22 sion in accordance with section 4.

23 (C) ANTI-DOPING AND MEDICATION CON-
24 TROL ENFORCEMENT AGENCY VETO AUTHOR-
25 ITY.—The Authority shall not approve any pro-

1 posed modification that renders an anti-doping
2 and medication control rule less stringent than
3 the baseline anti-doping and medication control
4 rules described in paragraph (2) (including by
5 increasing permitted medication thresholds,
6 adding permitted medications, removing prohib-
7 ited medications, or weakening enforcement
8 mechanisms) without the approval of the anti-
9 doping and medication control enforcement
10 agency.

11 **SEC. 7. RACETRACK SAFETY PROGRAM.**

12 (a) ESTABLISHMENT AND CONSIDERATIONS.—

13 (1) IN GENERAL.—Not later than the program
14 effective date, and after notice and an opportunity
15 for public comment in accordance with section 4, the
16 Authority shall establish a racetrack safety program
17 applicable to all covered horses, covered persons, and
18 covered horseraces in accordance with the registra-
19 tion of covered persons under section 5(d).

20 (2) CONSIDERATIONS IN DEVELOPMENT OF
21 SAFETY PROGRAM.—In the development of the
22 horseracing safety program for covered horses, cov-
23 ered persons, and covered horseraces, the Authority
24 and the Commission shall take into consideration ex-
25 isting safety standards including the National Thor-

1 oughbred Racing Association Safety and Integrity
2 Alliance Code of Standards, the International Fed-
3 eration of Horseracing Authority’s International
4 Agreement on Breeding, Racing, and Wagering, and
5 the British Horseracing Authority’s Equine Health
6 and Welfare program.

7 (b) ELEMENTS OF HORSERACING SAFETY PRO-
8 GRAM.—The horseracing safety program shall include the
9 following:

10 (1) A set of training and racing safety stand-
11 ards and protocols taking into account regional dif-
12 ferences and the character of differing racing facili-
13 ties.

14 (2) A uniform set of training and racing safety
15 standards and protocols consistent with the humane
16 treatment of covered horses, which may include lists
17 of permitted and prohibited practices or methods
18 (such as crop use).

19 (3) A racing surface quality maintenance sys-
20 tem that—

21 (A) takes into account regional differences
22 and the character of differing racing facilities;
23 and

24 (B) may include requirements for track
25 surface design and consistency and established

1 standard operating procedures related to track
2 surface, monitoring, and maintenance (such as
3 standardized seasonal assessment, daily track-
4 ing, and measurement).

5 (4) A uniform set of track safety standards and
6 protocols, that may include rules governing oversight
7 and movement of covered horses and human and
8 equine injury reporting and prevention.

9 (5) Programs for injury and fatality data anal-
10 ysis, that may include pre- and post-training and
11 race inspections, use of a veterinarian's list, and
12 concussion protocols.

13 (6) The undertaking of investigations at race-
14 track and non-racetrack facilities related to safety
15 violations.

16 (7) Procedures for investigating, charging, and
17 adjudicating violations and for the enforcement of
18 civil sanctions for violations.

19 (8) A schedule of civil sanctions for violations.

20 (9) Disciplinary hearings, which may include
21 binding arbitration, civil sanctions, and research.

22 (10) Management of violation results.

23 (11) Programs relating to safety and perform-
24 ance research and education.

1 (12) An evaluation and accreditation program
2 that ensures that racetracks in the United States
3 meet the standards described in the elements of the
4 Horseracing Safety Program.

5 (c) ACTIVITIES.—The following activities shall be car-
6 ried out under the racetrack safety program:

7 (1) STANDARDS FOR RACETRACK SAFETY.—
8 The development, by the racetrack safety standing
9 committee of the Authority in section 3(c)(2) of uni-
10 form standards for racetrack and horseracing safety.

11 (2) STANDARDS FOR SAFETY AND PERFORM-
12 ANCE ACCREDITATION.—

13 (A) IN GENERAL.—Not later than 120
14 days before the program effective date, the Au-
15 thority, in consultation with the racetrack safe-
16 ty standing committee, shall issue, by rule in
17 accordance with section 4—

18 (i) safety and performance standards
19 of accreditation for racetracks; and

20 (ii) the process by which a racetrack
21 may achieve and maintain accreditation by
22 the Authority.

23 (B) MODIFICATIONS.—

24 (i) IN GENERAL.—The Authority may
25 modify rules establishing the standards

1 issued under subparagraph (A), as the Au-
2 thority considers appropriate.

3 (ii) NOTICE AND COMMENT.—The
4 Commission shall publish in the Federal
5 Register any proposed rule of the Author-
6 ity, and provide an opportunity for public
7 comment with respect to, any modification
8 under clause (i) in accordance with section
9 4.

10 (C) EXTENSION OF PROVISIONAL OR IN-
11 TERIM ACCREDITATION.—The Authority may,
12 by rule in accordance with section 4, extend
13 provisional or interim accreditation to a race-
14 track accredited by the National Thoroughbred
15 Racing Association Safety and Integrity Alli-
16 ance on a date before the program effective
17 date.

18 (3) NATIONWIDE SAFETY AND PERFORMANCE
19 DATABASE.—

20 (A) IN GENERAL.—Not later than one year
21 after the program effective date, and after no-
22 tice and an opportunity for public comment in
23 accordance with section 4, the Authority, in
24 consultation with the Commission, shall develop
25 and maintain a nationwide database of race-

1 horse safety, performance, health, and injury
2 information for the purpose of conducting an
3 epidemiological study.

4 (B) COLLECTION OF INFORMATION.—In
5 accordance with the registration of covered per-
6 sons under section 5(d), the Authority may re-
7 quire covered persons to collect and submit to
8 the database described in subparagraph (A)
9 such information as the Authority may require
10 to further the goal of increased racehorse wel-
11 fare.

12 **SEC. 8. RULE VIOLATIONS AND CIVIL SANCTIONS.**

13 (a) DESCRIPTION OF RULE VIOLATIONS.—

14 (1) IN GENERAL.—The Authority shall issue, by
15 rule in accordance with section 4, a description of
16 safety, performance, and anti-doping and medication
17 control rule violations applicable to covered horses
18 and covered persons.

19 (2) ELEMENTS.—The description of rule viola-
20 tions established under paragraph (1) may include
21 the following:

22 (A) With respect to a covered horse, strict
23 liability for covered trainers for—

- 1 (i) the presence of a prohibited sub-
2 stance or method in a sample or the use of
3 a prohibited substance or method;
- 4 (ii) the presence of a permitted sub-
5 stance in a sample in excess of the amount
6 allowed by the horseracing anti-doping and
7 medication control program; and
- 8 (iii) the use of a permitted method in
9 violation of the applicable limitations es-
10 tablished under the horseracing anti-
11 doping and medication control program.
- 12 (B) Attempted use of a prohibited sub-
13 stance or method on a covered horse.
- 14 (C) Possession of any prohibited substance
15 or method.
- 16 (D) Attempted possession of any prohib-
17 ited substance or method.
- 18 (E) Administration or attempted adminis-
19 tration of any prohibited substance or method
20 on a covered horse.
- 21 (F) Refusal or failure, without compelling
22 justification, to submit a covered horse for sam-
23 ple collection.

1 (G) Failure to cooperate with the Author-
2 ity or an agent of the Authority during any in-
3 vestigation.

4 (H) Failure to respond truthfully, to the
5 best of a covered person's knowledge, to a ques-
6 tion of the Authority or an agent of the Author-
7 ity with respect to any matter under the jurisd-
8 iction of the Authority.

9 (I) Tampering or attempted tampering
10 with the application of the safety, performance,
11 or anti-doping and medication control rules or
12 process adopted by the Authority, including—

13 (i) the intentional interference, or an
14 attempt to interfere, with an official or
15 agent of the Authority;

16 (ii) the procurement or the provision
17 of fraudulent information to the Authority
18 or agent; and

19 (iii) the intimidation of, or an attempt
20 to intimidate, a potential witness.

21 (J) Trafficking or attempted trafficking in
22 any prohibited substance or method.

23 (K) Assisting, encouraging, aiding, abet-
24 ting, conspiring, covering up, or any other type
25 of intentional complicity involving a safety, per-

1 performance, or anti-doping and medication control
2 rule violation or the violation of a period of sus-
3 pension or eligibility.

4 (L) Threatening or seeking to intimidate a
5 person with the intent of discouraging the per-
6 son from the good faith reporting to the Au-
7 thority, an agent of the Authority or the Com-
8 mission, or the anti-doping and medication con-
9 trol enforcement agency under section 5(e), of
10 information that relates to—

11 (i) an alleged safety, performance, or
12 anti-doping and medication control rule
13 violation; or

14 (ii) alleged noncompliance with a safe-
15 ty, performance, or anti-doping and medi-
16 cation control rule.

17 (b) TESTING LABORATORIES.—

18 (1) ACCREDITATION AND STANDARDS.—Not
19 later than 120 days before the program effective
20 date, the Authority shall, in consultation with the
21 anti-doping and medication control enforcement
22 agency, establish, by rule in accordance with section
23 4—

1 (A) standards of accreditation for labora-
2 tories involved in testing samples from covered
3 horses;

4 (B) the process for achieving and main-
5 taining accreditation; and

6 (C) the standards and protocols for testing
7 such samples.

8 (2) ADMINISTRATION.—The accreditation of
9 laboratories and the conduct of audits of accredited
10 laboratories to ensure compliance with Authority
11 rules shall be administered by the anti-doping and
12 medication control enforcement agency. The anti-
13 doping and medication control enforcement agency
14 shall have the authority to require specific test sam-
15 ples to be directed to and tested by laboratories hav-
16 ing special expertise in the required tests.

17 (3) EXTENSION OF PROVISIONAL OR INTERIM
18 ACCREDITATION.—The Authority may, by rule in ac-
19 cordance with section 4, extend provisional or in-
20 terim accreditation to a laboratory accredited by the
21 Racing Medication and Testing Consortium, Inc., on
22 a date before the program effective date.

23 (4) SELECTION OF LABORATORIES.—

24 (A) IN GENERAL.—Except as provided in
25 paragraph (2), a State racing commission may

1 select a laboratory accredited in accordance
2 with the standards established under paragraph
3 (1) to test samples taken in the applicable
4 State.

5 (B) SELECTION BY THE AUTHORITY.—If a
6 State racing commission does not select an ac-
7 credited laboratory under subparagraph (A),
8 the Authority shall select such a laboratory to
9 test samples taken in the State concerned.

10 (c) RESULTS MANAGEMENT AND DISCIPLINARY
11 PROCESS.—

12 (1) IN GENERAL.—Not later than 120 days be-
13 fore the program effective date, the Authority shall
14 establish in accordance with section 4—

15 (A) rules for safety, performance, and anti-
16 doping and medication control results manage-
17 ment; and

18 (B) the disciplinary process for safety, per-
19 formance, and anti-doping and medication con-
20 trol rule violations.

21 (2) ELEMENTS.—The rules and process estab-
22 lished under paragraph (1) shall include the fol-
23 lowing:

1 (A) Provisions for notification of safety,
2 performance, and anti-doping and medication
3 control rule violations.

4 (B) Hearing procedures.

5 (C) Standards for burden of proof.

6 (D) Presumptions.

7 (E) Evidentiary rules.

8 (F) Appeals.

9 (G) Guidelines for confidentiality and pub-
10 lic reporting of decisions.

11 (3) DUE PROCESS.—The rules established
12 under paragraph (1) shall provide for adequate due
13 process, including impartial hearing officers or tribu-
14 nals commensurate with the seriousness of the al-
15 leged safety, performance, or anti-doping and medi-
16 cation control rule violation and the possible civil
17 sanctions for such violation.

18 (d) CIVIL SANCTIONS.—

19 (1) IN GENERAL.—The Authority shall estab-
20 lish uniform rules, in accordance with section 4, im-
21 posing civil sanctions against covered persons or cov-
22 ered horses for safety, performance, and anti-doping
23 and medication control rule violations.

24 (2) REQUIREMENTS.—The rules established
25 under paragraph (1) shall—

1 (A) take into account the unique aspects of
2 horseracing;

3 (B) be designed to ensure fair and trans-
4 parent horseraces; and

5 (C) deter safety, performance, and anti-
6 doping and medication control rule violations.

7 (3) SEVERITY.—The civil sanctions under para-
8 graph (1) may include—

9 (A) lifetime bans from horseracing,
10 disgorgement of purses, monetary fines and
11 penalties, and changes to the order of finish in
12 covered races; and

13 (B) with respect to anti-doping and medi-
14 cation control rule violators, an opportunity to
15 reduce the applicable civil sanctions that is
16 comparable to the opportunity provided by the
17 Protocol for Olympic Movement Testing of the
18 United States Anti-Doping Agency.

19 (e) MODIFICATIONS.—The Authority may propose a
20 modification to any rule established under this section as
21 the Authority considers appropriate, and the proposed
22 modification shall be submitted to and considered by the
23 Commission in accordance with section 4.

1 **SEC. 9. REVIEW OF FINAL DECISIONS OF THE AUTHORITY.**

2 (a) NOTICE OF CIVIL SANCTIONS.— If the Authority
3 imposes a final civil sanction for a violation committed by
4 a covered person pursuant to the rules or standards of
5 the Authority, the Authority shall promptly submit to the
6 Commission notice of the civil sanction in such form as
7 the Commission may require.

8 (b) REVIEW BY ADMINISTRATIVE LAW JUDGE.—

9 (1) IN GENERAL.—With respect to a final civil
10 sanction imposed by the Authority, on application by
11 the Commission or a person aggrieved by the civil
12 sanction filed not later than 30 days after the date
13 on which notice under subsection (a) is submitted,
14 the civil sanction shall be subject to de novo review
15 by an administrative law judge.

16 (2) NATURE OF REVIEW.—

17 (A) IN GENERAL.—In matters reviewed
18 under this subsection, the administrative law
19 judge shall determine whether—

20 (i) a person has engaged in such acts
21 or practices, or has omitted such acts or
22 practices, as the Authority has found the
23 person to have engaged in or omitted;

24 (ii) such acts, practices, or omissions
25 are in violation of this Act or the anti-
26 doping and medication control or racetrack

1 safety rules approved by the Commission;

2 or

3 (iii) the final civil sanction of the Au-
4 thority was arbitrary, capricious, an abuse
5 of discretion, or otherwise not in accord-
6 ance with law.

7 (B) CONDUCT OF HEARING.—An adminis-
8 trative law judge shall conduct a hearing under
9 this subsection in such a manner as the Com-
10 mission may specify by rule, which shall con-
11 form to section 556 of title 5, United States
12 Code.

13 (3) DECISION BY ADMINISTRATIVE LAW
14 JUDGE.—

15 (A) IN GENERAL.—With respect to a mat-
16 ter reviewed under this subsection, an adminis-
17 trative law judge—

18 (i) shall render a decision not later
19 than 60 days after the conclusion of the
20 hearing;

21 (ii) may affirm, reverse, modify, set
22 aside, or remand for further proceedings,
23 in whole or in part, the final civil sanction
24 of the Authority; and

1 (iii) may make any finding or conclu-
2 sion that, in the judgment of the adminis-
3 trative law judge, is proper and based on
4 the record.

5 (B) FINAL DECISION.—A decision under
6 this paragraph shall constitute the decision of
7 the Commission without further proceedings
8 unless a notice or an application for review is
9 timely filed under subsection (c).

10 (c) REVIEW BY COMMISSION.—

11 (1) NOTICE OF REVIEW BY COMMISSION.—The
12 Commission may, on its own motion, review any de-
13 cision of an administrative law judge issued under
14 subsection (b)(3) by providing written notice to the
15 Authority and any interested party not later than 30
16 days after the date on which the administrative law
17 judge issues the decision.

18 (2) APPLICATION FOR REVIEW.—

19 (A) IN GENERAL.—The Authority or a per-
20 son aggrieved by a decision issued under sub-
21 section (b)(3) may petition the Commission for
22 review of such decision by filing an application
23 for review not later than 30 days after the date
24 on which the administrative law judge issues
25 the decision.

1 (B) EFFECT OF DENIAL OF APPLICATION
2 FOR REVIEW.—If an application for review
3 under subparagraph (A) is denied, the decision
4 of the administrative law judge shall constitute
5 the decision of the Commission without further
6 proceedings.

7 (C) DISCRETION OF COMMISSION.—

8 (i) IN GENERAL.—A decision with re-
9 spect to whether to grant an application
10 for review under subparagraph (A) is sub-
11 ject to the discretion of the Commission.

12 (ii) MATTERS TO BE CONSIDERED.—
13 In determining whether to grant such an
14 application for review, the Commission
15 shall consider whether the application
16 makes a reasonable showing that—

17 (I) a prejudicial error was com-
18 mitted in the conduct of the pro-
19 ceeding; or

20 (II) the decision involved—

21 (aa) an erroneous applica-
22 tion of the anti-doping and medi-
23 cation control or racetrack safety
24 rules approved by the Commis-
25 sion; or

1 (bb) an exercise of discretion
2 or a decision of law or policy that
3 warrants review by the Commis-
4 sion.

5 (3) NATURE OF REVIEW.—

6 (A) IN GENERAL.—In matters reviewed
7 under this subsection, the Commission may—

8 (i) affirm, reverse, modify, set aside,
9 or remand for further proceedings, in
10 whole or in part, the decision of the admin-
11 istrative law judge; and

12 (ii) make any finding or conclusion
13 that, in the judgement of the Commission,
14 is proper and based on the record.

15 (B) DE NOVO REVIEW.—The Commission
16 shall review de novo the factual findings and
17 conclusions of law made by the administrative
18 law judge.

19 (C) CONSIDERATION OF ADDITIONAL EVI-
20 DENCE.—

21 (i) MOTION BY COMMISSION.—The
22 Commission may, on its own motion, allow
23 the consideration of additional evidence.

24 (ii) MOTION BY A PARTY.—

1 (I) IN GENERAL.—A party may
2 file a motion to consider additional
3 evidence at any time before the
4 issuance of a decision by the Commis-
5 sion, which shall show, with particu-
6 larity, that—

7 (aa) such additional evidence
8 is material; and

9 (bb) there were reasonable
10 grounds for failure to submit the
11 evidence previously.

12 (II) PROCEDURE.—The Commis-
13 sion may—

14 (aa) accept or hear addi-
15 tional evidence; or

16 (bb) remand the proceeding
17 to the administrative law judge
18 for the consideration of addi-
19 tional evidence.

20 (d) STAY OF PROCEEDINGS.—Review by an adminis-
21 trative law judge or the Commission under this section
22 shall not operate as a stay of a final civil sanction of the
23 Authority unless the administrative law judge or Commis-
24 sion orders such a stay.

1 **SEC. 10. UNFAIR OR DECEPTIVE ACTS OR PRACTICES.**

2 The sale of a covered horse, or of any other horse
3 in anticipation of its future participation in a covered race,
4 shall be considered an unfair or deceptive act or practice
5 in or affecting commerce under section 5(a) of the Federal
6 Trade Commission Act (15 U.S.C. 45(a)) if the seller—

7 (1) knows or has reason to know the horse has
8 been administered—

9 (A) a bisphosphonate prior to the horse's
10 fourth birthday; or

11 (B) any other substance or method the Au-
12 thority determines has a long-term degrading
13 effect on the soundness of the covered horse;
14 and

15 (2) fails to disclose to the buyer the administra-
16 tion of the bisphosphonate or other substance or
17 method described in paragraph (1)(B).

18 **SEC. 11. STATE DELEGATION; COOPERATION.**

19 (a) STATE DELEGATION.—

20 (1) IN GENERAL.—The Authority may enter
21 into an agreement with a State racing commission to
22 implement, within the jurisdiction of the State rac-
23 ing commission, a component of the racetrack safety
24 program or, with the concurrence of the anti-doping
25 and medication control enforcement agency under
26 section 5(e), a component of the horseracing anti-

1 doping and medication control program, if the Au-
2 thority determines that the State racing commission
3 has the ability to implement such component in ac-
4 cordance with the rules, standards, and require-
5 ments established by the Authority.

6 (2) IMPLEMENTATION BY STATE RACING COM-
7 MISSION.—A State racing commission or other ap-
8 propriate regulatory body of a State may not imple-
9 ment such a component in a manner less restrictive
10 than the rule, standard, or requirement established
11 by the Authority.

12 (b) COOPERATION.—To avoid duplication of func-
13 tions, facilities, and personnel, and to attain closer coordi-
14 nation and greater effectiveness and economy in adminis-
15 tration of Federal and State law, where conduct by any
16 person subject to the horseracing medication control pro-
17 gram or the racetrack safety program may involve both
18 a medication control or racetrack safety rule violation and
19 violation of Federal or State law, the Authority and Fed-
20 eral or State law enforcement authorities shall cooperate
21 and share information.

22 **SEC. 12. DETERMINATION OF BUDGETARY EFFECTS.**

23 The budgetary effects of this Act, for the purpose of
24 complying with the Statutory Pay-As-You-Go Act of 2010,
25 shall be determined by reference to the latest statement

— THE —
STRONACH
GROUP

February 5, 2021

California Horse Racing Board
Attn: Mr. Scott Chaney
1010 Hurley Way, Suite 300
Sacramento, CA 95825

California Horse Racing Board Commissioners and Executive Director Chaney:

In response to the concerns that were raised by several Commissioners at last month's Commission meeting, I felt it was important to provide some information regarding the Association of Racing Commissioners International (ARCI) Penalty Classification System.

The Penalty Classification system was originally developed by the Racing Medication and Testing Consortium (RMTC) for adoption by ARCI. The changes that are being presented to the CHRB for consideration are based upon recommendations from the RMTC's Scientific Advisory Committee. The Scientific Advisory Committee consists of the leading laboratory chemists and veterinarians from across the country – including several veterinary pharmacologists.

The Scientific Advisory Committee provides recommendations to the RMTC Board for approval. I can tell you in the 9 years I have been involved in the process, the RMTC Board has yet to overrule a recommendation from the Committee regarding classification. These recommendations are then forwarded to ARCI for review and approval – again this approval is largely a ministerial process.

To explain the changes, however, I requested the RMTC provide a list of substantive changes that have occurred in the past 18 months. A copy of that chart is attached. The chart not only provides the substance and classification but also includes the rationale for the classification or re-classification of the substance.

Moreover, based upon my review of the Horseracing Integrity and Safety Act, the RMTC's recommendations will provide the starting point for legislation. Therefore, adoption of this update will be keeping California racing consistent with the likely starting point for the Federal bill.

Finally, it is important to note – adoption of this update does not constrain the CHRB from modifying penalties assigned to each classification. In fact, the current CHRB penalty guidelines already vary from the ARCI's penalty guidelines. The Penalty Classification system is merely a

way for commissions to ensure that medications with similar effect and similar FDA approval status are treated consistently.

Please let me know if you have any questions about the Penalty Classification System.

Thank you for your consideration.

Regards,

A handwritten signature in black ink, appearing to read "Dionne Benson", with a long horizontal flourish extending to the right.

Dr. Dionne Benson
Chief Veterinary Officer
The Stronach Group

Substance	Current ARCI UCFS status	SAC Recommendation	Comments
Arsenic	Unclassified	3/B with ability to mitigate to 3/C if there is credible evidence for environmental exposure (e.g. through cribbing or wood chewing behavior).	No FDA-approved products. Arsenic is a component of CaCo Copper a compounded product having historical use in horses as an appetite stimulant and in the treatment of anemia. Arsenic-containing veterinary products are commercially available in other countries (e.g. Jurocy® [Ceva] at 50 mg/ml sodium arsilate). Arsenic is present in pressure-treated lumber designated for non-residential use. Cribbing or wood chewing may result in exposure sufficient to result in concentrations in excess of the screening limit. Findings for arsenic warrant investigation into the route of exposure with mitigation to 3/C recommended when there is compelling evidence for environmental exposure rather than deliberate administration.
Alpha-pyrrolidinovalerophenone (also known as Alpha-PVP)	Unclassified	1/A	Potent stimulant that is a derivative of the synthetic cathinone 3,4 methylenedioxypropylvalerone (MDVP)-a DEA Schedule 1 substance. Alpha-PVP is also the psychoactive agent in Khat. Exerts its effect by inhibiting norepinephrine-dopamine reuptake. Also sold as Bath Salts. Confirmed finding AORC-2019. 1/A is consistent with 3,4 methylenedioxypropylvalerone.
Aripiprazole	Unclassified	2/A	FDA approved for human use as Abilify. Atypical antipsychotic; used to treat schizophrenia, bipolar I disorder, and major depressive disorder. It is also used to treat Tourette syndrome and irritability caused by autistic disorder. Confirmed finding AORC-2019. 2/A is consistent with other anti-psychotics, e.g. clozapine, risperidone.
Bisphosphonates	Unclassified	3/A	Bisphosphonates (BPs) are a class of drug that inactivate osteoclasts, the cell type that is responsible for removing damaged bone. Within this class of drug there are two sub-types, nitrogenous and non-nitrogenous, with the nitrogenous type having potency orders of magnitude greater than the non-nitrogenous. There are two non-nitrogenous BP products with FDA approval for use in the horse: Tildren (tiludronate sodium) and OsPhos (clodronate). These products carry label indications for use in the treatment of navicular disease in horses 4 years of age and older. Concern has been raised about the potential for BPs to impede or prevent bone adaptation to high-speed exercise when administered to young horses in race training. Failure to adapt and remodel in response to the biomechanical forces of high-speed exercise is associated with increased risk of fatal fracture. Recommendation for a 3/A classification for all bisphosphonates, making no distinction between nitrogenous and non-nitrogenous, and those with or without FDA approval.
Botulinum toxin	Unclassified	2/A	Botulinum toxin is a neuromuscular blocking agent produced by the bacteria <i>Clostridium botulinum</i> . The toxin has conventional use in (human) cosmetic medicine in decreasing facial wrinkles. It is also used to treat chronic migraine, spastic dysphonia, pathologic muscle contracture, and bladder dysfunction, among other conditions. Veterinary research has identified botulinum toxin as an adjunct in the treatment of laminitis, specifically in preventing rotation of the coffin bone when the bony laminae separate from the laminae of the hoof wall. Injection of botulinum toxin into the deep digital flexor muscle neutralizes the forces that pull the coffin bone away from the hoof wall thereby reducing pain and improving long-term prognosis. A botulinum toxin product labelled for use in the horse in the treatment of laminitis is anticipated to receive FDA approval within the next 12-18 months. There are legitimate concerns about the off-label injection of this product in manipulating horses' airways in addition to other un-approved uses. Further, there is risk to horse safety and welfare with improperly performed injections of this substance.
Ciclesonide	Unclassified	4/C	Corticosteroid recently afforded FDA-approval for treatment of equine asthma. Administered via inhalation. Recommendation of 4/C is consistent with other corticosteroids with FDA-approval.
Diisopropylamine	Unclassified	2/B	There is an Australian product with approval for veterinary use: DADA 250 (Ceva, Australia: https://www.ceva.com.au/Products/Products-list/DADA-250-Injection). The CEVA website states that it is a "detoxifier and vasodilator to increase blood flow to brain and peripheral tissues." Confirmed finding AORC-2019. As Hugalín, it is a human pharmaceutical with indications for the treatment of conditions angina pectoris, myocardial infarction, peripheral vascular disease, cerebrovascular disease and cerebral thrombosis and cerebral embolism, retinopathies, and hypertension. Confirmed finding AORC-2019. 2/B is consistent with nitroglycerin.
Dipyron	4/B	4/C	Non-steroidal anti-inflammatory drug (NSAID) that is used predominantly for its antipyretic (fever reducing) effects. A dipyron-containing product, Zimeta, recently received FDA-approval for use in the horse. Revise classification to be consistent with other FDA-approved NSAIDs.
Ethamsylate	Unclassified	4/B	Anti-thrombolytic agent that lacks FDA approval. It exerts an effect similar to tranexamic acid (commonly known as Tran-X), and has been recognized by international racing regulatory authorities as an illicit substance in the control of EIPH. Tranexamic acid is assigned a 4/C classification in consideration of its effect and that there is an FDA-approved tranexamic acid-containing product. 4/B is consistent with anti-thrombolytics lacking FDA approval.
Etofenamate	Unclassified	4/B	. No FDA approved products. NSAID. In a human study, when administered IM was determined to be similarly effective to HA. (Savas, G., et al., Effectiveness of etofenamate for treatment of knee osteoarthritis: a randomized controlled trial, <i>Ther Clin Risk Manag.</i> 2016; 12: 1693–1699). Confirmed finding AORC-2019. 4/B is consistent with other NSAIDs lacking FDA approval.
Flufenamic Acid	3/B	4/B	NSAID lacking FDA-approval. NSAIDs are assigned Class 4. Those with FDA-approval for use in the horse or other species are assigned Penalty Class C. Those lacking FDA-approval are assigned Penalty Class B.
Harpagoside	Unclassified	4/B	No FDA-approved product. Glycoside isolated from Devil's Claw plant, but also synthesized as a pure compound. Used as therapy for treatment of pain and osteoarthritis in human patients. Has historic use in horses but lacks scientific support for efficacy. Marketed in multiple OTC joint supplement products, with ingredient labelled as Devil's Claw. Huang, T., et al., Harpagoside suppresses lipopolysaccharide-induced iNOS and COX-2 expression through inhibition of NF-kappa B activation, <i>J Ethnopharmacol</i> , 2006 Mar 8; 104(1-2): 149-55. Axmann, S., et al., Pharmacokinetics of harpagoside in horses after intragastric administration of a Devil's claw (<i>Harpagophytum procumbens</i>) extract, <i>J Vet Pharmacol Therap.</i> , 42(1). https://doi.org/10.1111/jvp.12716 . 4/B is consistent with NSAIDs lacking FDA approval.
Hypoxia-inducible factor (HIF) activators	3/A	1/A	Blood doping agents. Should be classified consistent with Erythropoietin, Darbepoetin, etc.

Hypoxia-inducible factor (HIF) stabilizers (e.g. IOX-2)	Unclassified	1/A	No products with FDA-approval. Blood doping agents. No indication for use in the horse. 1/A is consistent with other blood doping agents.
Medroxyprogesterone	Unclassified	3/B	Applies to all genders. While this medication has historical use in the suppression of estrus in fillies and mares, research had demonstrated it to be ineffective. There is an FDA-approved product (Regumate/altrenogest) for estrus suppression so there is no justification for use of this substance for that effect. Medroxyprogesterone has been used to modify behavior in colts and geldings. Compounded formulations have resulted in anaphylactic reactions and death in treated horses. There is no legitimate use for this substance in the racehorse in racing or training and there is not insignificant risk to horse health in its use.
Methoxyprogesterone		Delete	No such substance exists.
Molidustat	Unclassified	1/A	No FDA-approved products. No indication for use in the horse. HIF stabilizer; blood doping agent. 1/A is consistent with Roxadustat, another HIF-stabilizer.
Norethisterone (norethindrone)	Unclassified	4/B all genders	No FDA approved products. Oral progestin used in birth control pills, menopausal hormone treatments, and gynecological disorders. No indications for use in the horse. Confirmed finding AORC-2019. FDA-approved progestogin Altrenogest (Regumate) is assigned 4/C when detected in horses other than intact females. However, there is no indication for use of this non-FDA approved product in horses of any gender, thus the recommendation of 4/B
Oliceridine	Unclassified	1/A	Opioid agonist with FDA-approval for intravenous use in treating moderate to severe pain in human patients. It is a DEA Schedule II substance. 1/A is consistent with oxycodone and other DEA Schedule II opioids.
Oripavine	Unclassified	2/A	DEA Schedule II substance; no FDA-approved products. Opioid and major metabolite of thebaine (2/A), also a DEA Schedule II substance. Toxicity can result in seizures and death. Confirmed finding AORC-2019.
Parecoxib	Unclassified	4/B	No FDA-approved products. NSAID, selective COX-2 inhibitor. Prodrug for valdecoxib. There were valdecoxib-containing human products with FDA-approval, but the product was withdrawn due to risk of heart attack and stroke. Confirmed finding AORC-2019. 4/B is consistent with other NSAIDs lacking FDA approval.
Pregabalin	Unclassified	3/B	A gabapentanoid with FDA approval for human use (Lyrica™) in the treatment of neuropathic pain and fibromyalgia, nerve damage due to diabetes or Shingles, anxiety, as well as some types of seizures. Confirmed finding AORC-2019. 3/B is consistent with gabapentin.
SARMs	Unclassified	2/A	Selective Androgen Receptor Modulators (SARMs) are in a class of drug that elicits an androgenic, anabolic effect. Within this class of drug, specific molecules can be developed to have differing ranges of anabolic and androgenic effects. SARMs have been used in human clinical trials, but to date no FDA-approved product exists. SARMs are on the World Anti-Doping Agency's Prohibited Substance list, and are also included in the scope of substances regulated by the ARCI Model Rule on Out of Competition Testing. Specific examples of SARMs are andarine, ostarine, ligandrol, and testolone. Many other SARMs that are in varying stages of research and development have internal alpha-numeric designations (e.g. LG121071) and have not yet been assigned names. It is for this reason that establishing a prohibition on the entire class of drug is important. In consideration of their anabolic effect, the SAC assigned SARMs a Class 2 designation. Anabolic steroids having FDA-approval are assigned a B penalty; those lacking FDA-approval are assigned A penalty status. The SAC recommends a 2/A classification for SARMs as a drug class, and andarine, ostarine, ligandrol, and testolone individually
Tapentadol	Unclassified	1/A	DEA Schedule II substance. FDA-approved human product (Nucynta™). Centrally acting opioid analgesic, μ -opioid receptor agonist and norepinephrine reuptake inhibitor. Similar to tramadol (2/B) in action. Analgesic efficacy in humans comparable to oxycodone (1/A). While there are indications for tramadol in equine veterinary medicine there is no literature supporting the use of tapentadol in the horse. Confirmed finding AORC-2019. 1/A to be consistent with oxycodone, in consideration of DEA Scheduling, and lack of indication for use in the horse.
Trometamol (Also known as tris-hydroxymethyl aminomethane [THAM])	Unclassified	3/B	Alkalinizing agent used as an alternative to sodium bicarbonate in the treatment of metabolic acidosis in human patients. 3/B is consistent with TCO2 violation--evidence of administration of an alkalinizing agent.
Valdecoxib	2/B	4/B	Correct to Class 4 to be consistent with all NSAIDs. While an FDA-approved product did exist, the penalty classification for this drug was augmented due to the health risks associated with its use and the availability of far safer NSAID alternatives.

STAFF ANALYSIS
February 17, 2021

Issue: APPLICATION FOR LICENSE TO OPERATE A MINISATELLITE WAGERING FACILITY AT THE SAHARA DUNES CASINO DBA LAKE ELSINORE HOTEL AND CASINO IN LAKE ELSINORE, CALIFORNIA, FOR A PERIOD OF UP TO FIVE YEARS

Sahara Dunes Casino DBA Lake Elsinore Hotel and Casino (Sahara), in collaboration with Southern California Off Track Wagering, Inc. (SCOTWINC), filed an application for a renewal of license to operate a minisatellite wagering site. The Sahara minisatellite application proposes to begin operations April 25, 2021 through April 25, 2026, for a period of up to five years.

- Sahara is a bar located in Lake Elsinore, California. The proposed wagering site will be located in the southern zone.

Business and Professions Code section 19605.25 (a) (1) provides no minisatellite may be within 20 miles of a racetrack, a satellite wagering facility, or a tribal casino that has a satellite wagering facility. If the proposed facility is within 20 miles of one of the above-referenced satellite facilities, then the consent of each facility within a 20-mile radius must be given before the proposed facility may be approved by the California Horse Racing Board (Board).

- SCOTWINC has provided that only Lake Perris Sports Pavilion is located within the 20 mile radius of Sahara, and that it has waived the 20 mile radius provision. Consent from Lake Perris Sports Pavilion has been received. The consent from Lake Perris Sports Pavilion expires on February 23, 2026, before the close of the proposed license period. The consent will therefore need to be renewed before expiration to cover the entire proposed license period.
- Sahara has contracts/agreements with the following racing associations:
 - California Authority of Racing Fairs
 - Del Mar Thoroughbred Club
 - Los Angeles County Fair Association
 - Los Alamitos Racing Association
 - Los Angeles Turf Club
 - Los Alamitos Quarter Horse Racing Association
 - Pacific Racing Association
 - Sonoma County Fair
 - Watch and Wager.com LLC
- Applicant proposes to operate minisatellite wagering site during racing hours, seven days a week.
- Estimated number of pari-mutuel terminal machines available is 12; Seating Capacity is 115 inside with an additional 100 seats in the outdoor patio; the

number of tables in the minisatellite wagering area is 33 tables in the wagering area. Forty-eight television monitors in the restricted area, additional monitors in the Casino and 8 monitors in the patio area. Roberts Communication Network will provide the satellite receivers and decoders.

- Staffing: Mutuel Supervisor or clerks to be determined by projected handle and attendance.

Specific information **still needed** to complete this application include:

1. Fire clearance
2. Full Disclosure Statement and CHRB-25A are still under review by the Board's Licensing and Enforcement Department.

RECOMMENDATION:

If the application is considered for approval, staff recommends an approval contingent upon the submission of the fire clearance.

Application is hereby made to the California Horse Racing Board (CHRB/Board) for a license to operate a minisatellite wagering facility in connection with a horseracing meeting and/or parimutuel wagering in accordance with the Business and Professions Code, Chapter 4, Division 8 (Horse Racing Law) and the California Code of Regulations, Title 4, Division 4 (Rules and Regulations of the California Horse Racing Board).

Part I: To be completed by applicant seeking to operate a minisatellite wagering facility pursuant to Business and Professions Code section 19605.25.

Part II: To be completed by association(s) that has/have reached an agreement with the applicant to conduct minisatellite wagering.

Part III: To be completed by simulcast organization that has reached an agreement to provide services necessary for the conduct of minisatellite wagering pursuant to Business and Professions Code sections 19605.25 & 19605.3.

**PART I
 MINISATELLITE WAGERING APPLICANT INFORMATION**

APPLICANT INFORMATION		
Name of applicant: The applicant is: <input type="checkbox"/> Racing Association <input type="checkbox"/> Fair <input type="checkbox"/> Federally Recognized Indian Tribe	<input type="checkbox"/> Card Room/Gambling Establishment <input checked="" type="checkbox"/> Restaurant/Bar <input type="checkbox"/> Other Business Entity	
Facility street address: 20930 Malaga Road		
Mailing address (if different from above):		
E-mail address: Tedk@lercasino.com		
City: Lake Elsinore	State: CA	Zip Code: 92530
Phone: 951-471-6700	Fax:	Website: cjsbar.com
County: Riverside	Zone Location: North <input type="checkbox"/> South <input type="checkbox"/> Central <input type="checkbox"/>	
(To be completed by CHRB staff)		

CONTACT PERSON (Authorized Representative)		
Name and title of the contact person: Ted Kingston		
Business street address: 20930 Malaga Road		
Mailing address (if different from above):		
City: Lake Elsinore	State: CA	Zip Code: 92530
County: Riverside		
Phone: 801-301-2179	E-mail: Tedk@lercasino.com	Fax:

State of California
California Horse Racing Board
Application for License to Operate a Minisatellite Wagering Facility
CHRB-228 (New 11/08)

Dates during which the applicant proposes to operate as a minisatellite wagering facility:

March 24 2021 to March 24 2023

NOTICE TO APPLICANT: If approved for license, the term of license shall not exceed two years pursuant to Business and Professions Code section 19605.25 (h).

Have you previously operated a licensed gaming operation in California or another state? Yes No

Do you currently operate a licensed gaming operation in California or another state? Yes No

If yes to either question above, provide the following:

Valid licensure period: Begin Date: January 2020 End Date: December 2020

Facility name and address: Lake Elsinore Hotel & Casino

City: Lake Elsinore State: CA Zip Code: 92530

County: Riverside

Zone Location:
North South Central
(To be completed by CHRB staff)

Have you had a gaming operation license that has been revoked or suspended. Yes No

If yes, provide the following if different from above:

Facility name and address:

City: State: Zip Code:

Racing Jurisdiction:

BUSINESS STRUCTURE

<input checked="" type="checkbox"/> Corporation <input type="checkbox"/> Public <input type="checkbox"/> Private <input type="checkbox"/> Sub-S <input type="checkbox"/> Sub-C <input type="checkbox"/> Limited Partnership <input type="checkbox"/> Limited Liability Company	<input type="checkbox"/> Partnership & Joint Venture <input type="checkbox"/> Sole Proprietorship	<input type="checkbox"/> Other If you have listed your company as other please identify your company structure:
--	--	--

Registered Business Name: L.E R Lounge Inc

Fictitious Business Name: CJ's Sports Grill & Turf Club

Address:
20930 Malaga Road

E-mail Address: Tedk@Lercasino.com

City: Lake Elsinore State: CA Zip Code: 92530

Phone: 951-471-6700 Fax:

State where registered or Articles of Organization are filed: CA Registry or File number: 1808472

CERTIFICATE TO OPERATE WITH CONDITIONS

SAHARA DUNES CASINO, LP dba LAKE ELSINORE HOTEL AND CASINO

Club Address: 20930 Malaga Road
Lake Elsinore, CA 92530

Authorized Number of Tables: 22

Issue Date: January 1, 2021

Expiration Date: December 31, 2021

This Certificate serves as your authorization to continue operating 22 tables at the Lake Elsinore Hotel and Casino. This Certificate is valid through December 31, 2021, or until your State Gambling License is either approved or denied.

The Certificate to Operate shall be posted at all times in a conspicuous place in the area where gambling is conducted at the Lake Elsinore Hotel and Casino. The issuance of this Certificate does not create a vested right toward the issuance of a State Gambling License.

YOLANDA MORROW
Assistant Director

For XAVIER BECERRA
Attorney General



LICENSE CONDITIONS

In accordance with the issuance of this provisional license, Lake Elsinore Hotel and Casino shall:

1. Establish and maintain an effective and continuous monitoring system that guarantees compliance with California Code of Regulations, title 11, section 2053, Adequate Financing. On a monthly basis, the gambling establishment shall submit documentation to the Bureau of Gambling Control (Bureau) outlining its compliance.
2. Maintain a separate, specifically designated, insured account with a licensed financial institution in an amount not less than the total value of the chips in use by the gambling establishment. The funds from that account may only be used to redeem the chips of that gambling establishment. This account may not be used as collateral, or encumbered or hypothecated in any fashion. The gambling establishment shall establish and maintain an effective and continuous monitoring system that guarantees compliance with this condition. On a monthly basis, the gambling establishment shall submit documentation to the Bureau outlining its compliance.
3. Maintain a separate, specifically designated, insured account with a licensed financial institution in an amount not less than the total amount of monies that patrons of that gambling establishment have on deposit with the gambling establishment. The funds from that account may only be used to return to the patrons the balance of monies on deposit with the gambling establishment. The gambling establishment shall establish and maintain an effective and continuous monitoring system that guarantees compliance with this condition. On a monthly basis, the gambling establishment shall submit documentation to the Bureau outlining its compliance.
4. Maintain a separate, specifically designated, insured account with a licensed financial institution in an amount not less than the total amount of all monies collected from patrons in administering player-funded jackpots. The funds from that account may only be used to pay patrons' winnings in a player-funded jackpot. The account may not be used as collateral, or encumbered or hypothecated in any fashion. The gambling establishment shall establish and maintain an effective and continuous monitoring system that guarantees compliance with this condition. On a monthly basis, the gambling establishment shall submit documentation to the Bureau outlining its compliance.
5. Establish and maintain an effective Anti-Money Laundering Program that is in compliance with 31 C.F.R. § 1021.210, Anti-money laundering program for casinos. The program shall be designed for the specific risks and services related to, and utilized for the particular use of the Lake Elsinore Hotel and Casino.
6. Establish and maintain an effective monitoring system that fully complies with the Gambling Control Act and documents Lake Elsinore Hotel and Casino's compliance with 31 C.F.R. § 1021.210, Anti-money laundering program for casinos. Supporting documentation shall be maintained on site for both internal and external compliance efforts. This includes the supporting documentation for any training, audit/compliance



reports and/or independent testing performed by outside consultants or other external professional.

LICENSE CONDITIONS CONTINUED

7. Submit photographs or copies of all gambling establishment advertisements to the Bureau, including advertising placed on social media. The gambling establishment shall also inform the Bureau of the methods by which these advertisements are accessible to employees and patrons, and shall notify the Bureau immediately of any changes or any new advertisements.
8. The gambling establishment shall notify the Bureau immediately of any changes to their Problem Gambling Program policies and procedures.
9. Submit video surveillance footage (including audio) of the count room during a count to the Bureau for review on a quarterly basis. The Bureau will notify the gambling establishment of a randomly selected day within each quarter for which the video surveillance footage is requested, and that video shall be produced on or before March 31, 2021; June 30, 2021; September 30, 2021; and December 31, 2021.

Attach a certified check payable to the Treasurer of the State of California in the amount of \$500 for the nonrefundable minisatellite application fee.

CHRB CERTIFICATION

Application filed on:	30-day Notice Letter:
Fee received by:	Approved on:
Reviewed by:	License number issued:

CERTIFICATION BY APPLICANT

I hereby certify under penalty of perjury that I have examined this application, that all of the foregoing statements in this application are true and correct, and that I am authorized by the applicant contractor to attest to this application on its behalf.

<i>Teel Kingston</i> Name	<i>[Signature]</i> Signature of Applicant Representative
<i>President</i> Title	<i>12-11-20</i> Date:

PART II

CONTRACTED ASSOCIATION INFORMATION

One copy of Part II shall be completed by each contracted association

Name and mailing address of association:

Telephone:

Fax number:

Racetrack name:

Name and title of the person(s) authorized to receive notices on behalf of the association in conjunction with this applicant application for approval to operate a minisatellite wagering facility:

Name

Signature of association representative

Title

Date:

**PART III
 SIMULCAST ORGANIZATION INFORMATION**

To be completed by approved simulcast organization that has executed an agreement approved by the CHRB with the association conducting a racing meeting with the minisatellite wagering facility pursuant to Business and Professions Code sections 19605.25 and 19605.3.

I. OPERATION OF THE MINISATELLITE WAGERING FACILITY

Simulcast organization engaged by the association to conduct simulcast wagering:

Attach the agreement between the association and simulcast organization permitting the minisatellite wagering facility to use the association's live audiovisual signal for wagering purposes and providing access to it's totalizator for the purpose of combining on-track and off-track pari-mutuel pools.

Submit a copy of each horsemen's written approvals.

Hours for operation of the facility:

Hours for operation of the minisatellite wagering site:

Time periods during the calendar year the facility **will not** be utilized as a minisatellite wagering facility (explain why):

If approved, wagering will be offered on live race meetings being held or conducted by the following California racing association(s):

List the host track from which the minisatellite wagering facility proposes to import out-of-state and/or out-of-country races. Include the dates imported races will be held, and whether or not a full card will be accepted. If the full card will not be imported, state "selected feature and/or stakes races":

Estimated number of pari-mutuel terminals machines available:

Attach a proposed staffing plan for the facility and/or minisatellite wagering site, to include the number of security personnel and the number of pari-mutuel clerks pursuant to Business and Professions Code section 19605.25 (5)(b).

II. SUPERVISION, SECURITY AND FIRE PREVENTION

Changes to management personnel and minisatellite manager(s)
 must be immediately reported to the Board.

Name of the individual(s) responsible for the day-to-day operation of the minisatellite facility:

Name and Title	CHRB License No. and Expiration Date

Attach a certificate of insurance for workers' compensation coverage including carrier and the policy number securing the applicant's liability for payment of workers' compensation is (if self-insured, provide details):

Attach a fire clearance from the fire authority having jurisdiction.

Attach a security plan to include: the name, title and phone number of the person having responsibility for security controls, the number of security officers and/or guards and the police or sheriff's department having jurisdiction for criminal law enforcement over the premises of the facility.

Is there a backup emergency plan for power failure? Yes No

If yes, describe.

III. MINISATELLITE WAGERING SITE

Attach a detailed scale plan of the facility indicating all points of access to facility, emergency exits, placement of offices, and food and beverage service location and detailing the location of the proposed minisatellite wagering site. Identify how the designated minisatellite wagering area will be restricted to patrons 21 years and over. Attach photos of the minisatellite wagering site.

NOTICE TO APPLICANT. Pursuant to Business and Professions Code section 19605.25(a) (4) wagers placed at a minisatellite site must be in an area that is restricted to those who are 21 years of age or older.

IV. FACILITY DESCRIPTION

Describe the food and beverage services to be offered (full meals served; cafeteria-style full meals; short-order counter service; pre-ordered prepared sandwiches and fast foods available; full bar services; or other description as appropriate):

The seating capacity in the minisatellite wagering facility is:

The number of tables in the minisatellite wagering area is:

Overall square footage in the minisatellite wagering area is:

Attach a photograph of the minisatellite wagering area.

Describe occupancy restrictions, if any, imposed by the fire authority having jurisdiction:

The total number of parking spaces available in the parking areas can accommodate (number of standard sized automobiles):

Describe any other activities to be scheduled on or near the facility premises that may have a negative impact on available parking:

V. EQUIPMENT PROVIDED BY THE MINISATELLITE WAGERING FACILITY

Describe the television equipment (satellite receivers, decoders, controls, monitors, etc.) to be utilized at the facility:


Describe the public address equipment (controls, microphones, speakers, etc.) to be utilized at the facility:

N

W

PATIO






5 TO Back Parking







Double Door
to Patio
And Back
Parking Lot
Patio

E

LEGEND

-  EXISTING WALL TO REMAIN
-  NEW WALL - 3 5/8" x 25 GA. STUDS @ 16" WITH 5/8" G.B. TYPE 'X' GYP. BD. ON EA. SIDE
-  WALL TO BE REMOVED
-  EXISTING DOOR TO REMAIN
-  DOOR TO BE REMOVED

-  NEW DOOR, PER DOOR SCHEDULE
-  EXISTING WINDOW TO REMAIN
-  WINDOW TO BE REMOVED
-  INDICATES EXIT SIGN
-  EXISTING PLUMBING FIXTURE TO REMAIN
-  PLUMBING FIXTURE TO BE REMOVED



EXISTING/DEMOLITION FLOOR PLAN

SCALE: 1/8" = 1'-0"



REVISIONS

PROJECT NAME:
**INTERIOR REMODEL
 LAKE ELSINORE
 CASINO
 LAKE ELSINORE**

It is the policy of the Architect to provide the Client with the most economical design possible. The Client is responsible for providing the Architect with all necessary information and approvals. The Architect is not responsible for the accuracy of the information provided by the Client. The Architect is not responsible for the accuracy of the information provided by the Client. The Architect is not responsible for the accuracy of the information provided by the Client.

JWDA
 ARCHITECTURE/INTERIOR/INTERIOR DESIGN
 Joseph Wong Design Associates
 8550 Fourth Avenue
 San Diego, California 92121-1000
 Phone (619) 533-9777 FAX (619) 577-0241

SHEET TITLE:
**EXISTING/
 DEMOLITION FLOOR
 PLAN**


DATE: 2016-01-14
SCALE: AS NOTED
DRAWN: TVT
JOB NO.: JWDA3057
FILE NAME:
SHEET:

D-1

LAKE ELSINORE CASINO REMODEL / ADDITION LAKE ELSINORE, CA

20930 MALAGA RD.
LAKE ELSINORE, CA

PROJECT TEAM	PROJECT DATA	SHEET SCHEDULE									
<p>ARCHITECT: JOSEPH WONG DESIGN ASSOCIATES, INC. 2354 4TH AVENUE SAN DIEGO, CA 92101 TEL: (619) 235-6111 FAX: (619) 237-0541 CONTACT: TOMAS VEGA e-mail: tvega@jwda.com</p> <p>STRUCTURAL ENGINEER: LOVELACE ENGINEERS 5480 CORNERSTONE COURT N. SUITE 100 SAN DIEGO, CA 92121 TEL: (619) 595-4111 FAX: (619) 595-1924 CONTACT: cturner@lovelaceeng.com e-mail: CHRIS TURNER</p>	<p>DESCRIPTION OF WORK: REMOTE PORTION OF WALL TO CREATE A BIGGER OPENING REMODEL EXISTING BAR ADD CASHIER WINDOWS (3)</p> <p>OWNER: LAKE ELSINORE CASINO 20930 MALAGA ROAD LAKE ELSINORE, CA 92530 TEL: (951) 674-5160 FAX: (951) 674-4071 CONTACT: GREG BARTON</p> <p>PROJECT ADDRESS: 20930 MALAGA ROAD LAKE ELSINORE, CA</p> <p>EXISTING USE: CASINO / RESTAURANT / BAR</p> <p>PROPOSED USE: CASINO / RESTAURANT / BAR, (NO CHANGES)</p> <table border="1" style="width: 100%; margin-top: 10px;"> <tr> <td>AREAS OF REMODEL:</td> <td>RESTAURANT / BAR (EXISTING FLOOR AREA= 2444 S.F.)</td> </tr> <tr> <td></td> <td>BAR/RESTAURANT AREA OR REMODEL: 2764 S.F.</td> </tr> <tr> <td></td> <td>CASHIER WINDOWS 185 S.F.</td> </tr> <tr> <td></td> <td>TOTAL FLOOR AREA OR REMODEL: 2444 S.F.</td> </tr> </table> <p>EXISTING OCCUPANCY GROUP: A-2 AND B</p> <p>PROPOSED OCCUPANCY GROUP: A-2 AND B (NO CHANGES)</p> <p>TYPE OF CONSTRUCTION: V A (NO SPRINKLERS)</p> <p>NUMBER OF STORIES: ONE</p>	AREAS OF REMODEL:	RESTAURANT / BAR (EXISTING FLOOR AREA= 2444 S.F.)		BAR/RESTAURANT AREA OR REMODEL: 2764 S.F.		CASHIER WINDOWS 185 S.F.		TOTAL FLOOR AREA OR REMODEL: 2444 S.F.	<p>ARCHITECTURAL</p> <p>CS COVER SHEET A-1 SITE PLAN D-1 EXISTING/DEMOLITION FLOOR PLAN A-2 PROPOSED OVERALL FLOOR PLAN A-3 ENLARGED BAR AND RESTROOM FLOOR PLAN A-4 DOOR AND FINISH SCHEDULES</p> <p>STRUCTURAL</p> <p>S1 GENERAL NOTES S2 MAIN BUILDING FOUNDATION PLAN S3 MAIN BUILDING ROOF FRAMING PLAN S-4 STRUCTURAL DETAILS</p>	<p>THIS PROJECT SHALL COMPLY WITH THE FOLLOWING CODES:</p> <p>2016 CALIFORNIA BUILDING CODE 2016 CALIFORNIA MECHANICAL CODE 2016 CALIFORNIA ELECTRICAL CODE 2016 CALIFORNIA PLUMBING CODE 2016 CALIFORNIA FIRE CODE</p>
AREAS OF REMODEL:	RESTAURANT / BAR (EXISTING FLOOR AREA= 2444 S.F.)										
	BAR/RESTAURANT AREA OR REMODEL: 2764 S.F.										
	CASHIER WINDOWS 185 S.F.										
	TOTAL FLOOR AREA OR REMODEL: 2444 S.F.										



**INTERIOR REMODEL
LAKE ELSINORE
CASINO
LAKE ELSINORE**

THIS PROJECT SHALL COMPLY WITH THE FOLLOWING CODES:
2016 CALIFORNIA BUILDING CODE
2016 CALIFORNIA MECHANICAL CODE
2016 CALIFORNIA ELECTRICAL CODE
2016 CALIFORNIA PLUMBING CODE
2016 CALIFORNIA FIRE CODE

JWDA
ARCHITECTURE/ENGINEERING/INTERIOR DESIGN
Joseph Wong Design Associates
2354 4th Avenue
San Diego, California 92101-1008
Phone: (619) 237-0541 Fax: (619) 237-0544



**COVER SHEET
PROJECT DATA,
VICINITY MAP**

DATE: 2016-01-14
SCALE: NONE
DRAWN: TVT
JOB NO.: JWDA3057
FILE NAME:
SHEET:


CS













VI. ADVERTISING AND PATRON DEVELOPMENT

Describe any advertising or promotional plans:

Describe any improvements to the facility that will directly benefit minisatellite wagering:

NOTICE TO APPLICANT: Pursuant to Board Rule 2066 all advertisement shall contain a statement that persons under 21 are not allowed to participate in minisatellite wagering. All advertisement shall contain contact information for a recognized problem-gambling support organization.

VII. ADMISSIONS, CHARGES AND SERVICE FEES

Complete if applicable and note N/A if not

Admissions charges, if any, are:

Parking charges, if any, are:

Program charges, if any, are:

Seating charges, if any, are:

VIII. RENEWAL

Complete this section only if renewing your license.

Is this a renewal application: Yes No

Have there been any changes since the submission of your last application for authorization to operate a minisatellite wagering facility? Yes No

Have any changes occurred affecting ownership or controlling interest in your business structure or establishment since your last application? Yes No

If you have answered, "Yes", to any of the questions above please attach a detailed statement describing the change.

Renewal of existing License.

How many years have you been an approved minisatellite wagering facility?

Approx. 4.5 years

AGREEMENTS

Attach copies of all applicable county, city or agency agreements that may affect the minisatellite wagering facility.

NOTICES TO APPLICANT

Notice is given to the applicant that its application, if approved by the Board, authorizes the applicant to offer pari-mutuel wagering at its minisatellite wagering facility for a period of two years per Business and Professions Code section 19605.25(h).

Notice is given that retention of and control over all moneys generated from pari-mutuel wagering held or conducted at the facility is the responsibility of the simulcast organization(s) which contract(s) to provide the pari-mutuel equipment and pari-mutuel employees; and that such organization(s) is (are) responsible for its proper distribution in accordance with the law and the rules and regulations of the Board.

Notice is given that CHRB Rules 1870 and 1871 require that the Board be given 15 days notice in writing of any intention to terminate operations, engagements, or services by any licensee, or approved contractor.

DECLARATIONS

All labor agreements, concession contracts, service contracts, horsemen's agreements, lease agreements, agreements with the



January 25, 2021

Lake Elsinore Hotel & Casino
Attn: Ted Kingston
20930 Malaga Road
Lake Elsinore, CA 92530

Dear Mr. Kingston,

Thank you for contacting the City of Lake Elsinore regarding your efforts to bring off-track horse race betting to the Lake Elsinore Casino.

As the City of Lake Elsinore is the "Action Sports Capital of the World," these efforts will align with our goals to attract greater tourism and economic development.

While the City is not required to provide any formal approval related to off-track horse-race betting, we support and appreciate your efforts to bring new opportunities to Lake Elsinore.

The City is honored to have your growing business here and we look forward to doing what we can to support your future success.

Sincerely,

Jason Simpson
Assistant City Manager

951.674.3124

130 S. MAIN STREET

LAKE ELSINORE, CA 92530

WWW.LAKE-ELSINORE.ORG

**CONSENT TO ESTABLISHMENT OF MINI-SATELLITE WAGERING
FACILITY**

WHEREAS, Southern California off Track Wagering, Inc., a California Corporation ("Scotwinc") has entered, or is about to enter, into an agreement with Lake Elsinore Hotel and Casino with respect to the establishment of a Minisatellite Wagering facility at 20930 Malaga Rd., Lake Elsinore, California (the "Lake Elsinore Minisatellite"), and

WHEREAS, such facility will be located within twenty (20) statute miles of the Lake Perris Fairgrounds where the Lake Perris -Sports Pavilion at the Farmer's Fair operates as a satellite wagering facility, and

WHEREAS, Section 19605.25(a)(1) of the California Business and Professions Code prohibits, absent the consent of the operator of the Satellite Wagering Facility, the location of a Minisatellite within the twenty (20) statute miles of an existing Satellite Wagering Facility.

NOW THEREFORE, Lake Perris Fairgrounds gives it consent to the establishment and operation of the Lake Elsinore Minisatellite for a period of ten (10) years commencing on Feb. 23, 2016.

By 

State of California
 California Horse Racing Board
 Application for License to Operate a Minisatellite Wagering Facility
 CHRB-228 (New 11/08)

simulcast organization(s) necessary to conduct and operate the simulcast wagering program at the facility, lease or rental agreement with the facility landlord and all applicable county, city or agency agreements that may affect the minisatellite wagering facility have been finalized except as follows (if there are no exceptions, so state):

All service contractors and concessionaires have valid State, County or City licenses authorizing each to engage in the type of service to be provided and have valid labor agreements (when applicable) which remain in effect for the entire term of the license except as follows (if there are no exceptions, so state):

Absent natural disasters or causes beyond the control of the applicant, its service contractors, concessionaires or employees engaged at the facility, no reasons are believed to exist that may result in a stoppage to the conduct of pari-mutuel wagering at the facility or the withholding of any vital service to the applicant except as follows (if there are no exceptions, so state):

By authority of Article 9.2, Chapter 4, of the Business and Professions Code; and the Federal Indian Gaming Act; to allow an evaluation of the competence, integrity, and character of potential simulcast facility operators, any person, corporation, trust association, partnership, joint venture, or management firm who submits an application for such license or who is named in such application and who is not a State or County entity, or has not previously completed such disclosure when filing for a horseracing application pursuant to Article 4, section 19480 of the Business and Professions Code shall be required to complete and submit a full disclosure statement.

CERTIFICATION BY APPLICANT

I hereby certify under penalty of perjury that I have examined this application, that all of the foregoing statements in this application are true and correct, and that I am authorized by the applicant to attest to this application on its behalf.

Print name of minisatellite facility applicant representative:

Teal Kingston

Date:

12-11-20

Signature of minisatellite facility representative:

Teal Kingston

Date:

12-11-20

Print name of association representative:

Date:

Signature of association representative:

Date:

Print name of simulcast organization representative:

Date:

Signature of simulcast organization representative:

Date:

INSTRUCTION SHEET FOR FULL DISCLOSURE STATEMENT

Background Information and Ownership

By authority of Chapter 4, Division 8, sections 19420 and 19440 of the California Business and Professions Code; and to allow an evaluation of the competence, integrity, and character of potential licensees, all applicants for license as contractors, sub-contractors and all concessionaires applying for Board approval, including any person, corporation, trust, association, partnership or joint venture which submits an application for license or approval shall comply with the provisions set forth below. Please use a separate sheet of paper to supply the requested information.

I. BACKGROUND INFORMATION

(A) **PERSONAL INFORMATION** - Application documents must include for each individual who is a director, officer, or partner in the application, or an owner of an interest in the applicant of 5 percent or more:

- (1) The individual's full name and any previous names or aliases;
- (2) the individual's date of birth;
- (3) a physical description of the individual;
- (4) the individual's business addresses and telephone numbers and
- (5) a disclosure of employment, educational and military history for the past 20 years or since the age of 18 years.

(A1) **PERSONAL HISTORY** - Application documents must include a completed Personal History Record, CHRB-25A, for each individual named in subsection (A) who is a director, officer, or partner in the application or an owner of an interest in the applicant of 5 percent or more.

(B) **RELATIONSHIP** - The application documents must state, for each individual providing information under subsection (A) of this section, whether the individual is related to a member of the California Horse Racing Board or an employee of the Board. A half-relationship or step-relationship is considered to be a familial relationship for purposes of this section.

(C) **CORPORATIONS** - If the applicant is a corporation, the application documents must state:

- (1) The state in which the applicant is incorporated and
- (2) the name and address of the applicant's agent for service of process in California.

(D) **INDICTMENTS OR CONVICTIONS**

If the applicant is a corporation, the application documents must include a statement disclosing whether the corporation is presently or has ever been indicted or convicted of a criminal offense, e.g., felony or misdemeanor.

II. OWNERSHIP

(A) **IDENTIFICATION AND LOCATION** - The application documents must include:

- (1) A list of all names used by the applicant; and
- (2) the name of the agent and the address and telephone number of the office of the applicant for service of process in California.

(B) **BUSINESS STRUCTURE** - The application documents must describe the applicant's business structure and include an organizational chart.

State of California
California Horse Racing Board
Application for License to Operate a Minisatellite Wagering Facility
CHRB-228 (New 11/08)

- (C) ORGANIZERS - If the applicant is not an individual and was organized less than five years before the date on which the application documents are submitted to the Board, the application documents must state:
- (1) The name of each individual who was an organizer or promoter of the applicant;
 - (2) the nature and amount of assets, services, or other consideration contributed to the applicant by an organizer or promoter of the applicant; and
 - (3) the nature and amount of anything of value given by the applicant to an organizer or promoter of the applicant.
- (D) ORGANIZATIONAL DOCUMENTS
- (1) If the applicant is a corporation, the application documents must include:
 - (a) A statement of when and in what state the corporation was organized;
 - (b) a certified copy of the articles of incorporation and by-laws of the applicant;
 - (c) a statement and documentation of whether the corporation has been reorganized or reincorporated during the five year period preceding the date on which the application documents are submitted to the Board; and
 - (d) a statement and documentation of whether the corporation has filed restated articles of incorporation.
 - (2) If the applicant is an unincorporated business association, the application documents must include:
 - (a) A certified copy of each organizational document for the applicant, including any partnership agreement; and
 - (b) a description of any oral agreements involving the organization of the partnership.
- (E) CAPITAL STOCK
- (1) If the applicant is authorized to issue capital stock, the application documents must include the information required by this section.
 - (2) The applicant must state the classes of stock authorized and the total shares of each class authorized. The applicant must state, for each class of stock:
 - (a) The par value, if any;
 - (b) the voting rights;
 - (c) the current rate of dividend; and
 - (d) the number of shares outstanding and the market value of each share.
 - (3) The application documents must list the name and address of each person who owns, of record or beneficially, at least 5 percent of stock. For each person listed under this subsection, the application documents must describe the nature of the person's ownership interest and the person's percentage of the total ownership interest.
 - (4) The application documents must include a certified copy of each voting trust or voting agreement in which at least 5 percent of the capital stock is held and must state:
 - (a) The name and address of each stockholder participating in the trust or agreement;
 - (b) the class of stock involved; and
 - (c) the total number of shares held by the trust or agreement.
- (F) DIRECTORS, OFFICERS, AND PARTNERS

State of California
California Horse Racing Board
Application for License to Operate a Minisatellite Wagering Facility
CHRB-228 (New 11/08)

- (1) If the applicant is not an individual, the application documents must include a list of the individuals who are serving or who are designated to serve, during the first year after the date the application documents are submitted to the Board, as a director, officer, or partner of the applicant.
- (2) The list must state, for each individual listed under subsection (1) of this section:
 - (a) The individual's name and business address;
 - (b) each position or office of the applicant held by the individual;
 - (c) the individual's principal occupation during the five-year period preceding the date on which the application documents are submitted to the Board; and
 - (d) the nature and extent of any ownership interest that the individual has in the applicant.
- (3) Application documents must include a completed Personal History Record, CHRB-25A, for each individual named under subsection (1) of this section.

(G) CONTROLLING ENTITY

- (1) The application documents must state whether another entity exercises or is in a position to exercise control in the management or financial affairs of the applicant. The documents must describe the nature of the relationship between the entity and the applicant and the extent of control exercised by the entity.
- (2) If a non-individual entity owns an interest of 5 percent or more in the applicant, the application documents must include the information required by subsection (1) of this section as it relates to the non-individual entity.
- (3) The application documents must include information required by subsection (2) of this section for each non-individual entity identified in the application documents to the extent necessary to determine the identity of each individual who is an indirect holder of an ownership interest in the applicant.

(H) OUTSIDE INTERESTS AND LICENSE HISTORY

- (1) The application must state whether the applicant or a director, officer, or partner of the applicant;
 - (a) Has ever held an ownership interest in a licensee of the Board; or
 - (b) is currently engaged in the business of racing in another state.

Application is hereby made to the California Horse Racing Board (CHRB/Board) for a license to operate a minisatellite wagering facility in connection with a horseracing meeting and/or parimutuel wagering in accordance with the Business and Professions Code, Chapter 4, Division 8 (Horse Racing Law) and the California Code of Regulations, Title 4, Division 4 (Rules and Regulations of the California Horse Racing Board).

Part I: To be completed by applicant seeking to operate a minisatellite wagering facility pursuant to Business and Professions Code section 19605.25.

Part II: To be completed by association(s) that has/have reached an agreement with the applicant to conduct minisatellite wagering.

Part III: To be completed by simulcast organization that has reached an agreement to provide services necessary for the conduct of minisatellite wagering pursuant to Business and Professions Code sections 19605.25 & 19605.3.

**PART I
 MINISATELLITE WAGERING APPLICANT INFORMATION**

APPLICANT INFORMATION

Name of applicant: The applicant is: <input type="checkbox"/> Racing Association <input type="checkbox"/> Fair <input type="checkbox"/> Federally Recognized Indian Tribe		<input type="checkbox"/> Card Room/Gambling Establishment <input checked="" type="checkbox"/> Restaurant/Bar <input type="checkbox"/> Other Business Entity
Facility street address:		
Mailing address (if different from above):		
E-mail address:		
City:	State:	Zip Code:
Phone:	Fax:	Website:
County:	Zone Location: North <input type="checkbox"/> South <input type="checkbox"/> Central <input type="checkbox"/> (To be completed by CHRB staff)	

**CONTACT PERSON
 (Authorized Representative)**

Name and title of the contact person:		
Business street address:		
Mailing address (if different from above):		
City:	State:	Zip Code:
County:		
Phone:	E-mail:	Fax:

State of California
 California Horse Racing Board
 Application for License to Operate a Minisatellite Wagering Facility
 CHRB-228 (New 11/08)

Dates during which the applicant proposes to operate as a minisatellite wagering facility:

March 24 2021 to March 24 2026

NOTICE TO APPLICANT: If approved for license, the term of license shall not exceed two years pursuant to Business and Professions Code section 19605.25 (h).

Have you previously operated a licensed gaming operation in California or another state? Yes No

Do you currently operate a licensed gaming operation in California or another state? Yes No

If yes to either question above, provide the following:

Valid licensure period: Begin Date: _____ End Date: _____

Facility name and address:

City: _____ State: _____ Zip Code: _____

County: _____

Zone Location:
 North South Central
 (To be completed by CHRB staff)

Have you had a gaming operation license that has been revoked or suspended. Yes No

If yes, provide the following if different from above:

Facility name and address:

City: _____ State: _____ Zip Code: _____

Racing Jurisdiction: _____

BUSINESS STRUCTURE

<input checked="" type="checkbox"/> Corporation <input type="checkbox"/> Public <input type="checkbox"/> Private <input type="checkbox"/> Sub-S <input type="checkbox"/> Sub-C <input type="checkbox"/> Limited Partnership <input type="checkbox"/> Limited Liability Company	<input type="checkbox"/> Partnership & Joint Venture <input type="checkbox"/> Sole Proprietorship	<input type="checkbox"/> Other If you have listed your company as other please identify your company structure:
--	--	--

Registered Business Name: LER Lounge Inc.

Fictitious Business Name: CJ'S Sports Grill & Turf Club

Address:
 20930 Malaga Rd

E-mail Address: CJsbar.com

City: Lake Elsinore State: CA Zip Code: 92530

Phone: 951-471-6700 Fax: 951-674-4071

State where registered or Articles of Organization are filed: CA Registry or File number: 1808472

Attach a certified check payable to the Treasurer of the State of California in the amount of \$500 for the nonrefundable minisatellite application fee.

CHRB CERTIFICATION

Application filed on:

30-day Notice Letter:

Fee received by:

Approved on:

Reviewed by:

License number issued:

CERTIFICATION BY APPLICANT

I hereby certify under penalty of perjury that I have examined this application, that all of the foregoing statements in this application are true and correct, and that I am authorized by the applicant contractor to attest to this application on its behalf.

Teal Kingston

Name

[Signature]

Signature of Applicant Representative

President

Title

12-11-20

Date:

PART II

CONTRACTED ASSOCIATION INFORMATION

One copy of Part II shall be completed by each contracted association

Name and mailing address of association: CJ'S Sports Grill & Turf Club

20930 Malaga Road Lake Elsinore CA 92530

Telephone:
951-471-6700


Fax number: 951-674-4071

Racetrack name:

Name and title of the person(s) authorized to receive notices on behalf of the association in conjunction with this applicant application for approval to operate a minisatellite wagering facility:

Name
Ted Kingston

Signature of association representative



Title
President

Date: 12-29-2020

**PART III
SIMULCAST ORGANIZATION INFORMATION**

To be completed by approved simulcast organization that has executed an agreement approved by the CHRB with the association conducting a racing meeting with the minisatellite wagering facility pursuant to Business and Professions Code sections 19605.25 and 19605.3.

I. OPERATION OF THE MINISATELLITE WAGERING FACILITY

Simulcast organization engaged by the association to conduct simulcast wagering:

Attach the agreement between the association and simulcast organization permitting the minisatellite wagering facility to use the association's live audiovisual signal for wagering purposes and providing access to its totalizator for the purpose of combining on-track and off-track pari-mutuel pools.

Submit a copy of each horsemen's written approvals.

Hours for operation of the facility: 6am to 2am 7 Days a week

Hours for operation of the minisatellite wagering site: Wednesday to Sunday 10am to Last Race

Time periods during the calendar year the facility **will not** be utilized as a minisatellite wagering facility (explain why): Monday and Tuesday CHRB Decision – Not enough Volume

If approved, wagering will be offered on live race meetings being held or conducted by the following California racing association(s): CHRB

List the host track from which the minisatellite wagering facility proposes to import out-of-state and/or out-of-country races. Include the dates imported races will be held, and whether or not a full card will be accepted. If the full card will not be imported, state "selected feature and/or stakes races":

Estimated number of pari-mutuel terminals machines available: 3 Teller, 8 Tote, 1 Voucher.


Attach a proposed staffing plan for the facility and/or minisatellite wagering site, to include the number of security personnel and the number of pari-mutuel clerks pursuant to Business and Professions Code section 19605.25 (5)(b).

II. SUPERVISION, SECURITY AND FIRE PREVENTION

Changes to management personnel and minisatellite manager(s)
must be immediately reported to the Board.

Name of the individual(s) responsible for the day-to-day operation of the minisatellite facility:

Name and Title	CHRB License No. and Expiration Date
Ted Kingston - <i>President</i>	324851 December 2020



Evacuation Plan


IN CASE OF EMERGENCY CALL 911

FIRE DEPT: (951) 674-2161

POLICE: (951) 245-3300

Evacuate Immediately

CJ's Sports Grill & Turf Club
20930 Malaga Rd
Lake Elsinore, CA 92530
(951) 674-3101



Attach a certificate of insurance for workers' compensation coverage including carrier and the policy number securing the applicant's liability for payment of workers' compensation is (if self-insured, provide details):

- Attach a fire clearance from the fire authority having jurisdiction.

Attach a security plan to include: the name, title and phone number of the person having responsibility for security controls, the number of security officers and/or guards and the police or sheriff's department having jurisdiction for criminal law enforcement over the premises of the facility.

Is there a backup emergency plan for power failure? Yes No

• If yes, describe.

III. MINISATELLITE WAGERING SITE

Attach a detailed scale plan of the facility indicating all points of access to facility, emergency exits, placement of offices, and food and beverage service location and detailing the location of the proposed minisatellite wagering site. Identify how the designated minisatellite wagering area will be restricted to patrons 21 years and over. Attach photos of the minisatellite wagering site.

NOTICE TO APPLICANT. Pursuant to Business and Professions Code section 19605.25(a) (4) wagers placed at a minisatellite site must be in an area that is restricted to those who are 21 years of age or older.

IV. FACILITY DESCRIPTION

Describe the food and beverage services to be offered (full meals served; cafeteria-style full meals; short-order counter service; pre-ordered prepared sandwiches and fast foods available; full bar services; or other description as appropriate): Full Restaurant service and Full Bar Service

The seating capacity in the minisatellite wagering facility is: 99

The number of tables in the minisatellite wagering area is: 18 plus seating at the bar

Overall square footage in the minisatellite wagering area is: Estimated 1800 Square Feet

Attach a photograph of the minisatellite wagering area.

Describe occupancy restrictions, if any, imposed by the fire authority having jurisdiction:
None

The total number of parking spaces available in the parking areas can accommodate (number of standard sized automobiles):
250 Parking Spaces

Describe any other activities to be scheduled on or near the facility premises that may have a negative impact on available parking:
None

V. EQUIPMENT PROVIDED BY THE MINISATELLITE WAGERING FACILITY

Describe the television equipment (satellite receivers, decoders, controls, monitors, etc.) to be utilized at the facility:
60 - 60 inch televisions plus 1 video wall (240 inch)

Describe the public address equipment (controls, microphones, speakers, etc.) to be utilized at the facility:

Microphone and custom programmed tv controller

VI. ADVERTISING AND PATRON DEVELOPMENT

Describe any advertising or promotional plans:

Digital Billboard on property by I-15 Freeway – Social Media

Describe any improvements to the facility that will directly benefit minisatellite wagering:

NOTICE TO APPLICANT: Pursuant to Board Rule 2066 all advertisement shall contain a statement that persons under 21 are not allowed to participate in minisatellite wagering. All advertisement shall contain contact information for a recognized problem-gambling support organization.

VII. ADMISSIONS, CHARGES AND SERVICE FEES

Complete if applicable and note N/A if not

Admissions charges, if any, are:	None
Parking charges, if any, are:	None
Program charges, if any, are:	Yes - Standard Price
Seating charges, if any, are:	None

VIII. RENEWAL

Complete this section only if renewing your license.

Is this a renewal application: Yes No

Have there been any changes since the submission of your last application for authorization to operate a minisatellite wagering facility? Yes No

Have any changes occurred affecting ownership or controlling interest in your business structure or establishment since your last application? Yes No

If you have answered, "Yes", to any of the questions above please attach a detailed statement describing the change.

Renewal Of Existing License

How many years have you been an approved minisatellite wagering facility? Approximately 4 ½ Years

AGREEMENTS

Attach copies of all applicable county, city or agency agreements that may affect the minisatellite wagering facility.

NOTICES TO APPLICANT

Notice is given to the applicant that its application, if approved by the Board, authorizes the applicant to offer pari-mutuel wagering at its minisatellite wagering facility for a period of two years per Business and Professions Code section 19605.25(h).

Notice is given that retention of and control over all moneys generated from pari-mutuel wagering held or conducted at the facility is the responsibility of the simulcast organization(s) which contract(s) to provide the pari-mutuel equipment and pari-mutuel employees; and that such organization(s) is (are) responsible for its proper distribution in accordance with the law and the rules and regulations of the Board.

Notice is given that CHR-228 Rules 1870 and 1871 require that the Board be given 15 days notice in writing of any intention to terminate operations, engagements, or services by any licensee, or approved contractor.

DECLARATIONS

All labor agreements, concession contracts, service contracts, horsemen's agreements, lease agreements, agreements with the

State of California
 California Horse Racing Board
 Application for License to Operate a Minisatellite Wagering Facility
 CHRB-228 (New 11/08)

simulcast organization(s) necessary to conduct and operate the simulcast wagering program at the facility, lease or rental agreement with the facility landlord and all applicable county, city or agency agreements that may affect the minisatellite wagering facility have been finalized except as follows (if there are no exceptions, so state):

All service contractors and concessionaires have valid State, County or City licenses authorizing each to engage in the type of service to be provided and have valid labor agreements (when applicable) which remain in effect for the entire term of the license except as follows (if there are no exceptions, so state):

Absent natural disasters or causes beyond the control of the applicant, its service contractors, concessionaires or employees engaged at the facility, no reasons are believed to exist that may result in a stoppage to the conduct of pari-mutuel wagering at the facility or the withholding of any vital service to the applicant except as follows (if there are no exceptions, so state):

By authority of Article 9.2, Chapter 4, of the Business and Professions Code; and the Federal Indian Gaming Act; to allow an evaluation of the competence, integrity, and character of potential simulcast facility operators, any person, corporation, trust association, partnership, joint venture, or management firm who submits an application for such license or who is named in such application and who is not a State or County entity, or has not previously completed such disclosure when filing for a horseracing application pursuant to Article 4, section 19480 of the Business and Professions Code shall be required to complete and submit a full disclosure statement.

CERTIFICATION BY APPLICANT

I hereby certify under penalty of perjury that I have examined this application, that all of the foregoing statements in this application are true and correct, and that I am authorized by the applicant to attest to this application on its behalf.

Print name of minisatellite facility applicant representative: <i>Teal Kingston</i>	Date: <i>12-11-20</i>
Signature of minisatellite facility representative: <i>Teal Kingston</i>	Date: <i>12-11-20</i>
Print name of association representative:	Date:
Signature of association representative:	Date:
Print name of simulcast organization representative:	Date:
Signature of simulcast organization representative:	Date:

Application is hereby made to the California Horse Racing Board (CHRB/Board) for a license to operate a minisatellite wagering facility in connection with a horseracing meeting and/or parimutuel wagering in accordance with the Business and Professions Code, Chapter 4, Division 8 (Horse Racing Law) and the California Code of Regulations, Title 4, Division 4 (Rules and Regulations of the California Horse Racing Board).

Part I: To be completed by applicant seeking to operate a minisatellite wagering facility pursuant to Business and Professions Code section 19605.25.

Part II: To be completed by association(s) that has/have reached an agreement with the applicant to conduct minisatellite wagering.

Part III: To be completed by simulcast organization that has reached an agreement to provide services necessary for the conduct of minisatellite wagering pursuant to Business and Professions Code sections 19605.25 & 19605.3.

**PART I
 MINISATELLITE WAGERING APPLICANT INFORMATION**

APPLICANT INFORMATION		
Name of applicant: Lake Elsinore Hotel & Casino The applicant is: <input type="checkbox"/> Racing Association <input type="checkbox"/> Fair <input type="checkbox"/> Federally Recognized Indian Tribe	<input checked="" type="checkbox"/> Card Room/Gambling Establishment <input type="checkbox"/> Restaurant/Bar <input type="checkbox"/> Other Business Entity	
Facility street address: 20930 Malaga Road		
Mailing address (if different from above):		
E-mail address: TedK@LerCasino.com		
City: Lake Elsinore	State: CA	Zip Code: 92530
Phone: (951) 674-3101	Fax: (951) 674-4071	Website: LerCasino.com
County: Riverside	Zone Location: North <input type="checkbox"/> South <input type="checkbox"/> Central <input type="checkbox"/> (To be completed by CHRB staff)	

CONTACT PERSON <small>(Authorized Representative)</small>		
Name and title of the contact person: Ted Kingston, General Manager		
Business street address: 20930 Malaga Road		
Mailing address (if different from above):		
City: Lake Elsinore	State: CA	Zip Code: 92530
County: Riverside		
Phone: (951) 674-3101	E-mail: TedK@LerCasino.com	Fax: (951) 674-4071

State of California
 California Horse Racing Board
 Application for License to Operate a Minisatellite Wagering Facility
 CHRB-228 (New 11/08)

Dates during which the applicant proposes to operate as a minisatellite wagering facility:
 Through expiration of license

NOTICE TO APPLICANT: If approved for license, the term of license shall not exceed two years pursuant to Business and Professions Code section 19605.25 (h).

Have you previously operated a licensed gaming operation in California or another state? Yes No

Do you currently operate a licensed gaming operation in California or another state? Yes No

If yes to either question above, provide the following:

Valid licensure period: Begin Date: 2015 End Date: 3/24/2021

Facility name and address: Lake Elsinore Hotel & Casino, 20930 Malaga Road

City: Lake Elsinore	State: CA	Zip Code: 92530
---------------------	-----------	-----------------

County: Riverside

Zone Location: North <input type="checkbox"/> South <input type="checkbox"/> Central <input type="checkbox"/> (To be completed by CHRB staff)

Have you had a gaming operation license that has been revoked or suspended. Yes No

If yes, provide the following if different from above:

Facility name and address:

City:	State:	Zip Code:
-------	--------	-----------

Racing Jurisdiction:

BUSINESS STRUCTURE

<input type="checkbox"/> Corporation <input type="checkbox"/> Public <input type="checkbox"/> Private <input type="checkbox"/> Sub-S <input type="checkbox"/> Sub-C <input checked="" type="checkbox"/> Limited Partnership <input type="checkbox"/> Limited Liability Company	<input type="checkbox"/> Partnership & Joint Venture <input type="checkbox"/> Sole Proprietorship	<input type="checkbox"/> Other If you have listed your company as other please identify your company structure:
--	--	--

Registered Business Name: Sahara Dunes Management, Inc

Fictitious Business Name: Lake Elsinore Hotel & Casino

Address: 20930 Malaga Road

E-mail Address: TedK@LerCasino.com

City: Lake Elsinore	State: CA	Zip Code: 92530
---------------------	-----------	-----------------

Phone: (951) 674-3101	Fax: (951) 674-4071
-----------------------	---------------------

State where registered or Articles of Organization are filed: California	Registry or File number: 855363
--	---------------------------------

State of California
 California Horse Racing Board
 Application for License to Operate a Minisatellite Wagering Facility
 CHR-228 (New 11/08)

Name of all officers, directors, and managers. For officers, directors, and managers that have no ownership, enter "0%" in the ownership column. For members of a Limited Liability Company, list membership interest in ownership column. For partners, following the individual's name indicate whether general or limited partners. (true names)

Entity/Individual Name and Title	Entity's Business Address/ Individual's Address of Record	Ownership% (if any)	Compensation Agreement
Sahara Dunes Management Inc, Ted Kingston, President	20930 Malaga Road, Lake Elsinore, CA 92530	5.00%	
Ted Kingston, President	Same as above	47.50%	
Joseph Kingston	3212 S. State Street, Salt Lake City, UT 84115	47.50%	

Are shares listed for public trade? Yes No If yes on what stock exchange?

If more than 50 percent of the shares are held by a parent corporation or are paired with any other corporation or entity, give the name of the parent and/or paired corporation or entity.

All entities that own 5 percent or more must fulfill the instructions for Full Disclosure Statement.
 On file with CHR

Attach the most recent annual financial statement for the applicant, including balance sheet and profit and loss statement, and a copy of a report made during the preceding 12 months to shareholders in the corporation and/or the Securities and Exchange Commission and/or the California Corporations Commission.

MANAGEMENT AND STAFF
 (Minisatellite Wagering Facility)

Name and title of the managing officer(s) and/or general manager(s) of the business.

Name	Title
Ted Kingston	Owner, General Manager
Pat Wilmes	Casino Manager

ASSOCIATION CONTRACT/AGREEMENT

Name(s) of racing association(s) with whom you intend to have a contract or agreement:
 See Exhibit A

Addresses of racing association(s):
 See Exhibit A

Racing association(s) phone numbers:
 See Exhibit A

Proposed contract dates: From: To: (inclusive). Through expiration of license

During term of minisatellite licensure

State of California
California Horse Racing Board
Application for License to Operate a Minisatellite Wagering Facility
CHRB-228 (New 11/08)

Attach a certified check payable to the Treasurer of the State of California in the amount of \$500 for the nonrefundable minisatellite application fee.

CHRB CERTIFICATION

Application filed on:	30-day Notice Letter:
Fee received by:	Approved on:
Reviewed by:	License number issued:

CERTIFICATION BY APPLICANT

I hereby certify under penalty of perjury that I have examined this application, that all of the foregoing statements in this application are true and correct, and that I am authorized by the applicant contractor to attest to this application on its behalf.

Name	Signature of Applicant Representative
Title	Date:

INSTRUCTION SHEET FOR FULL DISCLOSURE STATEMENT

Background Information and Ownership

By authority of Chapter 4, Division 8, sections 19420 and 19440 of the California Business and Professions Code; and to allow an evaluation of the competence, integrity, and character of potential licensees, all applicants for license as contractors, sub-contractors and all concessionaires applying for Board approval, including any person, corporation, trust, association, partnership or joint venture which submits an application for license or approval shall comply with the provisions set forth below. Please use a separate sheet of paper to supply the requested information.

I. BACKGROUND INFORMATION

- (A) PERSONAL INFORMATION - Application documents must include for each individual who is a director, officer, or partner in the application, or an owner of an interest in the applicant of 5 percent or more:
- (1) The individual's full name and any previous names or aliases;
 - (2) the individual's date of birth;
 - (3) a physical description of the individual;
 - (4) the individual's business addresses and telephone numbers and
 - (5) a disclosure of employment, educational and military history for the past 20 years or since the age of 18 years.
- (A1) PERSONAL HISTORY - Application documents must include a completed Personal History Record, CHRB-25A, for each individual named in subsection (A) who is a director, officer, or partner in the application or an owner of an interest in the applicant of 5 percent or more.
- (B) RELATIONSHIP - The application documents must state, for each individual providing information under subsection (A) of this section, whether the individual is related to a member of the California Horse Racing Board or an employee of the Board. A half-relationship or step-relationship is considered to be a familial relationship for purposes of this section.
- (C) CORPORATIONS - If the applicant is a corporation, the application documents must state:
- (1) The state in which the applicant is incorporated and
 - (2) the name and address of the applicant's agent for service of process in California.
- (D) INDICTMENTS OR CONVICTIONS
- If the applicant is a corporation, the application documents must include a statement disclosing whether the corporation is presently or has ever been indicted or convicted of a criminal offense, e.g., felony or misdemeanor.

II. OWNERSHIP

- (A) IDENTIFICATION AND LOCATION - The application documents must include:
- (1) A list of all names used by the applicant; and
 - (2) the name of the agent and the address and telephone number of the office of the applicant for service of process in California.
- (B) BUSINESS STRUCTURE - The application documents must describe the applicant's business structure and include an organizational chart.

State of California
California Horse Racing Board
Application for License to Operate a Minisatellite Wagering Facility
CHRB-228 (New 11/08)

- (C) ORGANIZERS - If the applicant is not an individual and was organized less than five years before the date on which the application documents are submitted to the Board, the application documents must state:
- (1) The name of each individual who was an organizer or promoter of the applicant;
 - (2) the nature and amount of assets, services, or other consideration contributed to the applicant by an organizer or promoter of the applicant; and
 - (3) the nature and amount of anything of value given by the applicant to an organizer or promoter of the applicant.
- (D) ORGANIZATIONAL DOCUMENTS
- (1) If the applicant is a corporation, the application documents must include:
 - (a) A statement of when and in what state the corporation was organized;
 - (b) a certified copy of the articles of incorporation and by-laws of the applicant;
 - (c) a statement and documentation of whether the corporation has been reorganized or reincorporated during the five year period preceding the date on which the application documents are submitted to the Board; and
 - (d) a statement and documentation of whether the corporation has filed restated articles of incorporation.
 - (2) If the applicant is an unincorporated business association, the application documents must include:
 - (a) A certified copy of each organizational document for the applicant, including any partnership agreement; and
 - (b) a description of any oral agreements involving the organization of the partnership.
- (E) CAPITAL STOCK
- (1) If the applicant is authorized to issue capital stock, the application documents must include the information required by this section.
 - (2) The applicant must state the classes of stock authorized and the total shares of each class authorized. The applicant must state, for each class of stock:
 - (a) The par value, if any;
 - (b) the voting rights;
 - (c) the current rate of dividend; and
 - (d) the number of shares outstanding and the market value of each share.
 - (3) The application documents must list the name and address of each person who owns, of record or beneficially, at least 5 percent of stock. For each person listed under this subsection, the application documents must describe the nature of the person's ownership interest and the person's percentage of the total ownership interest.
 - (4) The application documents must include a certified copy of each voting trust or voting agreement in which at least 5 percent of the capital stock is held and must state:
 - (a) The name and address of each stockholder participating in the trust or agreement;
 - (b) the class of stock involved; and
 - (c) the total number of shares held by the trust or agreement.
- (F) DIRECTORS, OFFICERS, AND PARTNERS

State of California
California Horse Racing Board
Application for License to Operate a Minisatellite Wagering Facility
CHRB-228 (New 11/08)

- (1) If the applicant is not an individual, the application documents must include a list of the individuals who are serving or who are designated to serve, during the first year after the date the application documents are submitted to the Board, as a director, officer, or partner of the applicant.
- (2) The list must state, for each individual listed under subsection (1) of this section:
 - (a) The individual's name and business address;
 - (b) each position or office of the applicant held by the individual;
 - (c) the individual's principal occupation during the five-year period preceding the date on which the application documents are submitted to the Board; and
 - (d) the nature and extent of any ownership interest that the individual has in the applicant.
- (3) Application documents must include a completed Personal History Record, CHRB-25A, for each individual named under subsection (1) of this section.

(G) CONTROLLING ENTITY

- (1) The application documents must state whether another entity exercises or is in a position to exercise control in the management or financial affairs of the applicant. The documents must describe the nature of the relationship between the entity and the applicant and the extent of control exercised by the entity.
- (2) If a non-individual entity owns an interest of 5 percent or more in the applicant, the application documents must include the information required by subsection (1) of this section as it relates to the non-individual entity.
- (3) The application documents must include information required by subsection (2) of this section for each non-individual entity identified in the application documents to the extent necessary to determine the identity of each individual who is an indirect holder of an ownership interest in the applicant.

(H) OUTSIDE INTERESTS AND LICENSE HISTORY

- (1) The application must state whether the applicant or a director, officer, or partner of the applicant;
 - (a) Has ever held an ownership interest in a licensee of the Board; or
 - (b) is currently engaged in the business of racing in another state.

PART II

CONTRACTED ASSOCIATION INFORMATION

One copy of Part II shall be completed by each contracted association

Name and mailing address of association:

Telephone:

Fax number:

Racetrack name:

Name and title of the person(s) authorized to receive notices on behalf of the association in conjunction with this applicant application for approval to operate a minisatellite wagering facility:

Name

Signature of association representative

Title

Date:

State of California
California Horse Racing Board
Application for License to Operate a Minisatellite Wagering Facility
CHRB-88 (New 11/08)

PART II
Lake Elsinore Renewal
CONTRACTED ASSOCIATION INFORMATION

One copy of Part II shall be completed by each contracted association

Name and mailing address of association:

California Authority of Racing Fairs
1776 Tribute Road, Sacramento, CA 95815

Telephone:

(916) 927-7223


Fax number:

(916) 263-3341

Racetrack name:

Ferndale, Fresno, Pleasanton, and Sacramento

Name and title of the person(s) authorized to receive notices on behalf of the association in conjunction with this applicant application for approval to operate a minisatellite wagering facility:

Name Larry Swartzlander	Signature of association representative 
Title Executive Director	Date: 12/17/20

State of California
California Horse Racing Board
Application for License to Operate a Minisatellite Wagering Facility
CHRB-88 (New 11/08)


PART II
Lake Elsinore
CONTRACTED ASSOCIATION INFORMATION
One copy of Part II shall be completed by each contracted association

Name and mailing address of association:
Sonoma County Fair & Exposition, Inc.
1350 Bennett Valley Road, Santa Rosa, CA 95404

Telephone: (707) 545-4200
Fax number: (707) 573-9342

Racetrack name:
Santa Rosa Racetrack - Sonoma County Fair

Name and title of the person(s) authorized to receive notices on behalf of the association in conjunction with this applicant application for approval to operate a minisatellite wagering facility:

Name Rebecca Bartling	Signature of association representative 
Title CEO	Date: 12/16/2020

State of California
California Horse Racing Board
Application for License to Operate a Minisatellite Wagering Facility
CHRB-88 (New 11/08)

PART II
Lake Elsinore

CONTRACTED ASSOCIATION INFORMATION

One copy of Part II shall be completed by each contracted association

Name and mailing address of association:

Del Mar Thoroughbred Club
2260 Jimmy Durante Blvd, Del Mar, CA 92014

Telephone:

(858) 755-1141

Fax number:

(858) 794-1007

Racetrack name:

Del Mar

Name and title of the person(s) authorized to receive notices on behalf of the association in conjunction with this applicant application for approval to operate a minisatellite wagering facility:

Name

Josh Rubinstein

Title

President & COO

Signature of association representative

Date:

12/15/20

State of California
California Horse Racing Board
Application for License to Operate a Minisatellite Wagering Facility CHRB-
88 (New 11/08)

PART II
Lake Elsinore
CONTRACTED ASSOCIATION INFORMATION

One copy of Part II shall be completed by each contracted association Name

and mailing address of association:

Watch and Wager.com LLC
20 California Street, 7th Floor, San Francisco, CA 94111

Telephone:
(916) 800-1390

Fax number:
(916) 800-1395

Racetrack name:
California State Fair & Exposition - Cal Expo Harness

Name and title of the person(s) authorized to receive notices on behalf of the association in conjunction with this applicant application for approval to operate a minisatellite wagering facility:

Name Ben Kenney	Signature of association representative 
Title CFO	Date: 11/22/2020

State of California
California Horse Racing Board
Application for License to Operate a Minisatellite Wagering Facility
CHRB-88 (New 11/08)

PART II
Lake Elsinore

CONTRACTED ASSOCIATION INFORMATION

One copy of Part II shall be completed by each contracted association

Name and mailing address of association:

Los Angeles County Fair Association
1101 W. McKinley Avenue, Pomona, CA 91768

Telephone:
(909) 865-4203

Fax number:
(909) 865-2481

Racetrack name:

Los Angeles County Fair, racing at Los Alamitos Race Course

Name and title of the person(s) authorized to receive notices on behalf of the association in conjunction with this applicant application for approval to operate a minisatellite wagering facility:

Name
Jack Liebau

Title
Vice President

Signature of association representative

Jack Liebau

Date:
12/22/2020

State of California
California Horse Racing Board
Application for License to Operate a Minisatellite Wagering Facility
CHRB-88 (New 11/08)

PART II
Lake Elsinore Renewal

CONTRACTED ASSOCIATION INFORMATION

One copy of Part II shall be completed by each contracted association

Name and mailing address of association:

Los Alamitos Quarter Horse Racing Association
4961 Katella Avenue, Los Alamitos, CA 90720

Telephone:

(714) 820-2800

Fax number:

Racetrack name:

Los Alamitos

Name and title of the person(s) authorized to receive notices on behalf of the association in conjunction with this applicant application for approval to operate a minisatellite wagering facility:

Name

JACK Liebaw

Title

Signature of association representative

Jack Liebaw

Date:

12/22/2020

State of California
California Horse Racing Board
Application for License to Operate a Minisatellite Wagering Facility
CHRB-88 (New 11/08)

PART II
Lake Elsinore

CONTRACTED ASSOCIATION INFORMATION

One copy of Part II shall be completed by each contracted association

Name and mailing address of association:

Los Alamitos Racing Association
4961 Katella Avenue, Los Alamitos, CA 90720

Telephone:

(714) 820-2800

Fax number:

Racetrack name:

Los Alamitos

Name and title of the person(s) authorized to receive notices on behalf of the association in conjunction with this applicant application for approval to operate a minisatellite wagering facility:

Name

JACK LIEBAU

Signature of association representative

Jack Liebau

Title

VP

Date:

12/22/2020

State of California
California Horse Racing Board
Application for License to Operate a Minisatellite Wagering Facility
CHRB-88 (New 11/08)

PART II
Lake Elsinore

CONTRACTED ASSOCIATION INFORMATION

One copy of Part II shall be completed by each contracted association

Name and mailing address of association:

Los Angeles Turf Club, Inc.
285 W. Huntington Drive, Arcadia, CA 91007

Telephone:

(626) 574-7223

Fax number:

(626) 821-1514

Racetrack name:

Santa Anita Park

Name and title of the person(s) authorized to receive notices on behalf of the association in conjunction with this applicant application for approval to operate a minisatellite wagering facility:

Name

Eric Sindler

Signature of association representative

Eric Sindler

Title

Asst. Secretary

Date:

12/31/2020

State of California
California Horse Racing Board
Application for License to Operate a Minisatellite Wagering Facility
CHRB-88 (New 11/08)

PART II
Lake Elsinore

CONTRACTED ASSOCIATION INFORMATION

One copy of Part II shall be completed by each contracted association

Name and mailing address of association:

Pacific Racing Association
1100 Eastshore Highway, Albany, CA 94706

Telephone:
(510) 559-7300

Fax number:
(510) 559-7465

Racetrack name:
Golden Gate Fields

Name and title of the person(s) authorized to receive notices on behalf of the association in conjunction with this applicant application for approval to operate a minisatellite wagering facility:

Name

Eric Sandler

Signature of association representative


Eric Sandler

Title

Asst Secretary

Date:

12/31/2020



December 15, 2020

Amanda Drummond
Manager of Policy and Regulations
California Horse Racing Board
1010 Hurley Way, Suite #300
Sacramento, CA 95825

RE: Lake Elsinore Minisatellite Facility

The Thoroughbred Owners of California approves the renewal licensing by the California Horse Racing Board for the Lake Elsinore minisatellite.

Sincerely,

Greg Avioli
President & CEO

xc: Scott Chaney, CHRB Executive Director
George Haines, SCOTWINC General Manager

285 W. HUNTINGTON DR., ARCADIA, CA 91007 (626) 574-6620

CHAIRMAN: NICK ALEXANDER
PRESIDENT & CEO: GREG AVIOLI
EXECUTIVE DIRECTOR: MARY FORNEY
NORTHERN CA LIAISON: WAYNE ATWELL
ADMINISTRATIVE ASSISTANT: ELSA PERON

December 15, 2020

Amanda Drummond
Manager of Policy and Regulations
California Horse Racing Board
1010 Hurley Way, Suite #300
Sacramento, CA 95825

RE: Lake Elsinore Minisatellite Facility

Dear Ms. Drummond,

The California Harness Horsemen's Association approves the renewal licensing by the California Horse Racing Board for the Lake Elsinore minisatellite.

Sincerely,

A handwritten signature in black ink, appearing to read "David Neumeister". The signature is fluid and cursive, with a long horizontal stroke at the end.

David Neumeister
President

xc: Scott Chaney, CHRB Executive Director
George Haines, SCOTWINC General Manager



Pacific Coast Quarter Horse Racing Association

December 15, 2020

Amanda Drummond
Manager of Policy and Regulations
California Horse Racing Board
1010 Hurley Way, Suite #300
Sacramento, CA 95825

RE: Lake Elsinore Minisatellite Facility

Dear Ms. Drummond,

The Pacific Coast Quarter Horse Racing Association approves the renewal licensing by the California Horse Racing Board of the Lake Elsinore minisatellite.

Sincerely,

Dino Perez
General Manager

xc: Scott Chaney, CHRB Executive Director
George Haines, SCOTWINC General Manager

State of California
 California Horse Racing Board
 Application for License to Operate a Minisatellite Wagering Facility
 CHR-228 (New 11/08)

All labor agreements, concession contracts, service contracts, horsemen's agreements, lease agreements, agreements with the simulcast organization(s) necessary to conduct and operate the simulcast wagering program at the facility, lease or rental agreement with the facility landlord and all applicable county, city or agency agreements that may affect the minisatellite wagering facility have been finalized except as follows (if there are no exceptions, so state): No exceptions

All service contractors and concessionaires have valid State, County or City licenses authorizing each to engage in the type of service to be provided and have valid labor agreements (when applicable) which remain in effect for the entire term of the license except as follows (if there are no exceptions, so state): No exceptions

Absent natural disasters or causes beyond the control of the applicant, its service contractors, concessionaires or employees engaged at the facility, no reasons are believed to exist that may result in a stoppage to the conduct of pari-mutuel wagering at the facility or the withholding of any vital service to the applicant except as follows (if there are no exceptions, so state): No exceptions

By authority of Article 9.2, Chapter 4, of the Business and Professions Code; and the Federal Indian Gaming Act; to allow an evaluation of the competence, integrity, and character of potential simulcast facility operators, any person, corporation, trust association, partnership, joint venture, or management firm who submits an application for such license or who is named in such application and who is not a State or County entity, or has not previously completed such disclosure when filing for a horseracing application pursuant to Article 4, section 19480 of the Business and Professions Code shall be required to complete and submit a full disclosure statement.

Lake Elsinore

CERTIFICATION BY APPLICANT

I hereby certify under penalty of perjury that I have examined this application, that all of the foregoing statements in this application are true and correct, and that I am authorized by the applicant to attest to this application on its behalf.

Print name of minisatellite facility applicant representative:	Date:
Signature of minisatellite facility representative:	Date:
Print name of association representative:	Date:
Josh Rubinstein Signature of association representative:	Date: 1/1/21
Print name of simulcast organization representative:	Date:
George Haines Signature of simulcast organization representative:	Date: 1/1/21

**PART III
SIMULCAST ORGANIZATION INFORMATION**

To be completed by approved simulcast organization that has executed an agreement approved by the CHRB with the association conducting a racing meeting with the minisatellite wagering facility pursuant to Business and Professions Code sections 19605.25 and 19605.3.

I. OPERATION OF THE MINISATELLITE WAGERING FACILITY

Simulcast organization engaged by the association to conduct simulcast wagering: SCOTWINC

Attach the agreement between the association and simulcast organization permitting the minisatellite wagering facility to use the association’s live audiovisual signal for wagering purposes and providing access to it’s totalizator for the purpose of combining on-track and off-track pari-mutuel pools.

On file with CHRB

Submit a copy of each horsemen’s written approvals. Attached

Hours for operation of the facility: 24/7

Hours for operation of the minisatellite wagering site: 7 days a week during hours when parimutuel wagering is made available by host tracks

Time periods during the calendar year the facility **will not** be utilized as a minisatellite wagering facility (explain why): None expected

If approved, wagering will be offered on live race meetings being held or conducted by the following California racing association(s):

Wagering will be offered on all California cards

List the host track from which the minisatellite wagering facility proposes to import out-of-state and/or out-of-country races. Include the dates imported races will be held, and whether or not a full card will be accepted. If the full card will not be imported, state “selected feature and/or stakes races”: Wagering will be offered on all cards imported by California racing associations throughout the year.

Estimated number of pari-mutuel terminals machines available: 12

Attach a proposed staffing plan for the facility and/or minisatellite wagering site, to include the number of security personnel and the number of pari-mutuel clerks pursuant to Business and Professions Code section 19605.25 (5)(b).

The host track parimutuel manager will determine the number of mutuel employees based upon the projected handle and attendance for day or night cards. On most weekdays, one or two mutuel employees will be assigned, with up to three on weekends and special events as needed. At least one security officer will be present at all times.

II. SUPERVISION, SECURITY AND FIRE PREVENTION
 Changes to management personnel and minisatellite manager(s)
 must be immediately reported to the Board.

Name of the individual(s) responsible for the day-to-day operation of the minisatellite facility:

Name and Title	CHRB License No. and Expiration Date
George Haines, General Manager of SCOTWINC	068136, expires 6/30/2023

Attach a certificate of insurance for workers' compensation coverage including carrier and the policy number securing the applicant's liability for payment of workers' compensation is (if self-insured, provide details):
 Attached

Attach a fire clearance from the fire authority having jurisdiction. Attached

Attach a security plan to include: the name, title and phone number of the person having responsibility for security controls, the number of security officers and/or guards and the police or sheriff's department having jurisdiction for criminal law enforcement over the premises of the facility. Captain Hansel Loria (Lake Elsinore Casino Public Safety) is responsible for security operations. His land line number is (951) 674-3101 and his cell number is (951) 334-9867. The facility is staffed according to the needs of the property, with nine fulltime public safety officers. At least one officer is present 24 hours a day, seven days a week, and there are two or more present on weeknights. One weekends, three to five officers are present, depending upon occupancy and special events. Criminal law enforcement agencies include the Lake Elsinore Police Department and Riverside County Sherriff's Department.

Is there a backup emergency plan for power failure? Yes No

If yes, describe.

III. MINISATELLITE WAGERING SITE

Attach a detailed scale plan of the facility indicating all points of access to facility, emergency exits, placement of offices, and food and beverage service location and detailing the location of the proposed minisatellite wagering site. Identify how the designated minisatellite wagering area will be restricted to patrons 21 years and over. Attach photos of the minisatellite wagering site. Scale plan and photographs are on file with CHRB. Members of the security staff, who are present seven days a week, 24 hours a day, will insure that the minisatellite wagering area is restricted to those 21 years of age or older.

NOTICE TO APPLICANT. Pursuant to Business and Professions Code section 19605.25(a) (4) wagers placed at a minisatellite site must be in an area that is restricted to those who are 21 years of age or older.

IV. FACILITY DESCRIPTION

Describe the food and beverage services to be offered (full meals served; cafeteria-style full meals; short-order counter service; pre-ordered prepared sandwiches and fast foods available; full bar services; or other description as appropriate): Full meal and bar services.

The seating capacity in the minisatellite wagering facility is: 115 inside, 100 outside, with additional seating in the card room area.	The number of tables in the minisatellite wagering area is: 33 tables in the wagering area
---	--

Overall square footage in the minisatellite wagering area is: 2,870 sq feet in the indoor area plus an additional 3,278 square feet in the outdoor patio area

Attach a photograph of the minisatellite wagering area. Photographs on file with CHRB

Describe occupancy restrictions, if any, imposed by the fire authority having jurisdiction: 157 indoors

The total number of parking spaces available in the parking areas can accommodate (number of standard sized automobiles): 400, including 10 spaces for handicapped customers

Describe any other activities to be scheduled on or near the facility premises that may have a negative impact on available parking: None

V. EQUIPMENT PROVIDED BY THE MINISATILLITE WAGERING FACILITY

Describe the television equipment (satellite receivers, decoders, controls, monitors, etc.) to be utilized at the facility: The restricted area includes 48 high definition monitors and there are additional monitors in other areas of the casino, including 8 in the outdoor patio area. Roberts Communication Network provides the satellite reception services.

Describe the public address equipment (controls, microphones, speakers, etc.) to be utilized at the facility: Sound Image provides the public address system.

VI. ADVERTISING AND PATRON DEVELOPMENT

Describe any advertising or promotional plans: A digital sign, viewable from the freeway, advertises the casino 24 hours a day, 7 days a week. Direct mail, email and social media are used to contact both existing and potential new customers in the targeted areas of Corona, Temecula and surrounding areas within a 60 to 80 mile radius.

Describe any improvements to the facility that will directly benefit minisatellite wagering:

NOTICE TO APPLICANT: Pursuant to Board Rule 2066 all advertisement shall contain a statement that persons under 21 are not allowed to participate in minisatellite wagering. All advertisement shall contain contact information for a recognized problem-gambling support organization.

VII. ADMISSIONS, CHARGES AND SERVICE FEES

Complete if applicable and note N/A if not

Admissions charges, if any, are:	None
Parking charges, if any, are:	None
Program charges, if any, are:	Program prices are determined by the host track
Seating charges, if any, are:	None

VIII. RENEWAL

Complete this section only if renewing your license.

Is this a renewal application: Yes No

Have there been any changes since the submission of your last application for authorization to operate a minisatellite wagering facility? Yes No

Have any changes occurred affecting ownership or controlling interest in your business structure or establishment since your last application? Yes No

If you have answered, "Yes", to any of the questions above please attach a detailed statement describing the change.

How many years have you been an approved minisatellite wagering facility? 6 years

AGREEMENTS

Attach copies of **all applicable county, city or agency agreements** that may affect the minisatellite wagering facility.

NOTICES TO APPLICANT

Notice is given to the applicant that its application, if approved by the Board, authorizes the applicant to offer pari-mutuel wagering at its minisatellite wagering facility for a period of two years per Business and Professions Code section 19605.25(h).

Notice is given that retention of and control over all moneys generated from pari-mutuel wagering held or conducted at the facility is the responsibility of the simulcast organization(s) which contract(s) to provide the pari-mutuel equipment and pari-mutuel employees; and that such organization(s) is (are) responsible for its proper distribution in accordance with the law and the rules and regulations of the Board.

Notice is given that CHRB Rules 1870 and 1871 require that the Board be given 15 days notice in writing of any intention to terminate operations, engagements, or services by any licensee, or approved contractor.

DECLARATIONS

All labor agreements, concession contracts, service contracts, horsemen's agreements, lease agreements, agreements with the simulcast organization(s) necessary to conduct and operate the simulcast wagering program at the facility, lease or rental agreement with the facility landlord and all applicable county, city or agency agreements that may affect the minisatellite wagering facility have been finalized except as follows (if there are no exceptions, so state):

All service contractors and concessionaires have valid State, County or City licenses authorizing each to engage in the type of service to be provided and have valid labor agreements (when applicable) which remain in effect for the entire term of the license except as follows (if there are no exceptions, so state):

Absent natural disasters or causes beyond the control of the applicant, its service contractors, concessionaires or employees engaged at the facility, no reasons are believed to exist that may result in a stoppage to the conduct of pari-mutuel wagering at the facility or the withholding of any vital service to the applicant except as follows (if there are no exceptions, so state):

By authority of Article 9.2, Chapter 4, of the Business and Professions Code; and the Federal Indian Gaming Act; to allow an evaluation of the competence, integrity, and character of potential simulcast facility operators, any person, corporation, trust association, partnership, joint venture, or management firm who submits an application for such license or who is named in such application and who is not a State or County entity, or has not previously completed such disclosure when filing for a horseracing application pursuant to Article 4, section 19480 of the Business and Professions Code shall be required to complete and submit a full disclosure statement.

CERTIFICATION BY APPLICANT

I hereby certify under penalty of perjury that I have examined this application, that all of the foregoing statements in this application are true and correct, and that I am authorized by the applicant to attest to this application on its behalf.

Print name of minisatellite facility applicant representative:	Date:
Signature of minisatellite facility representative:	Date:
Print name of association representative: Josh Rubinstein	Date:
Signature of association representative:	Date:
Print name of simulcast organization representative: George Haines	Date:
Signature of simulcast organization representative:	Date:

Lake Elsinore Hotel and Casino Minisatellite Wagering Application - Exhibit A

Part 1 – Minisatellite Wagering Applicant Information

Association Contract/Agreement:

Name(s) of racing associations(s) with a contract or agreement:

California Authority of Racing Fairs
1776 Tribute Road, Suite 205
Sacramento, CA 95812

Phone: (916) 927-7223

Fax: (916) 263-3341

Del Mar Thoroughbred Club
2260 Jimmy Durante Blvd
Del Mar, CA 92014

Phone: (858) 755-1141

Fax: (858) 794-1007

Los Angeles County Fair
c/o
4961 Katella Avenue
Los Alamitos, CA 90720

Phone: (714) 820-2760

Fax: (714) 820-2813

Los Angeles Turf Club
285 W. Huntington Drive
Arcadia, CA 91007

Phone: (626) 574-7223

Fax: (626) 821-1514

Los Alamitos Racing Association (T) & Los Alamitos Quarter Horse Racing Association
4961 Katella Avenue
Los Alamitos, CA 90720

Phone: (714) 820-2760

Fax: (714) 820-2813

Pacific Racing Association
1100 Eastshore Highway
Berkeley, CA 94710

Phone: (510) 559-7300

Fax: (510) 559-7464

Lake Elsinore Hotel and Casino Minisatellite Wagering Application - Exhibit A

Page 2

Association Contract/Agreement:

Name(s) of racing association(s) intended to have a contract or agreement:

Sonoma County Fair
1350 Bennett Valley Drive
Santa Rosa, CA 95404

Phone: (707) 545-4200
Fax: (707) 545-9342

Watch & Wager.com, LLC
1600 Exposition Road
Sacramento, CA 95815

Phone: (916) 263-3000
Fax: (916) 800-1395

Part III – Simulcast Organization Information

I Operation of the Minisatellite Wagering Facility:

Lake Elsinore will offer parimutuel wagering during racing hours, 7 days a week.

Wagering will be offered on all California cards plus races imported by all California racing associations from out of state and out of country tracks.

The host track pari-mutuel manager will determine the number of mutuel tellers based upon the projected handle and attendance for the day or night card. On most weekdays, one or two tellers will be assigned, with up to three on weekends and special events as needed. At least one security officer will be present at all times.

II Supervision, Security and Fire Prevention

Captain Hansel Loria (Lake Elsinore Casino Public Safety) is responsible for security operations. His land is line number is (951) 674-3101 and cell number is (951) 334-9867. Criminal law enforcement agencies include the Lake Elsinore Police Department and Riverside County Sheriff's Department.

The facility is staffed according to needs of the property with nine fulltime public safety officers. At least one officer is present 24 hours a day, seven days a week and there are two or more present on weeknights. On weekends, three to five officers are present, depending on occupancy and special events.

Lake Elsinore Hotel and Casino Minisatellite Wagering Application - Exhibit A

Page 3

III Minisatellite Wagering Site

Members of the security staff, present 24 hours a day, seven days a week, will insure that the minisatellite wagering area is restricted to those 21 years of age or older.

IV Facility Description

Jaxx restaurant offers full food and beverage services including breakfast, lunch and dinner. Special offerings include a Champagne Sunday brunch, happy hour drinks and, early bird food specials. Restaurant hours are 6 am to 9 pm Monday through Thursday & Sunday, and 6 am to midnight on Fridays and Saturdays. The Lounge will be open 6 am to 2 am, seven days a week.

The facility will seat 115 people inside with an additional 100 seats in the outdoor patio. Seating will also be available in the card room area. There will be 33 tables in the wagering area.

The overall square footage in the minisatellite area will be 2,870 sq. feet in the indoor area plus an additional 3,278 in the outdoor patio area.

V Equipment Provided by the Minisatellite Wagering Facility

The restricted area includes 48 high definition monitors and there are additional monitors in other areas of the Casino, including 8 in the outdoor patio area.

Roberts Communication Network provides the satellite reception services.

Sound Image provides public address system.

VI Advertising and Patron Development

A digital sign viewable from the freeway advertises the Casino 24 hours a day, 7 days a week. Direct mail, email will be utilized to contact both existing and potential new customers in the targeted areas of Corona, Norco, Temecula and surrounding areas within a 60 to 80 mile radius. Social media (Facebook, Twitter, Pinterest, Instagram, etc.) will also be utilized.

Lake Elsinore Hotel and Casino Minisatellite Wagering Application - Exhibit A

Part 1 – Minisatellite Wagering Applicant Information

Association Contract/Agreement:

Name(s) of racing associations(s) with a contract or agreement:

California Authority of Racing Fairs
1776 Tribute Road, Suite 205
Sacramento, CA 95812

Phone: (916) 927-7223

Fax: (916) 263-3341

Del Mar Thoroughbred Club
2260 Jimmy Durante Blvd
Del Mar, CA 92014

Phone: (858) 755-1141

Fax: (858) 794-1007

Los Angeles County Fair
c/o
4961 Katella Avenue
Los Alamitos, CA 90720

Phone: (714) 820-2760

Fax: (714) 820-2813

Los Angeles Turf Club
285 W. Huntington Drive
Arcadia, CA 91007

Phone: (626) 574-7223

Fax: (626) 821-1514

Los Alamitos Racing Association (T) & Los Alamitos Quarter Horse Racing Association
4961 Katella Avenue
Los Alamitos, CA 90720

Phone: (714) 820-2760

Fax: (714) 820-2813

Pacific Racing Association
1100 Eastshore Highway
Berkeley, CA 94710

Phone: (510) 559-7300

Fax: (510) 559-7464

Lake Elsinore Hotel and Casino Minisatellite Wagering Application - Exhibit A

Page 2

Association Contract/Agreement:

Name(s) of racing association(s) intended to have a contract or agreement:

Sonoma County Fair
1350 Bennett Valley Drive
Santa Rosa, CA 95404

Phone: (707) 545-4200

Fax: (707) 545-9342

Watch & Wager.com, LLC
1600 Exposition Road
Sacramento, CA 95815

Phone: (916) 263-3000

Fax: (916) 800-1395

Part III – Simulcast Organization Information

I Operation of the Minisatellite Wagering Facility:

Lake Elsinore will offer parimutuel wagering during racing hours, 7 days a week.

Wagering will be offered on all California cards plus races imported by all California racing associations from out of state and out of country tracks.

The host track pari-mutuel manager will determine the number of mutuel tellers based upon the projected handle and attendance for the day or night card. On most weekdays, one or two tellers will be assigned, with up to three on weekends and special events as needed. At least one security officer will be present at all times.

II Supervision, Security and Fire Prevention

Captain Hansel Loria (Lake Elsinore Casino Public Safety) is responsible for security operations. His land is line number is (951) 674-3101 and cell number is (951) 334-9867. Criminal law enforcement agencies include the Lake Elsinore Police Department and Riverside County Sheriff's Department.

The facility is staffed according to needs of the property with nine fulltime public safety officers. At least one officer is present 24 hours a day, seven days a week and there are two or more present on weeknights. On weekends, three to five officers are present, depending on occupancy and special events.

Lake Elsinore Hotel and Casino Minisatellite Wagering Application - Exhibit A

Page 3

III Minisatellite Wagering Site

Members of the security staff, present 24 hours a day, seven days a week, will insure that the minisatellite wagering area is restricted to those 21 years of age or older.

IV Facility Description

Jaxx restaurant offers full food and beverage services including breakfast, lunch and dinner. Special offerings include a Champagne Sunday brunch, happy hour drinks and, early bird food specials. Restaurant hours are 6 am to 9 pm Monday through Thursday & Sunday, and 6 am to midnight on Fridays and Saturdays. The Lounge will be open 6 am to 2 am, seven days a week.

The facility will seat 115 people inside with an additional 100 seats in the outdoor patio. Seating will also be available in the card room area. There will be 33 tables in the wagering area.

The overall square footage in the minisatellite area will be 2,870 sq. feet in the indoor area plus an additional 3,278 in the outdoor patio area.

V Equipment Provided by the Minisatellite Wagering Facility

The restricted area includes 48 high definition monitors and there are additional monitors in other areas of the Casino, including 8 in the outdoor patio area.

Roberts Communication Network provides the satellite reception services.

Sound Image provides public address system.

VI Advertising and Patron Development

A digital sign viewable from the freeway advertises the Casino 24 hours a day, 7 days a week. Direct mail, email will be utilized to contact both existing and potential new customers in the targeted areas of Corona, Norco, Temecula and surrounding areas within a 60 to 80 mile radius. Social media (Facebook, Twitter, Pinterest, Instagram, etc.) will also be utilized.

STAFF ANALYSIS
DISCUSSION AND ACTION BY THE BOARD ON THE APPROVAL FOR A
DISTRIBUTION FROM ADW MARKET ACCESS FEES FOR WAGERS PLACED BY
CALIFORNIA RESIDENTS ON ALL LIVE AND IMPORTED RACES HOSTED BY THE
SIGNATORY RACING ASSOCIATIONS FOR THE PERIOD APRIL 1 THROUGH
DECEMBER 31, 2021, TO BE UTILIZED TO FUND A CALIFORNIA CO-OP
MARKETING PROGRAM AS PERMITTED UNDER BUSINESS & PROFESSIONS
CODE SECTION 19604(F)(5)(E)

Regular Board Meeting
February 17, 2021

ISSUE:

The Thoroughbred Owners of California (TOC), Del Mar Thoroughbred Club, California Thoroughbred Breeders Association, and the Los Angeles Turf Club are seeking an approval of an agreement under Business and Professions Code (BPC) section [19604\(f\)\(5\)\(E\)](#) for the period April 1, 2021 through December 31, 2021, which will modify market access fee distributions for advance deposit wagering (ADW) wagers placed in the applicable zone on races hosted by the signatory host tracks. The Co-op Marketing Agreement allows the TOC and the tracks to continue programs that were previously supported by California Marketing Committee (CMC). CMC is no longer operating as BPC section 19605.73 allowing its existence has expired.

ANALYSIS:

The TOC and the tracks (Del Mar and Santa Anita) wish to continue certain CMC programs following the January 1, 2019 sunset of BPC section 19605.73, which authorized the CMC and its programs. The continuing programs include:

- Stakes Recruitment,
- Ship & Win,
- Significant Player Rebates,
- Calracing.com and Calracingcares.com Websites, and a
- TOC Administrative Fee

The cost of these programs will be shared between the TOC and the signatory parties on the Co-op Marketing Agreement.

The share of costs attributed to each of the tracks was based on the tracks' total product enhancement budget in 2020, and the amount needed for distribution from ADW market access fees was calculated by Bernie Thurman based on the 2020 budget for those programs.

BACKGROUND:

BPC section 19604(f)(5)(E) provides that notwithstanding any provision of this section to the contrary, the distribution of market access fees pursuant to this subparagraph may be altered upon the approval of the Board, in accordance with an agreement signed by all parties whose distributions would be affected.

RECOMMENDATION:

This item is presented for Board discussion and action. Staff recommends the Board hear from the Co-op Marketing Agreement representatives.

Coop Marketing Funding Agreement

This Agreement is entered into as of this 29 day of January, 2021 by and between the undersigned racing associations ("the Signatory Racing Associations") the Thoroughbred Owners of California ("TOC").

IT IS HEREBY AGREED AS FOLLOWS:

1. The distribution of Market Access fees from California resident Advanced Deposit Wagering, ("ADW") placed on all live and imported races hosted by the Signatory Racing Associations shall be altered by the creation of an additional deduction for a distribution therefrom, based upon a percentage of handle in the applicable California zones that would otherwise be payable as thoroughbred purses and track commissions. The deduction from ADW market access fees shall be utilized to fund a coop marketing program. The deduction percentage of ADW handle in the applicable zones for each host shall be:

Del Mar Thoroughbred Club race meets	0.320%
Los Angeles Turf Club race meets	0.420%



2. The parties shall immediately file this Agreement with the CHRB for the purposes of securing its approval of the deductions contemplated from market access fees placed on races hosted by the Signatory Racing Associations which is permitted pursuant to Business and Professions Code Section 19604 (f)(5)(E).

3. Subject to the requisite approval of the CHRB, the deduction from ADW set forth in #1 above shall be effective April 1, 2021 through December 31, 2021.

4. In addition to the distributions set forth above, there shall be a distribution from the ADW Deduction in order to pay administrative expenses that would otherwise have been distributed to TOC, CTT, and the Backstretch Workers Pension Plan.

Thoroughbred Owners of California

Los Angeles Turf Club



By: _____

By: _____

Del Mar Thoroughbred Club

By: _____

Coop Marketing Funding Agreement

This Agreement is entered into as of this 29 day of January, 2021 by and between the undersigned racing associations ("the Signatory Racing Associations") the Thoroughbred Owners of California ("TOC").

IT IS HEREBY AGREED AS FOLLOWS:

1. The distribution of Market Access fees from California resident Advanced Deposit Wagering, ("ADW") placed on all live and imported races hosted by the Signatory Racing Associations shall be altered by the creation of an additional deduction for a distribution therefrom, based upon a percentage of handle in the applicable California zones that would otherwise be payable as thoroughbred purses and track commissions. The deduction from ADW market access fees shall be utilized to fund a coop marketing program. The deduction percentage of ADW handle in the applicable zones for each host shall be:

Del Mar Thoroughbred Club race meets	0.320%
Los Angeles Turf Club race meets	0.420%

2. The parties shall immediately file this Agreement with the CHRB for the purposes of securing its approval of the deductions contemplated from market access fees placed on races hosted by the Signatory Racing Associations which is permitted pursuant to Business and Professions Code Section 19604 (f)(5)(E).
3. Subject to the requisite approval of the CHRB, the deduction from ADW set forth in #1 above shall be effective April 1, 2021 through December 31, 2021.
4. In addition to the distributions set forth above, there shall be a distribution from the ADW Deduction in order to pay administrative expenses that would otherwise have been distributed to TOC, CTT, and the Backstretch Workers Pension Plan.

Thoroughbred Owners of California


Los Angeles Turf Club



By: _____

By: _____

Del Mar Thoroughbred Club

By:  _____

CALIFORNIA HORSE RACING BOARD

February 17, 2021
REGULAR BOARD MEETING

There is no board package material for Item 7

CALIFORNIA HORSE RACING BOARD

February 17, 2021
REGULAR BOARD MEETING

There is no board package material for Item 8